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Abstract 
Human aldo-keto reductases (AKR) of the 1C subfamily have been implicated in the 
progression of prostate, breast and endometrial carcinomas as well as leukaemias due to their 
ability to modify key signaling molecules: steroid hormones and prostaglandins (PGs). In 
leukaemia, the AKR1C3 isoform has been identified as a novel therapeutic target since its 
PGD2 reductase activity prevents cell differentiation. Mice are ideal organisms for in vivo 
studies, using knock-out or over-expression strains. However, no mouse models for AKR1C 
enzymes have been generated to date since the functional conservation of these enzymes 
between human and mice is yet to be described. This study compared and characterised the 
phylogeny, substrate preference and tissue expression profile of the four human (AKR1C1,-
1C2, -1C3 and -1C4) and the eight mouse (AKR1C6, -1C12, -1C13, -1C14, -1C18, -1C19, -
1C20 and -1C21) isoforms. Despite being orthologues, AKR1C enzymes of mouse and 
humans have undergone significant divergence in number and sequence which was reflected 
in different substrate preference and tissue distribution. Mouse AKR1C isoforms lacked the 
PGD2 reductase activity but AKR1C6 was able to reduce PGE2 instead, an activity absent 
amongst human isoforms. Reduction of the key steroids androstenedione, 5α-
dihydrotestosterone, progesterone and estrone was performed by 4 of the murine isoforms. 
However, unlike humans, no AKR1C isoforms were detected in murine prostate, testes, uterus 
and haemopoietic progenitors. This study exposes significant lack of phylogenetic and 
functional conservation between human and murine AKR1C enzymes. Therefore, it is 
concluded that mice are not suitable to model the role of AKR1C in human carcinomas and 
leukemia. 
Additionally, the role of PGD2 in adult muscle differentiation was investigated using the 
mouse myoblast cell line C2C12. PGD2, but not PGE2 or PGF2α, inhibited myotube formation 
in a dose dependent manner. Exposure to PGD2 disrupted the expression of myogenic 
regulators (MyoD and myogenin) during differentiation and suppressed cell fusion, α-actin 
expression and creatine kinase activity. Inhibition of myogenesis was independent of PGD2 
surface receptors DP1 and DP2 and activation of the peroxisome proliferator-activated 
receptor γ (PPARγ) suggesting a new form of signaling is involved. This discovery has 
implications in the interplay between inflammation, where high levels of PGD2 are secreted, 
and adult muscle regeneration, two processes that are intimately related.  
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1 CHAPTER ONE: Introduction 
1.1 A short introduction to aldo-keto reductases in leukaemia  
In 1994, Bunce and colleagues identified indomethacin as a potentiator of differentiation of 
HL60 cells, a model of myeloid leukaemia (Bunce et al., 1994). Indomethacin is a non-
steroidal anti-inflammatory (NSAID) drug that acts by blocking cyclooxygenase (COX) 
activity and suppressing the synthesis of prostanoids. However, the authors could not provide 
evidence that COX was the molecular target that promoted HL60 differentiation and other 
targets of indomethacin were sought (Bunce et al., 1996). This led to the identification of an 
enzyme with 3α-hydroxysteroid dehydrogenase activity belonging to the aldo-keto reductase 
(AKR) superfamily as the molecular target of indomethacin (Bunce et al., 1996, Mills et al., 
1998). Subsequently, other known inhibitors of this enzyme were shown to potentiated HL60 
differentiation.  
The enzyme was later identified as AKR1C3, one of four closely related human aldo-keto 
reductases and found to be expressed in leukaemic cell lines and primary leukaemic cells 
from patients (Birtwistle et al., 2008). Whilst inhibition of AKR1C3 resulted in enhanced 
HL60 cell sensitivity to differentiation stimuli, over-expression yielded more resistant cells, 
confirming AKR1C3 as a suppressor of cell differentiation and a novel therapeutic target in 
acute myeloid leukaemia (AML) (Desmond et al., 2003). The anti-differentiation effects of 
AKR1C3 were shown to rely on its ability to catalyse the reduction of prostaglandin (PG) D2 
to 11β-PGF2α, thus preventing the spontaneous generation of 15-deoxy-Δ
12,14
-PGJ2 (15d-
PGJ2) a reactive molecule with anti-tumour effects (Khanim et al., 2009, Desmond et al., 
2003). 
Later it was shown that the combination of medroxyprogesterone acetate (MPA), also an 
AKR1C3 inhibitor, and bezafibrate, a lipid-lowering drug, was active in promoting 
differentiation or apoptosis of multiple primary leukaemic cells confirming the therapeutic 
advantage of targeting this enzyme (Hayden et al., 2009, Tiziani et al., 2009, Khanim et al., 
2009, Fenton et al., 2003). This therapeutic approach has since then been used in a small scale 
clinical trial and shown to be efficient against AML in elderly and relapsed patients (Murray 
et al., 2010). 
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The research project presented in this thesis originates from the need to understand the role of 
AKR1C3 in normal physiology: how the enzyme functions in the context of a whole organism 
and how it is involved in leukaemogenesis. Most studies elucidating the function of AKR1C3 
derive from isolated primary or immortalised cell lines. Therefore, the objective of this study 
was to interrogate the function of AKR1C3 in mice, a commonly used model for mammalian 
physiology that can be genetically manipulated. The use of total and conditional knock-out 
mouse strains for the homologue of human AKR1C3 would be a key tool to understand the 
biology of the enzyme. Thus, the objectives of the study were: 
A) Identification and characterisation of the AKR1C3 homologue (PGD2 11β-
ketoreductase) in mice. 
B) Generation of transgenic mouse strains (knock-out; inducible knock-down) to 
ascertain the physiological role of AKR1C3 in a whole organism. 
C) Facilitate the study of the role of AKR1C3 in the homeostasis of several organs, 
particularly in haematological tissues.   
What follows is an introduction to the enzymes of the AKR superfamily, their known 
substrates and roles in human disease. Also, an overview of the synthesis and signaling by 
steroid hormones and prostaglandins is presented. 
3 
 
1.2 The aldo-keto reductase superfamily 
1.2.1 Overview 
The AKRs are a large superfamily of enzymes present in bacteria, fungi, protozoans, plants 
and animals. AKRs are small (approximately 320 amino-acid residues in size), usually 
monomeric, share a common tertiary structure and catalyse the reversible reduction of 
carbonyl groups to hydroxyl groups using NADH or NADPH as a co-factor (Figure 1) (Jez et 
al., 1997a). Despite these common features, AKRs metabolise a wide variety of substrates 
including sugars, steroids, prostaglandins, aldehydes and isoflavonoids and are therefore 
involved in a myriad of biological processes (Jez et al., 1997a, Seery et al., 1998, Jez and 
Penning, 2001, Hyndman et al., 2003). 
.  
Figure 1 - AKRs reduce carbonyl groups to hydroxyl groups. 
Currently there are over 150 proteins attributed to the AKR superfamily, subdivided into 15 
families according to their phylogeny. A comprehensive database of known AKR proteins is 
available at the AKR homepage (http://www.med.upenn.edu/akr/) (Hyndman et al., 2003). 
The AKR homepage database includes the amino-acid sequences of the known members and 
their respective enzymatic activities, available crystal structures, the rules of the nomenclature 
system, phylograms of the superfamily and other useful resources. Furthermore, the website 
contains instructions for the assignment of new sequences to the superfamily.  
1.2.2 Tertiary structure of AKR enzymes 
AKRs are widely distributed across the kingdoms of life but have a conserved three-
dimensional structure (Jez et al., 1997a). Upon folding, AKRs adopt a (α/β)8-barrel structure, 
as determined by X-ray crystallography (El-Kabbani et al., 1998, Hoog et al., 1994, Lovering 
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et al., 2004). Figure 2 shows an example, the AKR1C3 (α/β)8-barrel fold. This structure is 
composed of eight parallel β-strands alternating with eight α-helices running anti-parallelly, 
thus forming the structure of a barrel that encloses the catalytic pocket. Also, the structure 
contains three flexible protruding loops which vary greatly in sequence and size amongst the 
AKR superfamily (see alignment in Figure 4) 
 
Figure 2 - Tertiary structure of an aldo-keto reductase. 
Aldo-keto reductases (AKRs) have a conserved tertiary structure.  This crystal structure was obtained 
from the super-imposition of several crystal structures obtained for AKR1C3 in complex with PGD2 and 
NADP
+
. Eight β-strands alternate (purple) with eight α-helixes (red) forming a barrel-like structure 
referred to as (α/β)8-barrel fold. The barrel encloses a wide catalytic pocket where conserved residues 
(blue) bind to the cofactor NAD(P)H and substrate to perform the reaction. The three protruding loops 
on top of the structure (A-, B- and C-loop) are flexible and are believed to be responsible for substrate 
recognition (created by Dr J Ride and Dr N Davies, University of Birmingham, UK) 
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The crystal structures obtained in previous studies revealed a spatial conservation of four 
catalytic residues inside the pocket: Asp50, Tyr55, Lys84 and His117 (Jez et al., 1997a). 
These residues interact with NAD(P)H and substrate ( 
Figure 3) and Tyr55 acts as the proton donor for the reduction reaction (Petrash et al., 1994). 
Due to the conservation of these residues it is believed that the catalytic mechanism is strictly 
conserved across the AKR superfamily. 
Substrate specificity in AKRs is thought to be determined by the size and sequence of the 
three protruding loops (Jez et al., 1997a). However, each AKR can usually accommodate 
several types of molecules in their catalytic pocket hence their substrate promiscuity. It is 
likely that AKRs evolved from a common multifunctional ancestor and, after gene duplication 
and divergence, substrate specialization occurred by modification of the protruding loops 
whilst maintaining the (α/β)8-barrel structure and the general catalytic mechanism.  
 
 
 
Figure 3 - The AKR active site. 
The three-dimensional structures of all AKRs retain the same spatial relationship between the active-
site residues (Asp50, Tyr55, Lys84 and His117), the nicotinamide cofactor (shown in pink) and a water 
molecule, as shown in this stereo-view of the rat liver 3α-HSD/AKR1C9•NADP+ binary-complex active 
site (Jez et al., 1997a). 
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Figure 4 - Multiple sequence alignment of several members of the AKR superfamily. 
(opposite page) Multiple sequence alignment showing the location of α-helices, β-strands and the 
three protruding loops. B1, B2, H1 and H2 are β-sheets and α-helices not forming the core of the 
(α/β)8-barrel structure. Invariant residues are highlighted in pink (Jez et al., 1997a). 
1.2.3 Nomenclature and organization of the superfamily 
Initially, AKR enzymes were named after their enzymatic activity. However, due to their 
broad substrate preference this nomenclature system became somewhat confusing. For 
instance, one AKR was known as dihydrodiol dehydrogenase 2, bile acid-binding protein and 
3α-hydroxysteroid dehydrogenase type III while another related AKR was known as 
dihydrodiol dehydrogenase 1 and 20α (3α)-hydroxysteroid dehydrogenase. Furthermore, 
enzymes of other superfamilies, such as the short-chain dehydrogenase/reductases (SDR), 
showed overlapping activities with members of the AKR superfamily. Therefore, in 1997 a 
unified and systematic nomenclature system based on amino-acid sequence identity was 
adopted for the AKR superfamily (Jez et al., 1997b). All enzymes with a predicted (α/β)8-fold 
have the root name “AKR”, for aldo-keto reductase, followed by an Arabic numeral (1, 2, 
3…) designating the family, a letter (A, B, C…) designating the subfamily and an Arabic 
numeral designating a unique sequence (Figure 5). 
 
Figure 5 - Nomenclature system of the AKR superfamily. 
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Delineation of families and subfamilies is based on the amino-acid sequence identity of the 
proteins. Enzymes with >40% amino-acid identity are grouped in the same family. Currently, 
the sequence alignment has determined a total of 15 AKR families (AKR1-AKR15). Families 
can be further divided into subfamilies that group enzymes sharing >60% amino-acid identity. 
Presently, 11 of the 15 families are divided into multiple subfamilies. When the nomenclature 
was adopted the individual numbers were attributed arbitrarily amongst the known AKRs 
(AKR1A1, AKR1A2, and AKR1A3 are the aldehyde reductases from human, pig, and rat, 
respectively). New additions to a subfamily are numbered chronologically. Any two AKR 
sequences sharing more than 97% amino-acid identity are considered alleles of the same gene 
unless they are coded by different genes, in which case the 3’-untranslated region of the 
mRNA will be different, and/or have different substrate preferences. Members of the AKR2, 
AKR6 and AKR7 families have been shown to form multimers (Hyndman et al., 2003). For 
these cases the nomenclature also informs about the stoichiometry of the multimer. For 
example, AKR7A1 : AKR7A4 (1:3) would designate a tetramer of the composition indicated 
(Jez et al., 1997b). 
1.2.4 The AKR families 
A summary of the 15 AKR families is shown on Table 1. Presently, the AKR1 family is the 
largest, with 49 sequences found exclusively in animals (metazoans) with particular incidence 
in vertebrates. This family includes six subfamilies including the aldehyde reductases 
(AKR1A), aldose reductases (AKR1B), hydroxysteroid dehydrogenases (AKR1C, discussed 
in detail in section 1.3) and the Δ4-3-ketosteroid-5β-reductases (AKR1D). 
Enzymes of the AKR6 and AKR7 families are also present in vertebrates. The AKR6 
enzymes are part of the voltage-gated potassium (Kv) channel complexes as β-subunits 
(Tipparaju et al., 2008). These enzymes associate with the cytosolic portion of the channel 
and modulate its opening by using NADPH. The AKR7 enzymes are highly conserved in 
mammals and are responsible for the detoxification of a commonly ingested fungal toxin, 
aflatoxin (Knight et al., 1999). Both AKR6 and AKR7 enzymes form homo- or heterodimers. 
AKR enzymes are also found in plants, yeasts, filamentous fungus and protozoans where they 
are involved in a variety of synthetic pathways. 
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Table 1 - Summary of the AKR families 
Family Subfamilies 
Number  
of 
sequences 
Organisms Function Notes 
AKR1 
A 4 
human, rat, wild 
boar, mouse 
Aldehyde reductases; metabolism of 
neurotransmitters; detoxification; 
osmoregulation 
 
B 15 
human, rabbit, 
mouse, rat, chinese 
hamster, chicken 
Conversion of glucose to sorbitol; 
detoxification; retinoic acid synthesis; PGF 
synthase (PGH2 → PGF2α) in the adrenal 
gland 
Enzymes coded in a 
single gene cluster 
C 24 
human, rabbit, 
mouse, rat, bovine, 
frog, horse, 
macaque 
Hydroxysteroid dehydrogenases 
(androgens, estrogens, glucocorticoids and 
progestins); PGF synthase using PGH2, 
PGE2 and PGD2 as substrate; 
detoxyification 
Enzymes coded in a 
single gene cluster; 
implications in 
regulation of nuclear 
receptors 
D 3 human, rat, rabbit 
Δ4-3-ketosteroid-5β-reductases; bile acid 
synthesis and steroid hormone catabolism  
Reduce C=C bonds 
rather than carbonyl 
groups due to a modified 
catalytic pocket 
E 2 human, mouse 
Reduction of 1,5-anhydro-D-fructose, a 
glycogen breakdown product, to 1,5-
anhydro-D-glucitol 
Enzymes coded in the 
same gene cluster as 
AKR1C enzymes 
G 1 C. elegans unknown function 
 
AKR2 A-E 14 
Plants, yeasts, 
filamentous fungi, 
insects 
Sugar metabolism 
 
AKR3 A-F 13 
yeasts, filamentous 
fungi 
Metabolism of arabinose, fucose, galactose 
and xylose  
AKR4 A-C 24 plants 
Oxidation and reduction of a wide variety 
of substrates; stress-responsive enzymes  
AKR5 A-G 10 
bacteria, 
Trypanosoma 
bruce, Leishmania 
major 
Ascorbic acid synthesis in bacteria; PGF 
synthase (PGH2 → PGF2α) in Trypanosoma 
and Leishmania 
 
AKR6 A-C 18 
human, rat, rabbit, 
mouse, Xenopus 
laevis, Drosophila, 
plants 
β-subunits of voltage-gated potassium (Kv) 
channels; regulate the opening of the 
channel 
Catalytic tetrad is not 
conserved with His117  
replaced by an Asn 
residue 
AKR7 A 5 human, rat, mouse 
Detoxification of the fungal carcinogen 
aflatoxin  
Expressed in liver, 
stomach and kidney; 
form hetero- or 
homodimers 
AKR8-15 12 15 bacteria, yeasts 
reduction of carbonyl groups in toxic 
compounds generated by  oxidants and 
heavy metals; biosynthesis of secondary 
metabolites  
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Figure 6 - Unrooted phylogram of all known AKR proteins. 
Unrooted phylogram produced from the amino-acid sequence alignment of all known AKR proteins. 
Family AKR1 (bottom right side of phylogram) groups most of the known AKRs and is subdivided into 
6 subfamilies (AKR1A-AKR1G). Phylogram obtained from the AKR homepage 
(http://www.med.upenn.edu/akr/tree.shtml) (Hyndman et al., 2003). 
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1.3 AKR1C subfamily 
To date, enzymes of the AKR1C subfamily have been described exclusively in vertebrates 
and, apart from frog AKR1C10, are all found in mammalian species. AKR1C enzymes have 
been extensively studied for their ability to modify important signaling molecules (steroids 
and prostaglandins) thus affecting a plethora of processes in normal physiology and disease. 
Furthermore, AKR1C activity has been implicated in both activation and inactivation of toxic 
compounds (Jin and Penning, 2007). A detailed description of the subfamily, with particular 
incidence on the human isoforms, is presented in this section.  
1.3.1 AKR1C gene cluster and tissue expression 
Currently, 24 sequences have been attributed to the AKR1C subfamily all belonging to 
vertebrate species (Table 2). In these species, multiple AKR1C-coding genes have been found 
clustered in a single locus of their respective genomes. Due to the availability of sequenced 
and annotated genomes, both human and mouse AKR1C gene clusters are well described 
(Nishizawa et al., 2000, Vergnes et al., 2003).  
Figure 7 shows a scale representation of the human AKR1C gene cluster, located on the short 
arm of chromosome 10. The four AKR1C genes are coded in the same orientation, sit in close 
proximity, have similar gene organization with identical size and number of exons and high 
sequence similarity suggesting a recent history of gene duplication. Two additional AKR-
coding genes coded in the opposite orientation can be found in this cluster. AKR1CL1 is 
coded between AKR1C3 and AKR1C4 and slightly overlaps the latter. This gene has an 
identical exon-intron organization but is considered a pseudogene in the NCBI database. 
Nevertheless the predicted enzyme coded in this gene has 68% amino-acid identity with the 
four AKR1C isoforms and would belong to the same subfamily. The AKR1E2 gene (also 
known as AKR1CL2) codes a protein of the AKR1E subfamily highly expressed in the testis 
and homologous to murine AKR1E1 (Azuma et al., 2004).  
A similar AKR1C-gene cluster has been described in mouse chromosome 13, the syntenic 
region of the human gene cluster (Vergnes et al., 2003). Like the human locus, the mouse 
cluster harbors all genes coding for known mouse AKR1C enzymes plus AKR1E1 (mouse 
AKR1C enzymes detailed in section 1.4). Likewise, the AKR1C enzymes described in Table 
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2 from rat, bull, macaque and horse are coded in similarly organized gene clusters on their 
respective genomes. This genomic organization suggests a common ancestral locus in which 
the number of subsequent gene duplications varied as the different mammalian lineages 
radiated. 
Tissue expression of AKR1C genes 
Each human AKR1C gene has a specific tissue distribution. Figure 8 shows two independent 
measurements of AKR1C expression in human tissues (Penning et al., 2000, Nishizawa et al., 
2000). AKR1C1 is present in the heart, liver, adrenal gland, kidney, muscle, peripheral blood 
lymphocytes (PBL), uterus and testis. AKR1C2 is highly expressed in the liver, kidney and 
muscle but can also be detected in the heart, adrenal gland, lung and testis.  AKR1C3 is the 
most broadly distributed isoform, being most expressed in the kidney, muscle, mammary 
gland, prostate, PBLs and uterus and also, but to a lesser extent, in liver, lung, heart, adrenal 
gland, ovary and testis. Unlike the other isoforms, AKR1C4 expression is fairly restricted, 
with almost exclusive presence in the liver and some expression in the adrenal gland. The 
presence of AKR1C enzymes in tissues such as the adrenal gland, mammary gland, prostate, 
testis, uterus, PBLs and liver is related with their activities towards steroid hormones and 
prostaglandins or as detoxifying enzymes. 
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Table 2 - Described members of the AKR1C subfamily (adapted from the AKR homepage) 
AKR Known enzymatic activities Species Identity (relative to AKR1C1) 
1C1 
20α-HSD 
Homo sapiens 100% 
dihydrodiol dehydrogenase 1 
1C2 
3α-HSD type III 
Homo sapiens 97% dihydrodiol dehydrogenase 2 
bile acid binding protein 
1C3 
3α-HSD type II 
Homo sapiens 87% 
dihydrodiol dehydrogenase 3 
17β-HSD type V 
PGD2 11β-ketoreductase 
PGH2 9,11-endoperoxide reductase 
1C4 
3α-HSD type I 
Homo sapiens 82% dihydrodiol dehydrogenase 4 
chlordecone reductase 
1C5 
PGE2 9-ketoreductase 
Oryctolagus cuniculus 80% 
20α-HSD 
1C6 
Estradiol 17β-HSD 
Mus musculus 76% 
17β-HSD type V 
1C7 
PGH2 9,11-endoperoxide reductase 
Bos taurus 77% 
PGD2 11β-ketoreductase 
1C8 20α-HSD Rattus norvegicus 68% 
1C9 3α-HSD Rattus norvegicus 69% 
1C10 rho-crystalline Rana temporaria 60% 
1C11 
PGH2 9,11-endoperoxide reductase 
Bos taurus 78% 
PGD2 11β-ketoreductase 
1C12 unknown Mus musculus 68% 
1C13 unknown Mus musculus 66% 
1C14 unknown Mus musculus 68% 
1C15 unknown Rattus norvegicus 69% 
1C16 unknown Rattus norvegicus 68% 
1C17 unknown Rattus norvegicus 67% 
1C18 20α-HSD Mus musculus 85% 
1C19 3(20α)-HSD Mus musculus 72% 
1C20 dihydrodiol dehydrogenase Mus musculus 73% 
1C21 17α-HSD Mus musculus 73% 
1C23 17β(20α)-HSD Equus ferus 80% 
1C24 17β-HSD Rattus norvegicus 68% 
1C25 3(20)α-HSD Macaca fuscata 82% 
    
 HSD, hydroxysteroid dehydrogenase; PG, prostaglandin; Homo sapiens, human; Oryctolagus cuniculus, rabbit; Mus musculus, mouse; Bos 
taurus, bull; Rattus norvegicus, rat; Equus ferus, horse; Macaca fuscata, macaque; Rana temporaria, common frog. 
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Figure 7 - Structure of the AKR1C gene cluster on human chromosome 10. 
The four human AKR1C isoforms, AKR1C1, -1C2, -1C3 and -1C4, are coded in a gene cluster located 
on the short arm of chromosome 10. The four isoforms are coded in the same orientation and sit in 
close proximity (green boxes). Two additional AKR genes are coded in the same cluster but in reverse 
orientation. The protein coded in the AKR1E2 / AKR1CL2 gene (orange box) shares less than 60% 
amino-acid identity with the remaining AKR1C enzymes and belongs to the AKR1E subfamily. The 
AKR1CL1 gene (blue box) overlaps AKR1C4 and is described in the NCBI database as a 
pseudogene. However, in the Ensembl database AKR1CL1 is considered a protein-coding gene and 
the predicted enzyme has 68% amino-acid identity with the remaining human AKR1C isoforms. 
Diagram is drawn to scale and was based on the genomic map from the Ensembl database (Hubbard 
et al., 2009).  
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Figure 8 - Tissue-expression pattern of human AKR1C enzymes. 
A. Reverse-transcriptase PCR (RT-PCR) measurement of human AKR1C enzymes: AKR1C1 (20α-
HSD), AKR1C2 (bile acid binding protein; BABP), AKR1C3 (PGF synthase; PGFS) and AKR1C4 
(dihydrodiol dehydrogenase 4; DD4). GAPDH was used as loading control. PBL; peripheral blood 
lymphocytes. Adapted from (Nishizawa et al., 2000). B. Expression of the four AKR1C enzymes was 
measured in several human tissues using RT-PCR (18 cycles). Products were separated by gel 
electrophoresis, transferred to nitrocellulose and Southern-blot analysed using cDNA probes. Density 
of bands was quantified and normalized to β-actin band. Figure taken from (Penning et al., 2000).  
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1.3.2 Steroid hormone metabolism 
AKR1C enzymes were first described because of their hydroxysteroid dehydrogenase (HSD) 
activities. By reducing specific carbonyl groups, AKR1C enzymes can potentiate or inactivate 
steroid hormones in a tissue-specific manner and affect their local signaling impact. This 
modulatory property of AKR1C enzymes is shared with members of the short-chain 
dehydrogenase/reductase (SDR) family (Mizrachi and Auchus, 2009). 
Human AKR1C enzymes have a variety of ketosteroid reductase activities towards steroid 
hormones such as progesterone, androstenedione, estrone, 5α-dihydrotestosterone (5α-DHT) 
and deoxycorticosterone (DOC) (Figure 10). AKR1C1 acts predominately as a 20α-HSD but 
also as a 3β-HSD. AKR1C2 and -1C4 have been described as 3α-HSD while AKR1C3 has 
both 17β- and 20α-HSD activity (Penning and Drury, 2007, Penning and Byrns, 2009). 
Similar activities have been described in other non-human AKRs, as described in Table 2. 
Although AKR1C enzymes can also catalyse oxidation of hydroxysteroids in vitro it is 
believed that in vivo they function predominantly as reductases. This is supported by the fact 
that AKR1C enzymes have 1000-fold higher affinity for NADPH than NAD+ and, when 
over-expressed in COS-1 cells, perform exclusively ketosteroid reduction (Penning and 
Byrns, 2009). The physiological implications of these activities are discussed below, after a 
short introduction to steroidogenesis and steroid signaling.    
1.3.2.1 Steroid hormone synthesis pathway 
Steroid hormones are lipid-derived endocrine signaling molecules. De novo synthesis of 
steroid hormones occurs mainly in the testis, ovary and adrenal gland and, to a lesser extent, 
in brain, placenta and adipose tissue. Enzymes involved in steroidogenesis belong to the 
cytochrome P450 (CYP), SDR and AKR superfamilies (Baker, 2004, Nebert and Russell, 
2002, Sanderson, 2006). A scheme of the steroid hormone synthesis pathway is shown in 
Figure 9. In the initial step, cholesterol, the precursor for all steroid hormones, is converted to 
pregnenolone by CYP11A, an enzyme bound to the mitochondrial membrane and expressed 
exclusively in steroidogenic tissues. Pregnenolone is converted to the active steroid 
progesterone by the 3β-HSD, a membrane-bound enzyme of the SDR superfamily 
(SDR11E1). Pregnenolone and progesterone form the precursors for all other steroid 
hormones (Sanderson, 2006). 
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Unlike the gonads, the adrenal gland is a vital organ and is considered the most important 
steroidogenic tissue. Steroid 21-hydroxylase (CYP21A1) is exclusively expressed in the 
adrenal gland and is responsible for the synthesis of glucocorticoids (initiated by the 
conversion of 17α-OH-progesterone to 11-deoxycortisol) and mineralocorticoids (initiated by 
the conversion of progesterone to deoxycorticosterone). The active hormones aldosterone and 
corticosol are then produced by CYP11B2 and CYP11B1, respectively, which are also 
exclusively expressed in the adrenal gland (Sanderson, 2006).  
CYP17A1 has two distinct catalytic sites and has both 17α-hydroxylase activity, converting 
pregnenolone and progesterone to the respective 17α-OH forms, and a 17,20-lyase activity, 
converting the 17α-OH steroids to the weak androgens dehydroepiandrosterone (DHEA) and 
androstenedione. This enzyme is expressed in the adrenal gland, ovaries and testis.  
 
 
Figure 9 - Enzymes involved in the synthesis of adrenal and sex steroids. 
Cholesterol is the precursor of adrenal and sex steroids. Steroid hormone synthesis is carried out by 
enzymes of the cytochrome P450 (CYP), SDR and AKR superfamilies (Baker, 2004).  
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In the testis, CYP17A1 catalyses the production of the weak androgens DHEA and 
androstenedione. Androstenedione is then converted to testosterone, a potent androgen, by 
enzymes with 17β-HSD activity. Seven types of human 17β-HSD have been described: types 
1, 2, 3, 4, 5, 7 and 8 (Luu-The, 2001). Of these, 17β-HSD type 5 is AKR1C3 while the 
remaining enzymes belong to the SDR family. Both type 3 and type 5 (AKR1C3) are 
expressed in the testis where they have been implicated in testosterone production (Luu-The, 
2001). When released into the blood stream, testosterone reaches the peripheral tissues where 
it can be further metabolised. For instance, in the prostate, testosterone can be oxidized back 
to androstenedione by 17β-HSD type 2 or be locally converted to 5α-dihydrotestosterone (5α-
DHT), the most potent endogenous androgen, by 5α-reductases (Sanderson, 2006). Both 17β-
HSD enzymes act as molecular switches, either reducing or enhancing the potency of 
testosterone in a tissue-specific manner. 
In the ovaries, the aromatase (CYP19arom) converts androstenedione to estrone which is 
further converted to estradiol by 17β-HSD type 1, 5 (AKR1C3) and 7. Inactivation of 
estradiol, a potent estrogen, back to estrone is also mediated by 17β-HSD type 2 (Sanderson, 
2006). In addition, testosterone can be directly converted to estradiol by aromatase. 
Due to their lipophilic nature, steroid hormones are able to cross cellular membranes without 
the aid of transporters and spread through the body via the bloodstream. In the plasma, steroid 
hormones are mainly found associated with specific protein carriers such as the steroid 
hormone-binding globulin (SHBG) for testosterone and 17β-estradiol, or the corticosteroid-
binding globulin (CBG) for cortisol and progesterone (Andreassen, 2006). These carriers also 
assist in the tissue-specific endocytic uptake of steroid hormones. Steroid hormones can reach 
peripheral organs, enter the cells and interact with steroid hormone receptors to elicit a 
response. Also, in peripheral tissues, steroid hormones can be activated or inactivated by 
locally expressed enzymes, such as AKRs. 
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Figure 10 - Steroid hormone reductase activities of human AKR1C enzymes. 
Human AKR1C enzymes have multiple hydroxysteroid dehydrogenase (HSD) activities towards 
several steroid hormones. AKR1C1 is predominantly a 20α-HSD but can also act as a 3β-HSD. Both 
AKR1C2 and -1C4 have 3α-HSD activity whereas AKR1C3 has 20α- and 17β-HSD activities.  
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1.3.2.2 Nuclear receptors 
Steroid hormones elicit their effects in target tissues by activating steroid hormone receptors. 
These are intracellular ligand-activated transcription factors that belong to the nuclear 
receptor (NR) superfamily. Recently, steroid hormones have also been shown to signal via 
surface receptors of the G protein-coupled receptor family (Levin, 2009). 
NRs have only been found in animals (metazoans) where they regulate many processes in 
embryonic development and adult physiology, such as reproduction, metabolism, 
differentiation and homeostasis (Escriva et al., 2004). All NRs share a common tertiary 
structure and are grouped in six subfamilies based on their amino-acid sequence comparison, 
much like the AKR families (Table 3). Humans have 48 NRs but for almost half of these 
proteins no naturally occurring ligand is known. These NRs are termed “orphan receptors”.  
1.3.2.2.1 The NR family 
Table 3 shows a list of all known human NRs, their common name, their systematic name 
(reflecting their phylogeny) and known natural or synthetic ligands. Steroid hormone 
receptors are highlighted in orange: estrogen receptor (ERα and -β), androgen receptor (AR), 
progesterone receptor (PR), glucocorticoid receptor (GR) and mineralocorticoid receptor 
(MR). Retinoic acid receptors are highlighted in blue: RARα, -β and -γ; RORβ and RXRα, -β 
and -γ. Thyroid hormone receptors are highlighted in pink (TRα and -β). The vitamin D 
receptor is highlighted in purple (VDR). Peroxisome-proliferator activated receptors that bind 
fatty acids and eicosanoids like 15d-prostaglandin J2 and leukotriene are highlighted in green 
(PPARα, -β and -γ). Other nuclear receptors, such as the pregnane X receptor (PXR) and the 
constitutive androstane receptor (CAR) are activated by xenobiotics and elicit a detoxification 
response. For many NRs no natural or synthetic ligand is known.  
1.3.2.2.2 Mechanisms of nuclear receptor transcriptional activation 
There are three main mechanisms by which NRs are activated, bind to DNA and modulate 
transcription (Figure 11). Steroid hormone receptors, AR, ER, PR, GR and MR, are 
synthesised in an inactive form that is sequestered in the cytoplasm by heat-shock proteins 
(HSPs). Binding of steroid hormone causes a conformation change in the NR that leads to its 
dissociation from the HSP complex followed by translocation to the nucleus. In the nucleus, 
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the receptor binds to the response elements in the target gene promoter as a homodimer and, 
associated with co-activators, induces gene transcription (Glass and Ogawa, 2006). 
Heterodimeric NRs, such as TR, VDR, RAR, LXR and PPARs, are constitutively bound to 
the response elements in the DNA with their binding partner, RXR. In the absence of ligand, 
heterodimeric NRs associate with co-repressors that induce tightening of the chromatin 
structure in the promoter region, suppressing gene transcription. Ligand binding induces a 
conformation change in the NR leading to dissociation from the co-repressor complex and 
interaction with co-activator proteins that promotie gene transcription (Glass and Ogawa, 
2006). 
Several NRs are known to bind to DNA as monomers. Most of these monomeric NRs are 
“orphan receptors” as no ligand is known to activate them. It is speculated that such NRs can 
modulate transcription by changes in their expression or by post-translational modification, 
such as phosphorylation or SUMOylation, induced by other signaling pathways (Glass and 
Ogawa, 2006). Additionally, some NRs, such as GR, LXR and the PPARs, can repress gene 
expression in a ligand-dependent manner. This is usually the ligand-dependent transrepression 
of other transcription factors such as nuclear factor-κB (NF-κB). Unlike other forms of NR-
mediated action, ligand-dependent transrepression does not seem to require binding to 
response elements or dimerization (Glass and Ogawa, 2006, Straus et al., 2000). However, the 
detailed molecular mechanisms leading to transrepression are still poorly understood. 
In conclusion, NRs have a diverse array of functions that depend not only on the type of 
ligand that can activate them but also in which tissue they are present, which co-activators and 
co-repressors are expressed in the same cell type, the combined activity of other transcription 
factors and the presence of enzymes that modify the ligands.   
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Figure 11 - Mechanism of nuclear receptor DNA binding and transcription activation. 
Three main mechanisms by which NRs influence gene transcription. A: Steroid hormone receptors are 
produced in an inactive form and, in the absence of ligand, are sequestered in the cytoplasm by heat-
shock proteins (HSPs). Upon ligand binding, the receptor dissociates from the HSP proteins, 
translocates to the nucleus and binds the response elements in the DNA as a homodimer. B: NRs, 
such as the PPARs, LXR are constitutively bound to the DNA in a heterodimer with RXR. In the 
absence of ligand, these heterodimers are associated with co-repressors and repress gene 
transcription. Upon ligand binding the receptor changes conformation and associates with co-
activators and promotes gene transcription. C: Monomeric NRs are often “orphan receptors” as no 
ligand is known to activate them. These NRs might modulate transcription by post-translational 
modifications induced by other signaling pathways (Glass and Ogawa, 2006) 
23 
 
Table 3 - Human nuclear receptors. 
Name Nomenclature Ligands 
TRα   NR1A1   Thyroid hormones 
TRβ  NR1A2  Thyroid hormones 
RARα  NR1B1  All-trans retinoic acid 
RARβ  NR1B2  All-trans retinoic acid 
RARγ  NR1B3  All-trans retinoic acid 
PPARα  NR1C1  Fatty acids, leukotriene B4, fibrates 
PPARβ  NR1C2  Fatty acids 
PPARγ  NR1C3  Fatty acids, 15d-prostaglandin J2, thiazolidinediones 
Rev-erbα  NR1D1  Orphan 
Rev-erbβ  NR1D2  Orphan 
RORα  NR1F1  Cholesterol, cholesteryl sulfate 
RORβ  NR1F2  Retinoic acid 
RORγ  NR1F3  Orphan 
LXRα  NR1H3  Oxysterols, T0901317, GW3965 
LXRβ  NR1H2  Oxysterols, T0901317, GW3965 
FXRα  NR1H4  Bile acids, fexaramine 
FXRβ  NR1H5  Lanosterol 
VDR  NR1I1  Vitamin D, 1,25-dihydroxyvitamin D3 
PXR  NR1I2  Xenobiotics, 16α-cyanopregnenolone 
CAR  NR1I3  Xenobiotics, phenobarbital 
HNF4α  NR2A1  Orphan 
HNF4γ  NR2A2  Orphan 
RXRα  NR2B1  9-cis retinoic acid, all-trans retinoic acid 
RXRβ  NR2B2  9-cis retinoic acid, all-trans retinoic acid 
RXRγ  NR2B3  9-cis retinoic acid, all-trans retinoic acid 
TR2  NR2C1  Orphan 
TR4  NR2C2  Orphan 
TLL  NR2E2  Orphan 
PNR  NR2E3  Orphan 
COUP-TFI  NR2F1  Orphan 
COUP-TFII  NR2F2  Orphan 
EAR2  NR2F6  Orphan 
ERα  NR3A1  Estradiol-17β, tamoxifen, raloxifene 
ERβ  NR3A2  Estradiol-17β, various synthetic compounds 
ERRα NR3B1  Orphan 
ERRβ  NR3B2  DES, 4-OH tamoxifen 
ERRγ  NR3B3  DES, 4-OH tamoxifen 
GR  NR3C1  Cortisol, dexamethasone, RU486 
MR  NR3C2  Aldosterone, spirolactone 
PR  NR3C3  Progesterone, medroxyprogesterone acetate, RU486 
AR  NR3C4  Testosterone, 5α-DHT, flutamide 
NGFI-B  NR4A1  Orphan 
NURR1  NR4A2  Orphan 
NOR1  NR4A3  Orphan 
SF1  NR5A1  Orphan 
LRH-1  NR5A2  Orphan 
GCNF  NR6A1  Orphan 
DAX-1  NR0B1  Orphan 
SHP  NR0B2  Orphan  
   Adapted from (Germain et al., 2006)   
24 
 
1.3.2.3 Co-evolution of steroid modifying enzymes and steroid hormone receptors 
The colonization of land by animals led to the evolution of new organs and more complex 
developmental mechanisms. This required the specialization of several high-affinity steroid 
hormone receptors as well as steroid-activating and -inactivating enzymes in the SDR, CYP 
and AKR superfamilies that regulate ligand access to the receptors in a tissue-specific and 
cell-selective manner (Baker, 2004). This form of regulation, known as pre-receptor 
regulation, is important in adult physiology but is often subverted in pathophysiology, such as 
cancer. 
1.3.3 Androgen metabolism and prostate cancer 
Prostate cancer is the most common invasive cancer in men, as is breast cancer in women 
(Risbridger et al., 2010). Prostate cancer is a hormone-dependent tumour in which malignant 
cells express AR and require androgens to drive proliferation and survival (Mellado et al., 
2009) (Figure 12). Estrogens, although much less prevalent than androgens in the male body, 
also play a role in prostate cancer, through stimulation of ERα and ERβ.  
Figure 12 - Hormone interactions in prostate cancer cells. 
Androgens (testosterone, T, and 5α-DHT) and 
estrogens (estradiol, E) have implications in prostate 
cancer. In the prostate, T can be converted into the 
potent androgen 5α-DHT by 5α-reductases (SRD5A1 
and -5A2) and both stimulate AR that drives cancer 
proliferation. Aromatase (CYP19A1) can convert T to E 
that can stimulate both ERα and ERβ in the prostate. 
However, ERα and ERβ have opposing effects, with 
the former being pro-proliferative and the latter anti-
proliferative. Nevertheless, in the male body the 
predominant sex steroids and drivers of cancer 
progression are the androgens. Adapted from 
(Risbridger et al., 2010). 
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Initially, all prostate cancer patients are submitted to hormonal therapy, i. e., restriction of 
either androgen synthesis or AR activation (Risbridger et al., 2010). However, most patients 
will gradually develop resistance and the cancer progresses even in the absence of androgen 
signaling.  
Despite castration causing a drastic decrease in serum testosterone levels, steroid precursors 
from the adrenal gland can still be locally activated in the prostate, creating a pro-androgenic 
environment. One enzyme capable of local androgenesis is the type 5 17β-HSD, AKR1C3 
(Mellado et al., 2009, Risbridger et al., 2010).  
1.3.3.1 AKR1C enzymes in prostate androgen metabolism 
Both AKR1C2 and AKR1C3 are expressed in the prostate and modulate AR activation 
(Penning and Byrns, 2009, Rizner et al., 2003, Penning et al., 2006) (Figure 13). Some studies 
have also reported the presence of AKR1C1 in this tissue (Bauman et al., 2006, Ji et al., 
2007). AKR1C3, with its 17β-HSD activity, locally converts androstenedione to testosterone 
which can be further converted to 5α-DHT by the 5α-reductases. Through its 3α-HSD 
activity, AKR1C2 inactivates 5α-DHT by converting it to the weak androgen 3α-
androstanediol (Penning and Byrns, 2009). Due to its unique 3β-HSD activity, AKR1C1 
converts 5α-DHT to 3β-androstanediol, an ERβ ligand. Therefore, in the prostate, AKR1C3 
activity induces cell proliferation via AR activation whereas AKR1C1 and -1C2 counteract it 
by catabolizing 5α-DHT. Furthermore, by producing an ERβ ligand, AKR1C1 generates an 
anti-proliferative stimulus (Figure 12 and Figure 13).  
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Figure 13 - Role of human AKR1C enzymes in prostate androgen metabolism and pre-receptor 
regulation. 
Prostate or adrenal gland-derived androstenedione is converted to testosterone (potent androgen) by 
AKR1C3 which is further converted to 5α-DHT (very potent androgen) by 5α-reductases. 
Subsequently, 5α-DHT can be inactivated by conversion to 3α-androstanediol (weak androgen) by 
AKR1C2 or 3β-androstanediol (potent estrogen) by AKR1C1 (Penning and Byrns, 2009). 
1.3.3.2 AKR1C enzymes in prostate cancer 
In a recent study, the gene expression pattern of 33 metastatic androgen-independent prostate 
cancer samples was compared with that of 22 primary androgen-dependent prostate cancer 
samples using Affymetrix microarrays (Stanbrough et al., 2006). Besides increased AR 
expression in the androgen-independent cancers, several enzymes involved in androgen 
synthesis and catabolism were found upregulated including 5α-reductase and AKR1C3. The 
over-expression of AKR1C3 in androgen-independent prostate cancer was also confirmed by 
immunohistochemistry in agreement with previous studies (Fung et al., 2006, Penning et al., 
2006). Both AKR1C1 and -1C2, involved in the inactivation of 5α-DHT, were also found 
upregulated in the androgen-independent tumours. However, the magnitude of amplification 
of these enzymes (3.1- and 3.4-fold, respectively) was less than that of AKR1C3 (5.3-fold). 
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The authors concluded that there was an overall increase in enzymes promoting local 
androgen synthesis. 
In another study, paired comparisons were made between primary prostate cancer samples 
and benign tissue from 13 patients to determine differences in 5α-DHT synthesis and 
catabolism (Ji et al., 2007, Ji et al., 2003). Expression levels of AKR1C1 and/or AKR1C2 
were found to be significantly decreased in 11 out of 13 tumour samples relative to their 
benign counterparts. In addition, levels of 5α-DHT were increased in all cancer samples by an 
average magnitude of 42%. Radio-labeled 5α-DHT was predominantly reduced to 3α- or 3β-
androstanediol in benign samples. Such catabolism of 5α-DHT was reduced in the tumour 
samples in a manner that correlated with AKR1C and -1C2 loss. Finally, over-expression of 
AKR1C1 and AKR1C2, but not AKR1C3, resulted in increased 5α-DHT turn-over and 
inhibited the 5α-DHT-stimulated proliferation of PC-3 and LAPC-4 cells (prostate cancer cell 
line). These results suggest that loss of AKR1C1 and -1C2 in prostate cancer promotes cell 
proliferation by reducing 5α-DHT inactivation. 
These and other studies have implicated the human AKR1C enzymes in pre-receptor 
regulation of AR in prostate cancer. In addition the pro-proliferative activity of AKR1C3 in 
prostate disease has rendered this enzyme a potential therapeutic target. 
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1.3.4 Estrogen metabolism and breast cancer 
Like prostate cancer, breast cancer is a sex steroid-driven malignancy. Estrogen activation of 
ERα is the most important stimulus driving proliferation and survival in breast cancer cells 
(Figure 14) (Risbridger et al., 2010). Estrogens also activate ERβ which counter-acts ERα 
activity by suppressing cell proliferation. However, expression of ERα in breast cancer is 
generally higher than ERβ, hence the proliferative outcome (Kurebayashi et al., 2000). 
Progesterone signaling via PR has both pro- and anti-proliferative actions in breast cancer, 
although in the long-term, these effects seem to be predominantly inhibitory (Purmonen et al., 
2008). Androgen signaling, via AR, also counter-acts the ERα-mediated pro-proliferative 
signaling. However, in the female body, the levels of estrogens are higher than those of 
androgens and thus AR activation in breast cancer is reduced. 
 
Figure 14 - Hormone interactions in breast cancer cells. 
Activation of ERα by estrogens (E) is considered the main 
proliferative and survival stimulus in breast cancer cells. 
ERα activation also causes upregulation of PR which can 
have both pro- and anti-proliferative effects when activated 
by progesterone. Activation of ERβ has anti-proliferative 
effects but this receptor is less expressed than ER α in 
breast cancer cells. Androgens (T, DHT) also play a role in 
breast cancer via AR activation, an anti-proliferative signal. 
Some evidence suggests AR activation inhibits PR activity, 
but this remains uncertain. Figure from (Risbridger et al., 
2010) 
 
 
As with prostate cancer patients, hormone therapy is the first treatment against breast cancer. 
However, the majority of patients also tend to relapse and develop an estrogen-independent 
disease, mainly by developing an intra-tumoural estrogen synthesis pathway. 
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1.3.4.1 AKR1C enzymes in estrogen and progesterone metabolism in breast cancer 
AKR1C3 is expressed in normal breast tissue and has consistently been found upregulated in 
breast cancer samples where it is associated with poor prognosis (Jansson et al., 2006, Lin et 
al., 2004). The two predominant activities of AKR1C3, 17β-HSD and 20α-HSD, create an 
advantageous pro-estrogenic environment in the malignant cells that stimulates cell 
proliferation. Firstly, the concerted activities of AKR1C3 and CYP19 aromatase convert 
androstenedione to the potent ER ligands estrone and 17β-estradiol (Figure 15). In addition, 
AKR1C3 can inactivate progesterone to its 20α-hydroxyl form thus preventing PR activation 
(Penning and Byrns, 2009). Artificial over-expression of AKR1C3 in MCF-7, a breast cancer 
cell line, resulted in enhanced testosterone and 17β-estradiol production from androstanediol 
and estrone, respectively, and progesterone inactivation. Furthermore, transfected cells had 
increased proliferation in response to estrone and 17β-estradiol, strongly implying AKR1C3 
in breast cancer development (Byrns et al., 2010). 
A paired comparison between 24 breast cancer samples and adjacent normal tissue revealed 
that AKR1C1 expression was substantially (>5-fold) decreased in 13 of those samples (Ji et 
al., 2004). In 6 of those 13 samples, AKR1C2 was also substantially down-regulated whereas 
AKR1C3 levels were unchanged in all samples. The authors speculate that this change in 
AKR1C expression results in modified progesterone metabolism advantageous for cancer 
progression. 
In addition to breast cancer, de-regulation of AKR1C expression has been observed in other 
estrogen-driven malignancies as  both AKR1C1 and -1C3 were found predominantly over-
expressed in endometrial (Rizner et al., 2006) and ovarian cancer samples (Smuc et al., 2009). 
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Figure 15 - Role of AKR1C3 in breast estrogen metabolism and pre-receptor regulation. 
The combined actions of AKR1C3 and CYP19 aromatase generate a pro-estrogenic environment in 
the breast. Aromatase converts androstenedione (weak androgen) to estrone (potent estrogen) which 
is further converted to 17β-estradiol (very potent estrogen) by AKR1C3. Alternatively, androstenedione 
can be converted to testosterone (potent androgen) by AKR1C3 which is then reduced to 17β-
estradiol by aromatase. Figure from (Penning and Byrns, 2009)  
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1.3.5 Deoxycorticosterone metabolism in the kidney 
AKR1C3 also exerts 20α-HSD activity towards deoxycorticosterone (DOC), a potent ligand 
for the mineralocorticoid receptor (MR). Highly expressed in the renal tubules, MR activity 
promotes the reabsorption of sodium in the urine affecting the water and salt balance of the 
body. AKR1C3 converts DOC to 20α-hydroxy-DOC, an inactive mineralocorticoid, thus 
preventing MR activation (Sharma et al., 2006). Expression of both AKR1C3 and MR was 
detected in renal duct epithelial cells suggesting a role in pre-receptor regulation. 
Furthermore, AKR1C3 over-expression has been detected in renal cell carcinoma, papillary 
urothelial carcinoma, and Wilms’ tumour (renal malignancies) (Azzarello et al., 2009). 
1.3.6 Prostaglandin metabolism 
In addition to steroids, AKR1C enzymes catalyse the ketoreduction of prostaglandins (PGs), 
lipid-derived signaling molecules involved in a variety of physiological processes such as 
inflammation, vaso and bronchoconstriction, platelet aggregation, regulation of sleep and cell 
proliferation (Funk, 2001). Prostaglandins belong to a larger group of molecules known as 
eicosanoids which are fatty acid-derived and have 20 carbons in their structure (eicosa- Greek 
for twenty). The molecular structures and sub-classes of eicosanoids are shown in  
 
 
Figure 16. 
The prostaglandins, PGE2, PGD2, PGF2α and PGI2 (prostacyclin), together with thromboxane 
(TXA2), compose the prostanoids. Prostanoids are characterised by a 5-carbon ring 
(cyclopentane ring) at the extremity of the structure, and result from the peroxidation and 
cyclization of the arachidonic acid (AA), a fatty acid derived from membrane phospholipids. 
The modifications in the cyclopentane ring vary amongst the prostanoids conferring them 
with different stabilities and signaling properties. 
Prostaglandins can not be stored in cells and are synthesised de novo in response to external 
stimuli. The amount and type of prostaglandins produced depends on the enzymatic 
machinery expressed in a given cell-type and, once released into the extra-cellular space, 
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these short-lived molecules interact locally with surface receptors of neighbouring cells to 
elicit autocrine and paracrine signaling effects. 
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Figure 16 - Molecular structure and classification of the eicosanoids. 
All eicosanoids are derived from C20 fatty acid precursors (eicosa- Greek for twenty), usually 
arachidonic acid (AA). Oxygenation of AA is required for the synthesis of epoxyeicosatrienoic acids 
(EETs) and hydroxyeicosatetraenoic acids (HETEs). Peroxidation and cyclization of AA is required for 
the synthesis of prostanoids, a class of eicosanoids that includes prostaglandins (PGE2, PGF2α, PGD2 
and prostacyclin) and thromboxane A2.  
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1.3.6.1 Prostaglandin synthesis pathway 
1.3.6.1.1 Eicosanoid synthesis begins with cPLA2 
Eicosanoids are short-lived molecules and can not be stored in cells. Instead, de novo 
eicosanoid synthesis occurs in cells after stimulation by a variety of agents such as cytokines, 
hormones, growth factors, neurotransmitters, mitogens, mechanical trauma, antigens and 
endotoxins (Clark et al., 1995, Hirabayashi et al., 2004) (Figure 19). These stimuli induce the 
translocation of cytosolic phospholipase A2 (cPLA2) from the cytoplasm to the perinuclear 
membranes. Once anchored to the lipid bilayer, cPLA2 hydrolyzes the sn-2 bond of membrane 
phospholipids, releasing arachidonic acid (AA), the eicosanoid precursor (Schaloske and 
Dennis, 2006). Activation of cPLA2 is the rate-limiting step in eicosanoid synthesis and is 
followed by a cascade of reactions leading to the production of active prostanoids.  
1.3.6.1.2 Cyclooxygenases initiate the production of prostanoids 
Released AA can be further metabolised by cyclooxygenases (COX), lipoxygenases (LOX) 
and P450 epoxygenases to generate prostanoids, hydroxyeicosatetraenoic acids (HETEs) or 
epoxyeicosatrienoic acids (EETs), respectively ( 
 
 
Figure 16). The most well characterised LOX metabolites are the leukotrienes, which promote 
accumulation of leukocytes during inflammation and their adhesion to vessel endothelial cells 
(Peters-Golden and Henderson, 2007). Epoxygenase-derived EETs are another class of 
eicosanoids and have been described as potent regulators of systemic blood pressure 
(Capdevila et al., 2007). 
Mechanism of COX activity 
COXs are the rate-limiting enzymes in prostanoid biosynthesis and important clinical targets. 
Like cPLA2, COXs are membrane-bound enzymes located at the perinuclear membranes and 
perform the cyclization of AA into prostaglandin H2 (PGH2), the unstable prostanoid 
precursor. This is a two-step reaction consisting of a cyclooxygenation followed by a 
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peroxidation resulting in the sequential conversion of AA to PGG2 and PGG2 to PGH2, 
respectively ( 
(a)
(b)
 
Figure 17). Therefore COX enzymes are bifunctional with two distinct catalytic sites. 
Nevertheless the two reactions are functionally coupled as the synthesis of PGH2 in the 
peroxidation site results in the reactivation of the cyclooxygenase site (Simmons et al., 2004, 
Chandrasekharan and Simmons, 2004, Dubois et al., 1998). 
Constitutive COX and inducible COX 
All vertebrates have two COX isoforms, COX-1 and COX-2, coded by two different genes. 
Despite sharing 60 to 75% amino-acid identity and performing the same reaction, each 
isoform has a particular physiological function. COX-1 is the constitutive cyclooxygenase and 
is expressed ubiquitously in tissues at relatively similar levels suggesting it works as a 
provider of prostanoids for homeostatic regulation (Dubois et al., 1998). It has particular 
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importance in the protection of gastric mucosa, kidney blood flow and is the only COX 
expressed in platelets where prostanoids regulate blood clotting (Simon, 1999).  
COX-2 expression is normally undetected in most tissues but can be quickly induced by a 
variety of pro-inflammatory factors such as interleukin-1 (IL-1), tumour necrosis factor-α 
(TNF-α), interferon-γ (INFγ), lipopolysaccharides (LPS), hormones and even prostanoids 
(Tanabe and Tohnai, 2002). This upregulation provides the cell with a sudden boost in 
prostanoid production. The effect is transient since COX-2 mRNA is naturally unstable and is 
quickly degraded upon termination of stimulus (Wu, 1996, Morita, 2002). 
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(a)
(b)
 
Figure 17 - Catalytic mechanism of cyclooxygenases 
A Cross-section of a COX monomer in the lumen of the endoplasmic reticulum. The COX active site 
(Cx) faces the membrane where the binding (Mb) domain anchors the enzyme. The peroxidation site 
(Px) faces the lumen of the organelle. B COXs perform two consecutive reactions. AA is 
cyclooxygenated to PGG2 followed by peroxidation yielding PGH2. Figure adapted from 
(Chandrasekharan and Simmons, 2004). 
 
Upregulation of COX-2 is particularly important in inflammation where prostanoid signaling 
plays a key role (Suleyman et al., 2007). In addition, COX-2 expression is often increased in a 
variety of tumours including lung (Patel and Chiplunkar, 2007), prostate (Aparicio Gallego et 
al., 2007), liver (Breinig et al., 2007), cervical (Young et al., 2008) and colon (Eisinger et al., 
2007).  
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COX inhibition with NSAIDs 
COXs are inhibited by synthetic molecules known as non-steroidal anti-inflammatory drugs 
(NSAIDs). These analgesic and anti-inflammatory drugs rely on their eicosanoid-depressing 
properties to exert function and include acetylsalicylate (aspirin), indomethacin, ibuprofen 
and acetaminophen (Paracetamol) (Blobaum and Marnett, 2007). However, in addition to 
their anti-inflammatory actions, NSAIDs have undesired side-effects such as the development 
of gastric ulcers, kidney malfunction and reduced blood clotting. 
Conventional NSAIDs inhibit both COX isoforms. Development of COX-2 specific inhibitors 
is possible and can be achieved by targeting small differences in the catalytic site. Examples 
of these COX-2 specific inhibitors are Celecoxib and Rofecoxib (Simon, 1999).  
1.3.6.1.3 PGH2 is converted to the five primary prostanoids 
PGH2 is a highly unstable and short-lived precursor that is quickly converted to one of the 
five primary prostanoids: PGE2, PGD2, PGF2α, PGI2 or TXA2 (Figure 19). These conversions 
are catalysed by the PGE synthases (PGES), PGD synthases (PGDS), PGF synthases (PGFS), 
PGI synthase (PGIS) and TXA synthase (TXAS), respectively. 
TXAS, a member of the CYP enzyme family, is highly expressed in platelets, the major site 
of TXA2 production (Nakahata, 2008). TXAS null mice have normal haemopoiesis but its 
platelets fail to aggregate, resulting in prolonged bleeding time (Yu et al., 2004). In 
agreement, certain mutations in human TXAS are associated with bleeding disorders (Wang 
and Kulmacz, 2002, Shen and Tai, 1998). PGIS, which is also a CYP enzyme, is most highly 
expressed in endothelial and smooth muscle cells (Wu and Liou, 2005). PGIS null mice show 
increased blood pressure due to thicker vascular walls and interstitial fibrosis, especially in 
the kidneys (Yokoyama et al., 2002). 
Three PGE2 synthases have been described. Two are membrane bound (mPGES-1 and 
mPGES-2) and one is cytosolic (cPGES). Both mPGES-2 and cPGES are constitutively 
expressed and produce basal levels of PGE2 whilst mPGES-1 is induced by pro-inflammatory 
agents (Park et al., 2006). These enzymes are widely distributed in the tissues and are 
involved in production of PGE2 for a variety of physiological processes, particularly 
inflammation and pain. 
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PGF2α synthases 
Several PGFS have been identified in humans and other animals. However, unlike the other 
primary prostanoids, PGF2α can be synthesised via reduction of PGH2, PGE2 or PGD2 (in the 
latter case the product is the stereoisomer 9α,11β-PGF2α) (Watanabe, 2002). Most enzymes 
with PGFS activity are members of the AKR superfamily (Figure 18). This is the case for 
human AKR1C3, which has both PGH2 9-,11-endoperoxide and PGD2 11β-ketoreductase 
activity (Suzuki-Yamamoto et al., 1999). Similar activities were found in bovine AKR1C7 
(lung) and -1C11 (liver) (Suzuki et al., 1999, Watanabe et al., 1985). AKR1B1 from human, 
AKR1B3 and -1B7 from mouse and AKR5A1 and -5A2 from trypanosome use exclusively 
PGH2 as substrate (Kabututu et al., 2009, Kubata et al., 2000) whereas rabbit AKR1C5 is the 
only described PGE2 9-ketoreductase (Wintergalen et al., 1995). Recently, an enzyme 
belonging to the thioredoxin-like superfamily from human and its mouse homologue were 
shown to have PGFS activity using PGH2 as substrate (Moriuchi et al., 2008). The PGD2 11β-
ketoreductase activity of AKR1C3 is essential in regulating leukaemic cell survival and is 
discussed in section 1.3.7. 
PGD2 synthases 
There are two PGDS each from a distinct protein family, exemplifying a case of convergent 
evolution (Urade and Eguchi, 2002). Haemopoietic-type PGDS (H-PGDS) belongs to the 
glutathione S-transferases (GST) family of enzymes and requires glutathione (GSH) as a co-
factor. H-PGDS is responsible for PGD2 synthesis in haemopoietic tissues such as mast cells, 
antigen presenting cells and Th2 cells (Kanaoka and Urade, 2003). Two studies revealed that 
H-PGDS knock-out mice have an augmented inflammatory response characterised by high 
pro-inflammatory cytokine production and lymphocyte proliferation (Rajakariar et al., 2007, 
Trivedi et al., 2006). H-PGDS was also shown to have protective effects in colon cancer. A 
mouse strain prone to develop intestinal adenomas, the Apc 
Min/+
 mice, was crossed with either 
transgenic or knock-out H-PGDS mice. Overexpression of H-PGDS resulted in ~80% less 
carcinomas whereas absence of H-PGDS caused a ~50% increase in carcinoma incidence 
(Park et al., 2007). 
Lipocalin-type PGDS (L-PGDS) also known as brain-type PGDS is a member of the lipocalin 
family. These are secreted proteins such as β-lactoglobulin and plasma retinol-binding protein 
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that bind and transport small lipophilic ligands. Interestingly, L-PGDS was the first member 
of the lipocalin family to be recognized as an enzyme. Structurally this activity relies on 
residue Cys65 as mutations of this amino-acid result in complete loss of PGDS activity 
(Ragolia et al., 2007). This cysteine residue is not present in other lipocalin proteins. It is also 
a target for N-glycosylation, another unprecedented characteristic of a lipocalin family 
member (Ragolia et al., 2007). L-PGDS is a small (~ 30 kDa) monomeric enzyme that 
requires free sulfhydril compounds (β-mercaptoethanol, GSH, dithiothreitol, cysteine or 
cysteamine) for the reaction. The enzyme is synthesised with an N-terminal signal peptide 
that targets the protein for secretion. L-PGDS has been found in body fluids such as 
cerebrospinal fluid (CSF), seminal plasma, blood plasma and ocular fluids. The protein still 
retains its lipocalin functions and binds with high affinity to small lipophilic molecules such 
as retinoic acid, bilirubin, biliverdin and thyroid hormone (Urade and Eguchi, 2002). L-PGDS 
expression can be modulated by steroid hormones since the upstream region of its gene 
contains thyroid hormone and glucocorticoid response elements (Leone et al., 2002).  
Alternatively L-PGDS can be found inside cells. In oligodendrocytes and arachnoid cells of 
rat brain, L-PGDS has been observed in the ER and perinuclear membranes, co-localizing 
with COX enzymes. Therefore it is proposed that L-PGDS is a bifunctional protein acting as a 
lipocalin when secreted and as a prostaglandin synthase when intracellular (Urade and 
Hayaishi, 2000a, Urade and Eguchi, 2002, Leone et al., 2002). In knock-out studies, mice 
lacking L-PGDS showed reduced reaction to tactile pain (allodynia) caused by injection of 
pain producing substances such as PGE2 and bicuculline. This lack of sensitivity was rescued 
by co-injection with femtogram amounts of PGD2 (Eguchi et al., 1999).  
Because L-PGDS protein levels are increased in fluids of type 2 diabetic patients (Hirawa et 
al., 2001), a study was undertaken to elucidate its role in insulin resistance. L-PGDS knock-
out mice were shown to have higher glucose intolerance and insulin resistance when fed a 
high-fat diet. This was accompanied by larger adipocytes, increased nephropathy and aortic 
thickening when fed a high-fat diet (Ragolia et al., 2003). Also, addition of L-PGDS to the 
culture media inhibited cell proliferation and induced glucose uptake in rat vascular smooth 
muscle cells, suggesting a role in sugar metabolism and possibly the development of diabetes 
(Ragolia et al., 2008, Ragolia et al., 2004). 
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Figure 18 - PGF synthases 
Enzymes producing PGF2α or the stereoisomer 9α,11β-PGF2α are considered PGF synthases. Three 
routes lead to PGF2α: 9-,11-endoperoxide reduction of PGH2; 9-ketoreduction of PGE2 or 11β-
ketoreduction of PGD2. The names of AKR enzymes with known PGFS activities are shown. Figure 
from (Kabututu et al., 2009).  
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Figure 19 - Prostanoid synthesis and actions. 
Prostanoid synthesis is induced by external stimuli such that induce the translocation of cytosolic phospholipase 
A2 (cPLA2) from the cytoplasm to the perinuclear membranes, where it catalyses the release of arachidonic acid 
(AA) from membrane phospholipids. Then, membrane-bound cyclooxygenases (COX-1 or COX-2) perform the 
cyclization and peroxidation of free AA into PGH2. COX activity can be blocked by NSAIDs such as aspirin or 
indomethacin. The terminal synthases PGES, PGDS, PGFS, PGIS and TxS then convert PGH2 to PGE2, PGD2, 
PGF2α, PGI2 (prostacyclin) or TXA2 (thromboxane). Newly synthesised prostanoids cross the cell membrane either 
by diffusion through the lipid bilayer or through the generic prostaglandin transporter (PGT). Prostanoids exert 
their effects in neighbouring cells via surface G protein-coupled receptors. TXA2 signals via TP to promote platelet 
aggregation and smooth-muscle cell constriction while PGI2 signals via IP to counter-act TXA2 signaling. PGF2α 
interacts with FP in uterine smooth muscle cells and induces contraction leading to parturition. PGD2 exerts 
multiple effects via DP1, such as activation of lung epithelial cells, and DP2 (CRTH2). PGE2 signals via four 
receptors, EP1-EP4, and is involved in a variety of processes such as bone resorption, fever generation, 
fertilization and pain response. Alternatively, some prostanoids resulting from spontaneous dehydration of PGE2 
and PGD2 can signal intracellularly by activating nuclear receptors such as PPARγ. Figure from (Funk, 2001). 
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1.3.6.2 Transport 
Once synthesised in the cytosol, prostanoids have to cross the cell membrane to reach the 
extracellular space and exert signaling effects. Most prostanoids can exit cells by slowly 
diffusing across the membrane (Schuster, 2002). Nevertheless, active prostaglandin 
transporters have been described. The rat prostaglandin transporter (PGT) was first 
characterised in 1995 (Kanai et al., 1995), followed by the human (Lu et al., 1996) and mouse 
(Pucci et al., 1999) homologues. These transporters bind to the five primary prostanoids with 
identical affinities and mediate both influx and efflux via a lactate exchange mechanism 
(Schuster, 2002). Transporters of other protein families have also been shown to transport 
prostanoids, but unlike PGT, these seem to have less affinity and transport other types of 
eicosanoids as well (Schuster, 2002).  
1.3.6.3 Signaling 
Once secreted, prostanoids exert their effects in neighbouring cells by activating surface G-
protein-coupled receptors (GPCRs). The end-result of prostanoid signaling depends on which 
types of receptors are expressed by cells near the site of synthesis (Figure 19). The several 
prostanoid receptors have a relatively high sequence homology, suggesting a common 
ancestral prostanoid receptor (Figure 20) (Bos et al., 2004). 
 
Figure 20 - Phylogenetic tree of 
primary prostanoid receptors. 
The different prostanoid 
receptors and their associated 
G-proteins. The histamine H1 
receptor is shown as 
reference. Figure from (Bos et 
al., 2004).  
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The receptors are named after their respective prostanoid ligands. TXA2 binds to TP; PGI2 
binds to IP; PGF2α binds to FP; PGD2 binds to DP1 and DP2 (also named CRTH2; not shown 
in phylogram) and PGE2 binds EP1, EP2, EP3 and EP4. Also, although each receptor has 
highest affinity for their cognate prostanoids significant cross-reactivity with other 
prostanoids also occurs (Breyer et al., 2001). Prostanoid receptors can be subdivided into 
three groups, depending on what type of G-protein they normally associate with. The relaxant 
receptors EP2, DP1, IP and EP4 activate Gs which stimulates cyclic AMP (cAMP) production 
to exert signaling. The contractile receptors EP1, TP and FP activate Gq protein that causes an 
increase in intracellular calcium. The EP3 isoforms signal via Gi proteins resulting in 
decreased cAMP levels. Nevertheless, the G-protein associated to the receptors may differ 
according to cell types (Bos et al., 2004). 
FP 
Levels of PGF2α increase immediately before parturition in gestational tissues, plasma, 
amnion fluids and urine leading to uterus contraction and consequently to birth. Also, PGF2α 
levels increase in plasma, urine and lymph causing luteolysis at the end of the oestrous cycle 
in ruminants (Unezaki et al., 1996). Broncho and vasoconstriction have also been associated 
with PGF2α signaling (Seibert et al., 1987). The upstream region of the FP gene contains 
estrogen and progesterone response elements linking yet again PGF2α and reproductive 
physiology (Abramovitz et al., 1994, Olson et al., 2003). FP-null mice develop normally but, 
when pregnant, fail to induce parturition at term (Sugimoto et al., 1997). 
DP1 and DP2/CRTH2 
High levels of PGD2 can be detected in the cerebrospinal fluid, spleen, bone marrow and 
during inflammation (Ujihara et al., 1988a, Ujihara et al., 1988b). Functions include 
mediation of pain perception, induction of sleep, inhibition of platelet aggregation, 
vasodilation, bronchoconstriction and mediation of inflammation as a chemotractor for Th2 
cells, eosinophils and basophils (Kostenis and Ulven, 2006). Tissue resident mast cells release 
large amounts of PGD2 upon stimulation (Schratl et al., 2007). 
DP1 is expressed in haematological and non-haematological tissues. Activation of DP results 
in stimulation of adenylyl cyclase (AC) and consequent increase in intracellular cAMP levels 
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(Figure 21). This induces platelet aggregation, bronchodilation and vasodilation as well as 
suppressing activation and/or migration of T cells, eosinophils, basophils, dendritic cells and 
fibroblasts (Kostenis and Ulven, 2006). This suggests that DP1 has an anti-inflammatory role. 
However, this notion was challenged by the phenotype of the DP1-null mice. When lungs of 
wild type mice were challenged with an allergen an increase in inflammatory cell infiltration 
was observed (mainly eosinophils and lymphocytes) accompanied by an increase in 
inflammatory cytokines (IL-4, IL-13 and IL-5). All these effects were abolished in DP-/- mice 
suggesting an important role in inducing allergic inflammation (Matsuoka et al., 2000). 
Indeed, a single-nucleotide polymorphism reducing DP transcription efficiency is associated 
with lower asthma susceptibility in humans (Oguma et al., 2004). 
DP2 was cloned and characterised in 1999. Although still a member of the GPCR 
superfamily, the receptor had higher sequence homology with the subgroup of 
chemoattractant receptors than with the other prostanoid receptors (Abe et al., 1999, Xue et 
al., 2005). DP2 is a promoter of chemotaxis of Th2 cells where it is highly expressed and is 
also named chemoattractant receptor homologous molecule expressed in Th2 cells (CRTH2). 
DP2 is otherwise known as CD294, a cell surface marker that allows distinction between Th2 
and Th1 cells. High expression of DP2 is found in haematological cells (Th2, eosinophils and 
basophils) but also in osteoblasts, brain, heart, stomach, adrenal gland and liver (Kostenis and 
Ulven, 2006). Stimulation of DP2 causes decrease in cAMP (by inhibiting AC) and 
mobilization of Ca
2+
 from ER stores (Figure 21). The increase of PGD2 at the inflammatory 
micro-environment attracts Th2 cells, eosinophils and basophils via DP2. For this reason DP2 
has been linked to pro-inflammatory signaling (Kostenis and Ulven, 2006, Nagata and Hirai, 
2003). Injection of allergens in mice skin results in increased local PGD2 production and 
recruitment of H-PGDS positive cells (lymphocytes, neutrophils, eosinophils and basophils). 
This effect is abrogated by either H-PGDS or CRTH2 specific inhibitors. Concordantly, DP2 
null mice show impaired allergic response to the same stimulus (Satoh et al., 2006). These 
studies relating PGD2 and allergy have instigated an interest in the development of new drugs 
that can block PGD2 synthesis and/or signaling as a means of treating chronic allergic 
conditions. 
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Figure 21 - Downstream signaling of the PGD2 receptors DP1 and DP2/CRTH2 
DP2/CRTH2 inhibits adenylyl cyclase (AC) through Gi proteins; this inhibition leads to a decrease of 
intracellular cAMP levels. Gi activation also stimulates PLCβ, which generate diacylglycerol (DAG) and 
inositol trisphosphate (IP3) that mobilizes Ca
2+
 from endoplasmic-reticulum stores. CRTH2 also 
signals through arrestin proteins in a G-protein-independent fashion. It is possible but not yet proven 
that arrestin recruitment might also lead to G-protein-independent MAP-kinase activation. Together, 
activation of various CRTH2 signaling pathways leads to immune-cell activation. The responses of 
immune cells that are elicited by CRTH2 activation are listed below the individual cells, and the nature 
of the response is indicated by green arrows. The DP receptor stimulates AC through Gs proteins and 
increases intracellular cAMP levels which, in immune cells, is generally linked to inhibition of cell 
functions. The consequences on immune cells of DP activation are indicated by orange arrows. On a 
cellular level, DP and CRTH2 can be regarded as antagonistic receptors: CRTH2 mediates pro-
inflammatory and pro-stimulatory effects and DP limits CRTH2 activation upon exposure to PGD2. 
Figure from (Kostenis and Ulven, 2006). 
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1.3.6.4 Cyclopentenone prostaglandins 
In addition to the primary prostanoids, another group of bioactive prostaglandins has 
important roles in physiology – the cyclopentenone prostaglandins. These prostaglandins 
result from spontaneous dehydration within the cyclopentane ring of PGE2 and PGD2 (Figure 
22). In aqueous solution, PGE2 gives rise to PGA2 whilst PGD2 gives rise to the J-series 
prostaglandins, with 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2) as the end product. The non-enzymatic 
process of PGD2 dehydration is accelerated by albumin (Straus and Glass, 2001). These 
prostaglandins are characterised by the presence of α,β-unsaturated carbonyl groups in their 
structure that contain highly-reactive electrophilic centres. PGA2 has one electrophilic centre 
while 15d-PGJ2 has two. The electrophilic centers react with free sulfhydryl groups of 
cysteine residues present in glutathione (GSH) or cellular proteins, covalently binding the 
prostaglandin to it (Straus and Glass, 2001). 
 
Figure 22 - Formation of cyclopentenone prostaglandins. 
Formation of cyclopentenone prostaglandins via dehydration in the cyclopentane ring of PGE2 (A) and 
PGD2 (B) into PGA2 and 15-deoxy-Δ
12,14
-PGJ2 (15d-PGJ2), respectively. Formation of 15d-PGJ2 
involves a sequence of non-enzymatic dehydration steps. Asterisks indicate the positions of the 
reactive electrophilic carbon atoms. Figure adapted from (Straus and Glass, 2001). 
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Intracellular generation of cyclopentenone prostaglandins affects important cellular pathways. 
GSH is a ubiquitous cellular molecule required for redox stability, correct protein folding and 
protection from cytotoxins. The cyclopentenone prostaglandin-GSH conjugate is excreted 
protecting the cell from the electrophilic carbons but can result in GSH depletion and 
induction of oxidative stress (Uchida and Shibata, 2008).  
Recently it was found that PGA2 binds to the ligand-binding domain of the nuclear orphan 
receptor 1 (NOR1), leading to its activation. Consistently, splenocytes from mice 
overexpressing NOR1 were more sensitive to PGA2-induced apoptosis (Kagaya et al., 2005). 
However, these actions were only observed with high PGA2 doses. The question still remains 
wheter PGA2 is generated in vivo in quantities required to exert these effects. 
 
 
Figure 23 - Targets and biological functions of 15d-PGJ2. 
Figure from (Uchida and Shibata, 2008) 
15d-PGJ2 has several cellular targets 
Unlike PGA2, significant levels of 15d-PGJ2 have been measured in vivo, particularly during 
inflammation (Giri et al., 2004, Rajakariar et al., 2007, Trivedi et al., 2006) and several 
biological targets have been identified (Figure 23). Intracellular accumulation of 15d-PGJ2 
affects important cellular pathways. GSH is a ubiquitous cellular molecule required for redox 
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stability, correct protein folding and protection from cytotoxins. The cyclopentenone 
prostaglandin-GSH conjugate is excreted protecting the cell from the electrophilic carbons but 
can result in GSH depletion and induction of oxidative stress (Uchida and Shibata, 2008). In 
addition, 15d-PGJ2 also induces the expression of enzymes involved in antioxidant response 
(Uchida and Shibata, 2008). This is achieved by covalently binding to and activating redox 
sensitive transcription factors such as activator protein 1 (AP-1), NF-E2 related factors (Nrf2), 
hypoxia inducible factor (HIF) and signal transducers and activators of transcription (STAT) 
(Kim and Surh, 2006). 
A major target of 15d-PGJ2 conjugation is the cytoskeletal component β-actin (Gayarre et al., 
2006). Disruption of cytoskeleton by 15d-PGJ2 results in morphological changes and also 
induces cellular stress. Also, 15d-PGJ2 was shown to inhibit the ubiquitin proteasome system, 
affecting the normal turn-over of cellular proteins (Uchida and Shibata, 2008). In addition, 
some pro-apoptotic and anti-proliferative effects of 15d-PGJ2 are related to its ability to 
activate the tumours-suppresors ataxia telangiectasia mutated (ATM) and p53 (Uchida and 
Shibata, 2008). 
In 1995 two groups independently reported that 15d-PGJ2 is a high-affinity ligand and trans-
activator of the nuclear receptor PPARγ, inducing adipocyte differentiation of mesenchymal 
stem cells (Kliewer et al., 1995, Forman et al., 1995). In leukocytes, activation of PPARγ also 
suppresses production of pro-inflammatory cytokines (Herlong and Scott, 2006). In the 
initiation phase of inflammation PGE2 and PGD2 are the prevalent COX products but levels of 
15d-PGJ2 increase during the resolution phase, suggests it may function as a feedback 
regulator of the inflammatory process (Gilroy et al., 1999). Indeed 15d-PGJ2 represses pro-
inflammatory gene expression in activated macrophages such as the inducible NO synthase 
(iNOS) and TNFα (Uchida and Shibata, 2008). These effects are only partially dependent on 
PPARγ activation suggesting 15d-PGJ2 is interfering with other proteins.  
The transcription factor nuclear factor-κB (NF-κB) is an important regulator of inflammation. 
In resting cells NF-κB is kept sequestered in the cytoplasm bound to its inhibitory protein 
IκB. Inflammatory stimuli activate the IκB kinase (IKK) which phosphorylates IκB and 
targets it for degradation. This releases NF-κB allowing it to translocate to the nucleus where 
it activates pro-inflammatory and pro-proliferative genes. Activation of NF-κB is inhibited by 
15d-PGJ2 in three crucial steps (Thomas et al., 2005, Straus et al., 2000). Firstly, 15d-PGJ2 
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conjugates to IKK and inhibits its kinase activity over IκB, therefore silencing the pathway 
between stimuli and NF-κB activation. Secondly, 15d-PGJ2 can conjugate to NF-κB directly 
preventing it from binding DNA and activating transcription. Finally, 15d-PGJ2 activation of 
PPARγ leads to transrepression of NF-κB target genes (Straus et al., 2000). Since COX-2, the 
source of inflammatory prostaglandins, is an NF-κB target gene, 15d-PGJ2 repression seems 
to work as a negative feedback signal to downregulate inflammatory prostaglandin 
production, such as PGE2 and PGD2. The anti-inflammatory properties of 15d-PGJ2 contrast 
with the pro-inflammatory properties of PGD2, mediated mainly by surface receptors 
(Herlong and Scott, 2006).  
NF-κB activity is found augmented in many malignancies such as myeloid and lymphoid 
leukaemia leading to apoptosis resistance and increased proliferation (Cilloni et al., 2007). In 
vitro treatment of leukemic cells with 15d-PGJ2 leads to differentiation and/or cell death 
partially by activation of PPARγ (pro-differenetiation) and NF-κB inactivation (anti-
proliferative) (Giri et al., 2004, Thomas et al., 2005, Ray et al., 2006, Shin et al., 2009). 
In summary, spontaneous dehydration of PGD2 yields 15d-PGJ2, a highly reactive 
prostaglandin with anti-proliferative, pro-differentiation, pro-apoptotic and oxidative 
properties. This cyclopentenone prostaglandin has been shown to have anti-tumour effects 
and inducing its accumulation in cancer cells is of therapeutical interest. 
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1.3.6.5 The isoprostane pathway 
In the early 1990s a new non-enzymatic pathway was discovered for prostaglandin synthesis 
that circumvents the need for COXs. Isoprostanes (IsoP) are prostaglandin isomers that result 
from the free radical-mediated oxidation of arachidonic acid (Morrow et al., 1992). IsoPs with 
prostaglandin-like ring structures can be found in vivo. These are isomers of PGE2 (E2-IsoP), 
PGD2 (D2-IsoP) and PGF2α (F2α-IsoP). Additionaly, D2-IsoP and E2-IsoP can give rise to 
cyclopentenone IsoPs, J2-IsoP and A2-IsoP, respectively (Figure 24). Importantly, IsoPs can 
be detected in vivo even in the presence of COX inhibitors, an observation that challenges the 
concept behind current anti-inflammatory drugs (Musiek et al., 2005). 
Although F2α/E2/D2-IsoPs have been reported to interact with prostanoid receptors, conversion 
to prostaglandins is possible (Musiek et al., 2005). In a buffered solution at physiological pH, 
E2-IsoP undergoes spontaneous time-dependent epimerization to form PGE2. Because this is a 
non-enzymatic reaction the product is a racemic mixture of PGE2 isomers (Gao et al., 2003). 
Similarly, racemic PGD2 and PGE2 mixtures have been identified in rat livers after oxidant 
injury, even in the presence of COX inhibitors. Since this alternative route for prostaglandin 
synthesis can bypass COXs and terminal synthases it is important to consider it when 
analysing the impact of enzyme inhibitors in any system (Musiek et al., 2005, Gao et al., 
2003, Morrow et al., 1990). 
Figure 24 - Formation of cyclopentenone 
IsoP 
The arachidonate endoperoxide 
intermediate can undergo reduction 
(facilitated by high local concentrations of 
GSH or α-tocopherol) to form stable F2-
IsoP. Alternatively,when the reducing 
conditions of the cell are depleted, the 
endoperoxide can undergo isomerization to 
form E2- and D2-IsoP, which spontaneously 
dehydrate to yield electrophilic A2- and J2-
IsoP, also known as cyclopentenone IsoP. 
(Musiek et al., 2005) 
.
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1.3.7 Prostaglandin metabolism and leukaemia 
Leukaemias (from Greek leukos- white, -aema, blood) are cancers of the blood, characterised 
by the abnormal accumulation of immature haemopoietic cells. In normal physiology, 
haemopoiesis is the process by which bone-marrow haemopoietic stem cells give rise to the 
different blood cell types (Figure 25). This is a tightly regulated and dynamic process that 
responds to physiological needs. For instance, more neutrophils will be generated during an 
infection and more red blood cells will be produced in low oxygen conditions. Haemopoiesis 
is regulated by a variety of internal and external signals, such as growth factors, hormones and 
cytokines (Figure 25). De-regulated proliferation of immature cells due to malignant 
transformation results in disrupted haemopoiesis, eventually leading to impaired blood 
functions and severe, often lethal, complications.   
Leukaemias are classified as acute or chronic depending upon wheter the disease progresses 
rapidly (weeks or months) or slowly (several months or years). Leukaemias are further 
classified according to the lineage giving rise to the disease: lymphoblastic or myeloid. 
Therefore, the main types of leukaemia are acute myeloid leukaemia (AML), chronic myeloid 
leukaemia (CML), acute lymphoblastic leukaemia (ALL) and chronic lymphoblastic 
leukaemia (CLL) (Hoffbrand et al., 2006). In addition, solid tumours of lymphoid origin often 
arise in peripheral lymph nodes. These are termed lymphomas and include Hodgkin’s 
lymphoma, B-cell lymphomas (such as Burkitt’s lymphoma) and T-cell lymphomas, amongst 
other types (Hoffbrand et al., 2006). 
Targeting leukaemia 
Patients with leukaemia are normally submitted to a chemotherapy regimen and, in some 
cases, bone-marrow transplant is used to replace the malignant stem cells with normal 
haemopoietic stem cells. Some subtypes of leukaemia are characterised by the presence of 
recurrent lesions such as mutations or chromosome translocations that can be targeted as 
adjuvant therapies. 
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Figure 25 - Haemopoiesis and its growth factors 
The bone-marrow pluripotent haemopoietic stem cell gives rise to a myeloid precursor (CFU-GEMM), 
a lymphoid stem cell or the natural killer (NK) cell precursor. The myeloid precursor gives rise to the 
erythroid (E) lineage for red blood cells, megakaryocytic (Meg) lineage for platelets, the granulocyte-
monocyte (GM) lineage for macrophages and neutrophils, the eosinophil (Eo) and basophil (Ba) 
lineages. The lymphoid stem cell gives rise to B and T lymphocytes. Figure from (Kufe, 2003). 
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For instance, CML is characterised by the translocation t(9;22)(q34;q11), between 
chromosomes 9 and 22, yielding the Philadelphia chromosome. The translocation results in a 
gene fusion, conjoining the 5’ exons of the BCR gene with the 3’ exons of the c-ABL proto-
oncogene. The resulting fusion protein has an increased tyrosine kinase activity relative to 
normal ABL that confers the cells with a proliferative advantage. The tyrosine kinase 
inhibitor Imatinib (Glivec) blocks BCR-ABL activity and, after 3 to 6 months of 
administration, causes a marked tumour decrease in the bone-marrow of nearly all CML 
patients. Imatinib is sufficient to keep the disease in check but eventually some patients 
develop mutations in the BCR-ABL protein rendering them resistant to the drug (Hoffbrand et 
al., 2006). 
The translocation t(15;17)(q22;q21) also creates a fusion gene between the PML gene in 
chromosome 15 and the nuclear receptor RARα gene in chromosome 17. This lesion 
characterises a subtype of AML known as acute promyelocytic leukaemia (APL) (Koken et 
al., 1994). Wild-type RARα is activated by retinoic acid and heterodimerizes with RXR to 
promote cell differentiation. However, the PML-RAR fusion protein forms homodimers 
preventing association with RXR. The presence of this dominant-negative form of RARα 
results in the suppression of cell differentiation. Patients with PML-RAR fusion respond to 
high doses of all-trans retinoic acid (ATRA) which induces differentiation of the abnormal 
cells resulting in improved prognosis (Hoffbrand et al., 2006). 
These are a few examples of molecular lesions being targeted in leukaemia. However, 
identification of new molecular targets that prevent proliferation and/or induce differentiation 
is essential for the development of new therapies. 
AKR1C3 in leukaemia 
Compounds such as NSAIDs (aspirin and indomethacin) and steroids (medroxyprogesterone 
acetate and 17β-estradiol) were shown to potentiate the ATRA-induced differentiation of HL-
60, a model of AML (Bunce et al., 1996, Bunce et al., 1994). The pro-differentiation effect of 
NSAIDs and steroids was later attributed to the inhibition of AKR1C3 (Mills et al., 1998). In 
primary AML samples AKR1C3 is the most highly expressed isoform, with 100- and 1000-
fold higher mRNA levels than AKR1C1 and -1C2, respectively ( 
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Figure 26) (Birtwistle et al., 2009).  Predominant expression of AKR1C3 is also the case in 
commonly used AML immortalised cell lines KG1a, HL-60 and NB4 and in non-malignant 
proliferating CD34
+ve
 cells, a population that includes the haemopoietic stem cells (Birtwistle 
et al., 2009). 
In agreement with the inhibitor studies, artificial over-expression of AKR1C3 in HL-60 
resulted in reduced sensitivity to ATRA-induced differentiation  (Figure 27) (Desmond et al., 
2003) while specific AKR1C3 knock-down in K562 cells using short hairpin RNA (shRNA) 
resulted in erythroid differentiation (Birtwistle et al., 2009) confirming the anti-differentiative 
role of AKR1C3 in leukaemic cells. 
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Figure 26 - Expression of AKR1C isoforms in leukemic cell lines and AML samples. 
Expression of AKR1C1, -1C2 and -1C3 measured by Taqman QRT-PCR and is shown relative to 
GAPDH levels. Expression was measured in 213 primary AML samples, normal human CD34
+ve
 cells 
and commonly used leukaemic cell lines: KG1a (AML), K562 (CML), HL-60 (AML), NB4 (APL) and 
U937 (histiocytic lymphoma) (Birtwistle et al., 2009). 
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Suppression of differentiation by AKR1C3 was not due to steroid hormone reduction as these 
substrates did not affect the ATRA-induced differentiation of HL-60 (Desmond et al., 2003). 
Instead, both PGD2 and its dehydration product PGJ2 mimicked the AKR1C3 inhibitors in 
promoting HL-60 differentiation (Desmond et al., 2003). These prostaglandins were also 
shown to have anti-neoplastic effects against a panel of leukemic cell lines (Tsao et al., 1986). 
In addition, the bone-marrow, which is the malignant stem cell niche, is a PGD2-rich 
environment (Ujihara et al., 1988b) suggesting that AKR1C3 protects the cells from 
endogenously generated 15d-PGJ2. 
The anti-neoplastic activity of PGD2 is in part conducted by PPARγ activation, suggesting 
that the spontaneous generation of the ligand 15d-PGJ2 occurs inside the cells (Desmond et 
al., 2003). Indeed it was shown that in myeloid leukaemic cell lines PPARγ activation with 
synthetic ligands, such as rosiglitazone, suppresses cell growth (Asou et al., 1999). It is likely 
that 15d-PGJ2 targets several other cellular processes that promote cell differentiation and 
suppress growth. 
These findings have positioned AKR1C3 activity as a regulator of differentiation in myeloid 
leukaemia and, possibly, other forms of leukaemia (Figure 28). By converting PGD2 to 11β-
PGF2α, AKR1C3 prevents the spontaneous generation of 15d-PGJ2, thus protecting the cells 
from an endgoneous anti-proliferative stimulus. 
The identification of AKR1C3 as a molecular target has led to the development of therapies 
that inhibit the enzyme in order to induce differentiation or death of malignant cells. 
Combination of medroxyprogesterone acetate (MPA), an AKR1C inhibitor, and bezafibrate 
(BEZ), a lipid-lowering drug and PPAR agonist, showed anti-leukaemic activity against AML 
cell lines and primary samples by increasing endogenous 15d-PGJ2 levels (Khanim et al., 
2009). BEZ induced the generation of ROS and, consequently, the generation of PGD2 via the 
isoprostane pathway while MPA prevented its conversion to 11β-PGF2α, resulting in 
accumulated 15d-PGJ2. The combined actions of BEZ and MPA caused GSH-depletion, 
PPARγ activation and NF-κB inhibition resulting in growth arrest, apoptosis and 
differentiation of malignant cells but not of normal myeloid progenitors. Moreover, BEZ and 
MPA were shown to have a consistent impact on the metabolism of three AML cell lines 
(KG1a, K562 and HL-60) mediated by generation of ROS (Tiziani et al., 2009). 
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Theses studies led to the application of BEZ and MPA in a small-scale clinical trial with 
elderly AML sufferers who are too frail to undergo intense chemotherapy (Murray et al., 
2010). The drug combination showed no haematological toxicity and  4 out of 15 patients 
who took the trial drugs for more than 4 weeks showed improved haemopoiesis. The results 
are promising since a non-toxic therapy was able to reestablish haemopoietic function in 
elderly AML patients and could be used as an alternative to chemotherapy. Dose-escalation of 
BEZ and MPA followed by randomized trials are the author’s suggestions for the future. 
Treatment of B-cell CLL (Hayden et al., 2009) and Burkitt’s lymphoma (Fenton et al., 2003) 
with BEZ and MPA has also been shown to repress cell proliferation and induce apoptosis, 
suggesting the treatment can be applied to other types of leukaemia. 
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Figure 27 - AKR1C3 overexpression results in increased resistance to ATRA-induced cell differentiation. 
A: analyses of CD11b expression. Top panel, wt-HL-60 ( ) and pcDNA3.1:HL-60
AKR1C3
 cells ( ) were 
treated for 5 days with the doses of ATRA shown and were analysed for expression of the 
differentiation-associated surface marker CD11b using FACS. Data are the mean ± SE of three 
experiments. Middle panel, MSCV:HL-60 ( ) and MSCV:HL-60
AKR1C3
 cells ( ) were treated for 5 days 
with the doses of ATRA shown and were analysed for expression of the differentiation-associated 
surface marker CD11b using FACS. Data are the mean ± SE of six experiments. Bottom panel, 
MSCV:HL-60 ( ) and MSCV:HL-60
AKR1C3
 cells ( ) were treated for 5 days with the doses of ATRA 
shown, and the actual numbers of cells expressing CD11b were determined from the data from the 
middle panel and the mean total numbers of cells/culture (x10
4
) for the same six experiments. B: 
analyses of cell morphology. Jenner-Giemsa-stained cytospin preparations of MSCV:HL-60 and 
MSCV:HL-60
AKR1C3
 cells, treated in parallel for 5 days with the doses of ATRA shown. HL-60 
neutrophil maturation is characterised by the development of pleiomorphic and, occasionally, fully 
lobed nuclei. The images show greater differentiation by ATRA-treated MSCV:HL-60 cells compared 
with MSCV:HL-60
AKR1C3
 cells (Desmond et al., 2003). 
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Figure 28 - Model for the role of AKR1C3 in preventing cell differentiation in leukaemia. 
Prostaglandin D2 (PGD2) can be taken up from the extracellular medium or be produced intracellularly 
by the cyclooxygenase (COX) pathway. When accumulated in cells, PGD2 suffers a series of 
spontaneous dehydration steps to generate 15d-PGJ2, a reactive prostaglandin with anti-neoplastic 
properties. In cells, 15d-PGJ2 interferes with several signaling pathways such as trans-activation of 
PPARγ, inhibition of NF-κB and generation of reactive oxygen species (ROS). Altogether, these 
effects promote cell differentiation and growth arrest. AKR1C3 prevents the generation of 15d-PGJ2 by 
converting PGD2 into 11β-PGF2α. This activity protects the cells from the anti-neoplastic effects of 15d-
PGJ2. 
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1.4 Mouse AKR1C enzymes 
Despite impressive advancements, the understanding of how AKR1C enzymes function in 
normal physiology and carcinogenesis is limited to studies using isolated cells. This is in part 
due to the absence of animal models, particularly transgenic ones, which can inform about the 
role of AKR1C enzymes in a whole organism. In this aspect, mice are ideal models. 
Mice are the most widely-used mammalian model to study the developmental and physiologic 
role of gene products. The generation of the first genetically modified mouse in 1982 sparked 
the development of techniques to alter the murine genome allowing researchers to study the 
function of genes and create models for human diseases. Mouse embryonic stem cells can be 
genetically manipulated so that a specific gene is ablated or over-expressed. The manipulated 
cells are injected into blastocysts and implanted in pseudo-pregnant mice where they develop 
into chimeric animals that can later be used to derive homozygously altered mouse strains.  
Transgenic mice have been a powerful tool to assert the role of certain genes in cancer. For 
instance, mice over-expressing the fusion protein PML-RARα developed acute promyelocytic 
leukaemia (Wojiski et al., 2009) whilst mice lacking the tumour-suppressor p53 are more 
sensitive to carcinogens (Yamamoto et al., 2000). Therefore, we aimed to use a transgenic 
mouse model approach to study the role of AKR1C3 in leukaemia and other types of cancer. 
1.4.1 The murine AKR1C locus 
In 2002, a gene cluster harboring all murine AKR1C genes was described on mouse 
chromosome 13 ( Figure 29) (Vergnes et al., 2003). The eight coded proteins share an average 
of 70% amino-acid sequence identity, though some enzymes, like AKR1C12 and AKR1C13, 
are 92% identical whilst others are relatively different, like AKR1C12 and AKR1C20 with 
merely 60% identity. Although part of the same subfamily, no murine AKR1C enzyme shares 
a particularly high sequence homology with a human enzyme. The average sequence identity 
between mouse and human isoforms is 70%. The most similar isoform to AKR1C3 is 
AKR1C6 with 74% identity. 
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Figure 29 - Structure of the AKR1C locus on mouse chromosome 13. 
Eight AKR1C-coding genes are located in the gene cluster on mouse chromosome 13. Akr1c14, -
1c13, -1c19, -1c6 and -1c21 are coded in the plus orientation and Akr1c18, -1c12 and -1c20 are 
coded in the minus orientation. In addition, a gene coding for an enzyme of the AKR1E subfamily 
(Akr1e1) is present in the minus orientation. The eight AKR1C genes have identical number and size 
of exons. Diagram is drawn to scale and was based on the genomic map from the Ensembl database 
(Hubbard et al., 2009). 
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1.4.2 Known mouse AKR1C functions 
AKR1C6 
AKR1C6 was first cloned from mouse liver in 1995 and found to be active against steroid 
hormones and xenobiotic compounds (Deyashiki et al., 1995). Both 17β-HSD activity 
towards androgens and estrogens and 20α-HSD activity towards progesterone were described. 
AKR1C12 and AKR1C13 
When a murine haemopoietic progenitor cell line (EML) was induced to differentiate into the 
myeloid lineage by a combination of IL-3 and ATRA, AKR1C12 was identified as a highly 
upregulated gene (Du et al., 2000). High AKR1C12 expression was also found in murine 
promyelocytic cell lines, suggesting this AKR may be involved in myelopoiesis. AKR1C12, 
together with AKR1C13, was also cloned from a mouse stomach cDNA library (Ikeda et al., 
1999). Both AKRs were predominantly expressed in the stomach, liver and ileum and the 
authors speculate about a possible role in dietary xenobiotic metabolism. Also, both enzymes 
were found to be inactive or poorly active towards prostaglandins and steroid hormones 
(Ikeda et al., 1999, Endo et al., 2006). 
AKR1C14 
The Akr1c14 gene was identified when the mouse AKR1C cluster was described (Vergnes et 
al., 2003). Since then, no studies have attempted to elucidate its substrate preferences or 
physiological role. The known enzyme most similar to AKR1C14 is rat AKR1C9 (87% 
identity), a 3α-HSD active against androgens (Cooper et al., 2007). 
AKR1C18 
In rat, the inactivation of progesterone in the ovaries is mediated by a 20α-HSD later renamed 
AKR1C8 (Miura et al., 1994). In 1999, using a probe against AKR1C8, the murine 
homologue was cloned from a mouse ovary cDNA library and named AKR1C18 (Maho 
Ishida, 1999). AKR1C18 has 93% amino-acid sequence identity with its rat homologue and 
was found to be expressed in the ovaries, uterus and placenta during the late stages of 
gestation. Of all murine AKR1C isoforms, AKR1C18 is the only enzyme to have been 
targeted in a mouse transgenic model (Piekorz et al., 2005). Mice lacking AKR1C18 
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developed normally and had apparent normal adult physiology. However, during pregnancy, 
AKR1C18-deficient females sustained high levels of progesterone even at the end of gestation 
resulting in delayed parturition. This study strongly suggests an anti-progestin role for 
AKR1C18 important at the term of pregnancy. 
AKR1C19 and AKR1C20 
Like AKR1C14, both AKR1C19 and AKR1C20 were firstly described upon the discovery of 
the murine AKR1C locus (Vergnes et al., 2003). A later study using recombinant purified 
AKR1C19 showed that the enzyme was inactive towards prostaglandins and steroid hormones 
(Ishikura et al., 2005). Similarly, recombinant AKR1C20 showed poor 3α-HSD activity but 
the preference for prostaglandins was not measured (Matsumoto et al., 2006). 
AKR1C21 
While AKR1C21 was also described for the first time by Vergnes et al., the subsequent 
description of this enzyme has been much more extensive. AKR1C21 and a variant with 5 
amino-acid substitutions were cloned from mouse kidney RNA (Ishikura et al., 2004). Both 
variants efficiently reduced 3- and 17-ketosteroids, including 5α-DHT. AKR1C21 was 
expressed almost exclusively in the kidney. Interestingly, the variant form was only detected 
in the kidney of female mice. A later study revealed that AKR1C21 has a rare 17α-HSD 
activity, converting androstenedione to epitestosterone (17α-Hydroxy-4-androsten-3-one) 
rather than testosterone (17β-Hydroxy-4-androsten-3-one) (Bellemare et al., 2005). This study 
also showed that AKR1C21 converts DHEA, androstanedione and androsterone to the 
respective 17α-hydroxyil forms and that the enzyme is highly expressed in mouse kidneys. 
Crystal structure and site-directed mutagenesis analysis revealed that the stereospecificity of 
AKR1C21 is attributed to the key residues Lys31 (Faucher et al., 2007), Gly225, Gly226 
(Dhagat et al., 2009) and Tyr224 (Dhagat et al., 2010) 
A murine AKR1C3 homologue? 
Comparison of human and mouse AKR1C enzymes reveals no particularly conserved 
sequences that would suggest functional homology. In terms of sequence identity, the mouse 
isoforms more closely related to AKR1C3 are AKR1C6 (74%) and AKR1C18 (73%). 
However, at the beginning of this project it was not known if any of these enzymes catalyse 
65 
 
the 11β-ketoreduction of PGD2 or have any other common substrates with AKR1C3. 
Interestingly, both AKR1C7 and AKR1C11 from bovine reduce PGD2 to 11β-PGF2α despite 
sharing merely 75% and 78% identity with AKR1C3, suggesting the activity may be present 
in the murine isoforms despite low sequence conservation. Therefore it was essential to 
address the question of whether any of the murine isoforms is a functional homologue of 
AKR1C3.  
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1.5 Prostaglandins and myogenesis 
1.5.1 Introductory note 
Although the role of AKR1C enzymes in cancer, especially the reduction of PGD2 in 
haemopoietic tissues, is the main topic of this thesis, another project was developed that 
branched from the original theme. Chapter 6 of the results section is focused on how PGD2 
affects adult myogenesis, that is, the differentiation of muscle stem cells (myoblasts) into 
functional muscle fibers. The serendipitous origin of this side-project is explained at the 
beginning of chapter 6. 
1.5.2 Origin of satellite cells 
During early vertebrate embryogenesis the paraxial mesoderm is segmented into transient 
structures known as somites, from where the skeletal muscle originates. The somites are 
generated in an anterior-posterior orientation and signal extensively with the neighbouring 
structures (notochord, neural tube and ectoderm). As the somites mature the myogenic 
progenitors become confined to the ventral epithelium of the structure known as the 
dermomyotome. Myogenesis is initiated when the cells of the dermomyotome undergo 
epithelial-to-mesenchymal transition (EMT) and spread to the trunk and limbs where they 
differentiate into skeletal muscle. A small portion of the muscle progenitor cells are kept and 
settle in a satellite position relative to the muscle fibers. These satellite cells remain quiescent 
in a niche between the basal lamina of the extracellular matrix and the sarcolema (the 
cytoplasmic membrane of muscle fibers) (Le Grand and Rudnicki, 2007, Buckingham, 2006). 
1.5.3 Satellite cells and adult myogenesis  
Disruption of the muscle tissue, caused by injury or exercise, results in satellite cell activation. 
Activated satellite cells, known as myoblasts, enter cell cycle and transiently proliferate to 
generate a pool of myogenic progenitors. Afterwards, myoblasts exit cell cycle and become 
committed to terminal myogenic differentiation (myocytes). Eventually myocytes fuse with 
the damaged myofibers, repairing them. All myofibers result from myoblast fusion and are 
multinucleated. Some of the myoblasts revert to the quiescent satellite cell form thereby 
keeping the stem cell pool in the tissue (Le Grand and Rudnicki, 2007, Sabourin and 
Rudnicki, 2000).  
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Eventually, as age progresses, satellite cells become less frequent and muscle regeneration is 
impaired leading to sarcopenia, the degenerative loss of skeletal muscle mass and strength (Le 
Grand and Rudnicki, 2007, Sabourin and Rudnicki, 2000). The muscle microenvironment 
also seems to play an important role in regeneration as satellite cell transplanted from old 
animals are able to replenish the satellite cell pool in younger animals. This shows that an 
ageing microenvironment can affect stem cell renewal and that muscle stem cell potential is 
determined by both intrinsic and extrinsic factors (Collins et al., 2007). 
 
 
Figure 30 - Schematic representation of adult myogenesis. 
Quiescent skeletal muscle satellite cell can become activated following stimuli originating from their 
associated fiber or from the micro-environment. Their proliferating progeny, the skeletal myoblasts, 
express the paired-box transcription factors Pax7 and Pax3, as well as the myogenic regulatory 
factors Myf5 and MyoD. Once committed to differentiation, myoblasts stop cycling and lose expression 
of Pax7, Pax3, and Myf5. Differentiating myogenin-positive myocytes will then align and fuse to form 
multinucleated myofibers. MRF4 is further required for hypertrophy of the new fibers. Figure from (Le 
Grand and Rudnicki, 2007). 
 
1.5.4 Genetic regulation of myogenesis 
The myogenic process is directed by two groups of transcription factors (Figure 30). The 
paired box (Pax) transcription factors Pax3 and Pax7 are important in the maintenance of 
muscle progenitor cells (Buckingham, 2007, Buckingham, 2006). Pax7 is highly expressed in 
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satellite cells where it prevents apoptosis. Mice lacking Pax7 have impaired muscle 
regeneration due to near absence of satellite cells. Pax3 is also expressed in satellite cells but 
at a lower level and does not prevent apoptosis. However, when cells become cycling 
myoblasts Pax3 expression is upregulated and, together with Pax7, promote the expression of 
myogenic target genes. As soon as the myogenic cascade of factors is initiated towards 
committed differentiation Pax3 and Pax7 are repressed. (Buckingham, 2007). 
The second wave of myogenic transcription factors involves members of the basic helix-loop-
helix (bHLH) superfamily. The myogenic regulatory factor (MRF) subfamily consists of 
myogenic differentiation 1 (MyoD), myogenic factor 5 (Myf-5), myogenin (Myog) and 
MRF4 (Buckingham, 2006, Bryson-Richardson and Currie, 2008). When overexpressed, all 
of these factors are able to convert non-muscle cell lines (like fibroblasts) into myogenic cells. 
However, MRFs work in a concerted manner to drive myogenesis in vivo. In activated 
satellite cells, Pax3 and Pax7 rapidly promote the upregulation of MyoD leading to cell cycle 
entry. Alternatively, some satellite cells upregulate Myf-5 to enter the proliferative state but 
eventually both MyoD and Myf-5 are co-expressed. After multiple rounds of division most 
myoblasts repress Pax3 and Pax7 expression. However, a fraction will retain Pax7, 
downregulate MRF expression and become quiescent satellite cells. Following proliferation, 
MRF4 and myogenin are upregulated in cells entering terminal differentiation. This leads to 
the formation of multinucleated fibers expressing contractile machinery proteins (myosin 
heavy chain, α-actin, desmin, etc.) and other markers of terminal muscle differentiation (such 
as creatine kinase) (Buckingham, 2006, Buckingham, 2007, Sabourin and Rudnicki, 2000). 
In summary, adult myogenesis is a tightly regulated process where a series of transcription 
factors act in cascade to drive the myogenic fate. Nevertheless, external factors have the 
power to promote or inhibit the process. 
1.5.5 Inflammation and muscle regeneration 
Disruption of muscle fibers by injury or exdrcise also activates tissue-resident mast cells, 
causing them to release large amounts of pro-inflammatory factors such as histamine, PGD2 
and leukotriene C4 (Cote et al., 2008). These factors initiate a local inflammatory response by 
attracting circulating neutrophils and macrophages (Tidball, 2005, Tidball, 2008). Initially, 
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the inflammatory response aggravates the damage in the tissue but, on the long-term, the 
factors secreted by leukocytes are beneficial for healing. 
Neutrophils are the first leukocytes to invade the injured muscle and their degranulation 
results in the secretion of oxygen radicals and proteases (Tidball, 2005). These reactive agents 
degrade the debris resulting from disrupted myofibers in order to facilitate their phagocytosis 
but also cause more damage. This is followed by the arrival of macrophages that remove the 
debris and secrete factors, such as IGF, TGF-β, LIF, IL-6 and CSF-1, that modulate myoblast 
proliferation and differentiation (Cantini et al., 2002, Massimino et al., 1997). 
Despite the evidence suggesting the long-term benefit of inflammation in muscle healing, 
most clinicians recommend the use of NSAIDs to attenuate inflammation and pain (Jarvinen 
et al., 2007). Studies with human volunteers have shown that the intake of over-the-counter 
doses of ibuprofen (Trappe et al., 2001) or indomethacin (Mackey et al., 2007) reduce the 
gain of muscle function caused by exercise. Both COX-1 and COX-2 are up-regulated after 
muscle injury suggesting prostaglandins are important in regeneration (Weinheimer et al., 
2007). 
1.5.6 Prostaglandins and adult myogenesis 
Many studies have attempted to determine the effect of COX inhibition during muscle 
regeneration using a wide variety of in vitro and in vivo models. Cyclical stretch increases 
proliferation of primary mouse myoblasts, accompanied by elevated PGE2 and PGF2α 
production. These effects are COX-2 dependent since myoblasts treated with SC-236 (COX-2 
selective inhibitor) and myoblasts derived from COX-2 null mice show no response to 
stretching (Otis et al., 2005). Whilst informative, in vitro models do not address physiological 
scenarios such as the role of inflammatory cells and their interaction with myoblasts. Mishra 
et al. subjected rabbits to exercise-induced injury and monitored the recovery after treatment 
with flurbiprofen (non-selective NSAID). Treated animals had better short-term recovery but 
a long-term deficit in force generation when compared to controls (Mishra et al., 1995). This 
observation highlights the concept that inflammation can be both beneficial and detrimental. 
Bondesen et al. focused on the role of COX-2 in muscle healing after injury (Bondesen et al., 
2004) and atrophy (Bondesen et al., 2006). The expression of COX-2 (but not COX-1) 
increased after these challenges and ablation of enzyme activity with SC-236 or in COX-2 
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null mice resulted in reduced myofiber diameter upon healing. Importantly, these COX-2 
deficient systems showed reduced myoblast and macrophage count in the regenerating 
environment confirming the importance of COX metabolites in the healing process. 
Altogether, these studies indicate that COX activity promotes muscle healing. However, the 
type of prostaglandins produced downstream of COX depends on the type of terminal 
synthases expressed. 
In the regenerating muscle the expression of prostaglandin synthases, receptors and its 
downstream signaling pathways has only recently begun to be described. In theory, 
modulating specific prostaglandin signaling in the healing muscle might be a more effective 
clinical approach than COX inhibition.  
Proliferating myoblasts have consistently been shown to produce PGE2 and PGF2α (Rossi et 
al., 1989, Otis et al., 2005, Bondesen et al., 2004, McArdle et al., 1994, Rodemann and 
Goldberg, 1982, Palmer et al., 1983, McLennan, 1991). Early studies demonstrated that 
inhibition of myoblast fusion with indomethacin could be overcome by adding PGE2 (Zalin, 
1979, Zalin, 1977, Entwistle et al., 1986). However, the expression of PGE synthases 
(mPGES-1, mPGES-2 and cPGES) or receptors (EP1-EP4) has not been characterised in the 
homeostatic and regenerating muscle. Thus the exact role of PGE2 in the healing context 
remains largely unknown. Interestingly, PGE2 is abundantly produced by leukocytes in the 
early phase of inflammation (Shen et al., 2008) and could also affect myoblast differentiation 
(Figure 31). 
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Figure 31 - Prostaglandin signaling in the regenerating muscle. 
After muscle injury, satellite cells become proliferating myoblasts that later commit to differentiation and fuse to 
damaged myofibers. Simultaneously, leukocytes (mainly neutrophils and macrophages) invade the damaged 
tissue and initiate an inflammatory response. During this process both cell types secrete PGs that may influence 
myogenesis. Both myoblasts and leukocytes produce PGE2 a promoter of myogenesis, but no PGE synthases or 
receptors have been shown to be expressed in myoblasts. PGF2α is produced by myoblasts and signals via the 
PGF receptor (FP) to prevent apoptosis and promote cell fusion. Similarly, PGI2 (prostacyclin) signals in autocrine 
fashion via the PGI receptor (IP) to restrain myoblast motility and enhance cell fusion. PGD2 is produced by 
inflammatory leukocytes but its synthesis and signaling in myoblasts is unknown. However, 15d-PGJ2, a PGD2 
dehydration metabolite, can inhibit myogenesis but the mechanism remains largely unknown. Figure from(Velica 
and Bunce, 2008). 
In isolated muscles, PGF2α was described as a promoter of protein synthesis and its 
production is increased upon exercise (Palmer et al., 1983, Trappe et al., 2001). Horsley et al. 
reported that primary mouse myoblasts treated with PGF2α generated myotubes of increased 
size by stimulating fusion with nascent fibers (Horsley and Pavlath, 2003). This growth was 
FP-dependent and caused the activation of the calcium-regulated nuclear factor of activated T 
cells, isoform C2 (NFATC2). In a follow up study, the authors show that PGF2α increases 
myotube size by preventing myoblast apoptosis, via the upregulation of BIR ubiquitin-
conjugating enzyme (BRUCE), an inhibitor of caspases (Jansen and Pavlath, 2008). BRUCE 
was naturally expressed in the later phases of adult myogenesis and its upregulation was 
ablated in NFATC2 null myoblasts. Importantly, PGF2α treated or BRUCE over-expressing 
myoblasts engraft more efficiently in a transplant model. These two studies characterised in 
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detail the autocrine signaling pathway of PGF2α in myoblasts, confirming an important 
myogenic role of a COX product. 
PGI2 is the main COX metabolite produced by vascular endothelial cells where it promotes 
vasodilation. Primary mouse myoblasts were shown to express PGI synthase, PGI receptor 
(IP) and produce PGI2 (Bondesen et al., 2007). IP null myoblasts had reduced fusion and 
differentiation but increased cell motility. The high motility rate of IP null myoblasts was 
blocked by Iloprost (stable PGI2 analogue) resulting in increased cell fusion. The authors 
propose that myoblast motility is inversely correlated with differentiation and that PGI2 plays 
a pivotal role in this balance. 
1.5.7 Can inflammatory PGD2 affect adult myogenesis? 
Studies have shown that like PGE2, synthesis and secretion of PGD2 is strongly induced in the 
early phase of inflammation (Rajakariar et al., 2007, Trivedi et al., 2006, Gilroy et al., 1999) 
and can have both pro- and anti-inflammatory roles, depending on the cell-type context. 
Despite the importance of inflammation in muscle healing, PGD2 synthesis and signaling has 
not been characterised in myoblasts. This could perhaps unravel a novel cross-talk pathway 
between inflammatory and muscle cells. 
Like PGD2, levels of 15d-PGJ2 are increased during inflammation (Rajakariar et al., 2007, 
Gilroy et al., 1999) and might modulate myoblast behaviour. Although PPARγ expression 
seems to be important in C2C12 myoblast differentiation (Singh et al., 2007), it was observed 
that micromolar doses of 15d-PGJ2 blocked myotube formation  in a PPARγ-independent 
manner (Hunter et al., 2001). This differentiation block could be mediated by the other 
properties of 15d-PGJ2 such as the generation of an oxidative environment which has also 
been shown to impair myogenesis (Ardite et al., 2004). However, due to its reactivity 15d-
PGJ2 rapidly binds to extracellular proteins such as albumin and it is unlikely that such high 
concentrations accumulate in the regenerating muscle. 
The observations discussed here compile a scenario where activated myoblasts co-exist with 
an inflammatory environment where PGD2 levels are high. Therefore, we analysed the impact 
of PGD2 in adult myogenesis using the C2C12 myoblast model and the results are shown in 
chapter 6. 
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2 CHAPTER TWO: Materials and Methods 
2.1 Sequence alignments 
Genomic, mRNA and amino-acid sequences were obtained from the following databases: 
National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/), Ensembl 
(http://www.ensembl.org/index.html) and the AKR homepage 
(http://www.med.upenn.edu/akr/). Amino-acid sequences were aligned using ClustalX2 
(http://bips.u-strasbg.fr/fr/Documentation/ClustalX/). Phylogenetic tree was generated using 
TreeView X software (http://darwin.zoology.gla.ac.uk/~rpage/treeviewx) with random 
number generator of 111 and number of bootstrap trials of 1000. 
2.2 Cell culture  
2.2.1 HPC-7 (haemopoietic stem cell-like cell line) 
The HPC-7 cell line was generated by transducing mouse embryonic stem cells with the 
transcription factor LH2 (expressed in mouse fetal liver during haemopoiesis) (Pinto do et al., 
2002, Pinto do et al., 1998). This resulted in a multipotent haemopoietic precursor cell line 
that requires stem cell factor (SCF) for growth and can be induced to differentiate into various 
mature myeloid lineages upon addition of other growth factors. The cell line was kindly 
supplied by Dr Carlsson (University of Umeå, Sweden) 
2.2.1.1 Production of SCF using CHO-K3 cells 
Chinese Hamster Ovarian (CHO) K3 cells stably transfected with mouse SCF were kindly 
supplied by the Frampton group (IBR, University of Birmingham, UK). Cells were expanded 
in DMEM supplemented with 10% FBS, 2 mM glutamine and antibiotics. For SCF 
production, CHO cells were seeded in 150 cm
2
 tissue culture flasks (Costar) and allowed to 
reach confluence. After that, growth media was replaced with 30 ml Stem Pro medium 
(Invitrogen) with 0.5% FBS and antibiotics. The media was refreshed the following day and 
left for 2 days during which CHO cells secrete SCF into the supernatant. The media was 
harvested, sterile-filtered with a 0.45 μm filter and stored at -20 °C.  
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2.2.1.2 Culturing HPC-7 cells 
HPC-7 cells were gently thawed from liquid nitrogen and resuspended in Stem Pro media 
supplemented with 2.6% Stem Pro serum replacement, 10% supernatant with SCF (see 
above), antibiotics and 2 mM glutamine. HPC-7 are non-adherent small cells and were kept 
between 1x10
6
 and 2.5 x10
6
 cells per ml in 24-well plates or 25 cm
2
 tissue cultures flasks 
(Costar). Medium was refreshed every 2 days. 
2.2.1.3 Differentiation of HPC-7 cells 
For differentiation, SCF was either replaced or used in combination with the following 
recombinant growth factors: 10 or 100 ng/ml murine IL-3 (with or without 100 nM ATRA), 4 
U/ml human EPO and 20 ng/ml mouse TPO (all from R&D systems). Media was replaced 
every 2 days and cells counted daily using a haemocytometer. Cells were harvested for RNA 
extraction at identical intervals. 
2.2.2  C2C12 and L6-C11 (myoblast cell lines) 
C2C12 cell line was purchased from the American Type Culture Collection (ATCC). C2C12 
is a subclone of the mouse myoblast cell line established by (Yaffe and Saxel, 1977). This cell 
line has a fibroblast-like appearance and can be driven to skeletal myogenic differentiation 
when at high confluence by reducing serum concentration, forming large multinucleated 
myotubes that result from cell fusion.  
The L6 cell line was derived from adult rat muscle samples and behave like myoblasts, 
forming myotubes at high-density (Yaffe, 1968). L6-C11 cells were obtained from Dr R 
Harris (School of Biosciences, University of Birmingham) 
2.2.2.1 Culture of C2C12 and L6-C11 
C2C12 and L6-C11 were expanded in DMEM supplemented with 10% FBS, 2 mM glutamine 
and antibiotics (growth media) at 5% CO2, 37°C. Cells were grown in 75 cm
2
 tissue culture 
flasks (Corning) and split before reaching confluence (to avoid loosing myogenic potential). 
Media was changed every two or three days. 
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2.2.2.2 Myogenic differentiation of C2C12 and L6-C11 
For differentiation, 5x10
4
 exponentially growing C2C12 cells were seeded per well in 6-well 
plates and kept in growth media for 2 days until reaching ~80% confluence. At this point, 
(day 0) growth media was replaced with DMEM supplemented with 5% Horse Serum 
(Gibco), 2 mM glutamine and antibiotics (differentiation media). Media was refreshed every 2 
days. The differentiation process was monitored daily using an inverted microscope and was 
terminated between day 4 and day 6 (post-confluence/media change). Usually, cell fusion was 
observed from day 2 and became more evident on the following days. 
For differentiation, L6 cells were seeded as above but always kept in growth media. In 
confluent cultures cells fuse to form long multinucleated myotubes. 
2.2.2.3 Treatments of C2C12 cells 
To assess the effect of certain molecules (prostaglandins, receptor agonists and antagonists) 
C2C12 were differentiated as detailed above. Treatments were initiated at day 0, upon 
replacement with differentiation media and were always done in biological triplicates. Control 
cultures were treated with equivalent amounts of solvent (ethanol, DMSO or water). 
Treatments were either added only at the beginning of the experiment or every two days until 
the end of the experiment. To determine the effect of these molecules on C2C12 
differentiation, several methods were used as explained in section 2.6. 
2.2.3 BA/F3 
BA/F3 is a bone marrow-derived immortalized murine pro-B-cell line that requires IL-3 to 
survive and proliferate. BA/F3 was purchased from ATCC and grown in RPMI media 
supplemented with 10% FBS, 2 mM glutamine, 0.1% β-mercaptoethanol, 1% IL-3 
conditioned media and antibiotics. 
2.2.4 J774 
J774 is a macrophage cell line derived from a solid tumor of a BALB/c mouse. J774 was a 
kind gift from the May lab (School of Biosciences, University of Birmingham) and was 
grown in DMEM supplemented with 10% FBS, 4 mM glutamine and antibiotics. 
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2.2.5 K562 
K562 are an eryhtroleukemia cell line derived from a chronic myeloid leukemia patient in 
blast crisis. K562 were purchased from ATCC and were cultured in RPMI media 
supplemented with 10% FBS, 2 mM glutamine and antibiotics. 
2.2.6 CHO 
CHO (Chinese Hamster Ovary) cells were a kind gift from Dr. J Rappoport (School of 
Biosciences, University of Birmingham). Generation of stable recombinant CHO cells is 
relatively easy and these cells are commonly used to over-express secreted factors. CHO cells 
were grown in DMEM supplemented with 10% FBS and antibiotics. 
2.3 General molecular biology techniques  
2.3.1 RNA sourcing 
Tissue culture cells (2x10
6
 or less) were spun down, flash-frozen using liquid nitrogen and 
stored at -20 °C. For whole tissues, CD1 male and female (both pregnant and non-pregnant) 
mice were sacrificed for the dissection of spleen, liver, lung, stomach, small intestine, colon, 
kidney, prostate, testes, uterus and ovary (in triplicate). Each tissue was cut to a ~3 mm cube, 
stabilized in RNAlater (RNA Stabilization Reagent; Qiagen) and stored at -80 °C. 
2.3.2 RNA extraction 
RNA was extracted using Qiagen’s RNeasy Mini Kit according to manufacturer instructions. 
Homogenization of tissue culture samples was done by adding 350 μl RLT (lysis) buffer, 
mixing, pipetting directly into a QIAshredder spin column (Qiagen) and centrifuging for 2 
minutes at 1200 rpm. Homogenization of stabilized mouse tissues was done by placing the 
tissue in liquid nitrogen and grinding it thoroughly with a mortar and pestle. Mortar and pestle 
were thoroughly washed with ethanol to avoid cross-contamination of tissue samples. Ground 
tissue was resuspended in 600 μl RLT buffer, transferred to a QIAshredder spin column and 
centrifuged for 2 minutes at 1200 rpm. After homogenization, RNA was bound to an RNeasy 
spin column, washed with Qiagen wash buffer and eluted with 30 – 50 μl of RNase-free 
water.  
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RNA was quantified by diluting the original sample 1/100 or 1/50 in water and measuring the 
absorbance at 260 nm. RNA concentration (in ng/μl) was calculated as follows: Abs260nm x 40 
x (dilution factor). RNA purity was assessed by the Abs260nm/Abs280nm ratio (should be 
between 1.9 and 2.1). 
2.3.3 cDNA synthesis 
Synthesis of cDNA from RNA used Super Script II Reverse Transcriptase (Invitrogen). 
Reaction mixtures were as follows:                                               
 sample RNA………………………... 0.35 – 2 μg 
 10 mM dNTPs……………………… 1.0 μl (0.5 mM) 
 3 μg/μl random hexamers…………... 0.5 μl (75 ng/μl) 
 RNase-free water…………………… up to 12 μl 
Reactions were incubated at 65 °C for 6 minutes and then cooled on ice to promote annealing 
of random hexamers to RNA. After this, the following were added: 
 5X FS buffer……………………….... 4.0 μl (1X) 
 0.1 M DTT…………………………... 2.0 μl (10 mM) 
 40 U/μl RNasin (RNAse inhibitor)….. 1.0 μl (2 U/μl) 
 200 U/μl SuperScript II RT………….. 1.0 μl (10 U/μl) 
The final mixture was incubated at 25 °C for 10 minutes followed by 45° C for 90 minutes 
and finally 70 °C for 15 minutes. The synthesized cDNA was then diluted 1:2 or 1:4. 
2.3.4 Standard PCR reaction 
Quality of cDNA was assessed by RT-PCR for the control house-keeping gene Gapdh 
(primers 40 and 41, Table 6). The PCR mix was as follows: 
 10X buffer…………………….……. 2.0 μl (1X) 
 50 mM MgCl2………………………. 0.6 μl (1.5 mM) 
 10 mM dNTPs………………………. 2.0 μl (1 mM) 
 9 μM forward primer……………..… 2.0 μl (0.9 μM) 
 9 μM reverse primer………………… 2.0 μl (0.9 μM) 
 1 U/μl BioTAQ Red DNA pol………  1.0 μl (0.05 U/μl) 
 Sample cDNA……………………….. 1.0 μl 
 Water……………………………..…. up to 20 μl 
Reactions were incubated in an ABI9600 thermal cycler with the following cycling 
parameters: 96 °C for 5 minutes; (96 °C for 30 seconds; 65 °C for 30 seconds; 70 °C for 30 
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seconds) x 25; 70 °C for 7 minutes. The resulting amplified products were separated in 2% 
agarose gel stained with ethidium bromide and visualized on a UV transilluminator. 
2.3.5 Taqman quantitative real-time (QRT)-PCR 
In Taqman QRT-PCR two primers and one internal probe anneal in close proximity on the 
target sequence. The probe has a fluorochrome on its 5’ end that is kept inactive by a 
quencher on the 3’ end. During the elongation step of the PCR, as the polymerase amplifies 
the target sequence, it degrades the probe releasing the fluorochrome from the influence of the 
quencher, resulting in enhanced fluorescence. This allows the monitoring of product 
formation at the end of each cycle (“real-time”). By the end of the PCR cycles, an exponential 
curve followed by a plateau is obtained for each reaction. From the curves it is possible to 
define a fluorescence level (“threshold”) at which all samples are in the exponential phase, 
thus determining a cycle number (CT) that is proportional to the initial amount of target 
sequence. Given the exponential nature of PCR, CT or ΔCT values (the difference between 
two CT values) have to be transformed using the formula 2^(-CT) or 2^(-ΔCT)  . 
Primers and probes were designed using the Primer Express software (Applied Biosystems). 
The oligonucleotides generated a product between 75 and 100 bp with optimal melting 
temperatures for QRT-PCR. The sequences were tested for specificity by using the BLAST 
algorithm (NCBI) against the mouse transcriptome. Primers were obtained from Sigma 
Genosys (Sigma) and are described in Table 6 (labeled “QRT F” or “QRT R”). Primers were 
tested using RT-PCR (as in page 74) before ordering the dual-labeled probes from 
Eurogentec. A list of all probes used with the respective 3’-quenchers and 5’-fluorochromes is 
presented on Table 7. 
For each gene a “primers and probe” mix was prepared beforehand containing 9 μM of each 
primer and 1.25 μM of probe. A 2X QRT mastermix containing buffer, magnesium, 
polymerase and dNTPs was purchased from Eurogentec. The Taqman QRT-PCR reaction mix 
was prepared as follows: 
 2X QRT master mix …….  10 μl 
 Primers & Probe mix ……    2 μl 
 Water……………….…….   7 μl 
 cDNA……………………… 1 μl 
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QRT-PCR for each sample was performed in triplicate 20 µl reactions in optical grade 96 well 
plates using standard cycle conditions for 44 cycles on an ABI Prism 7700 sequence detector 
(Applied Biosystems). 
2.3.6 Western blotting 
Sample protein concentrations were determined using the Protein Quantification kit (BioRad) 
and BSA standard curve. A fixed amount of protein was used (10 – 30 μg), mixed with gel 
loading buffer and boiled at 100 °C for 10 minutes. Proteins were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) using 10-12.5% gels depending on the size 
of the protein to be probed. 
After electrophoresis, proteins were transferred to Immobilon-P membranes (Millipore Corp, 
Bedford, MA, USA), blocked with 5% milk in TBS-T for 1 hour (or overnight) and incubated 
with the primary antibody (diluted in blocking solution) for 1 hour at room temperature. Anti-
LPGDS monoclonal antibody (rat, clone 10A5) was purchased from Cayman Chemicals and 
used at a 1/500 or 1/1000 dilution. Anti-6xHis polyclonal antibody (rabbit, H-15) was 
purchased from Santa Cruz Biotechnology and used at 1/1000 dilution. After incubation and 
washing with TBS-T, membranes were incubated with secondary antibodies at 1:1000 to 
1:5000 dilutions. Rabbit polyclonal HRP-conjugated anti-rat IgG antibody was purchased 
from Abcam. Goat polyclonal HRP-conjugated anti-rabbit IgG antibody was purchased from 
Pierce. Detection was done using ECL Supersignal West Pico Chemiluminescent substrate 
(Pierce) and exposing the membrane to auto-radiography film. 
2.3.7 Site-directed mutagenesis 
Site-directed mutagenesis is a technique that allows for specific nucleotide changes in plasmid 
DNA using a PCR-based approach. The QuickChange XL Site-Directed Mutagenesis kit 
(Stratagene) was used according to manufacturer’s instructions. 
Mutagenic primers were designed using Stratagene’s QuickChange Primer Design Program. 
Both complementary mutagenic primers contain the desired mutation and anneal to the same 
sequence on opposite strands of the plasmid. 
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Mutant strand synthesis reaction was performed in a thermal cycler using 10 or 50 ng original 
plasmid and the kit’s PfuTurbo DNA polymerase (high-fidelity). Importantly, the original 
plasmid must have been grown in a bacterial strain that methylates DNA, such as DH5α. PCR 
reactions were prepared to a final volume of 50 μl as follows: 
 10X reaction buffer…………………...5 μl 
 10 ng/μl pcDNA-L-PGDS……….1 or 5 μl 
 125 ng/μl sense primer………………..1 μl 
 125 ng/μl anti-sense primer……….…..1 μl 
 10 mM dNTP mix…………………….1 μl 
 Stratagene Quick solution………….…3 μl 
 
At the end of the PCR reaction, DpnI was added and incubated for 1 hour at 37 °C. This 
enzyme digests the methylated DNA chains (original plasmid) leaving the un-methylated 
DNA (mutated) intact. The mutated single-strands were transformed into E. coli strain XL10-
Gold (Stratagene). Success of mutation-reaction was confirmed by nucleotide sequencing. 
2.3.8 PCR using proof-reading polymerase 
The coding regions of murine AKRs were cloned using a reverse transcriptase (RT)-PCR 
strategy (Figure 32). The sequences of primers and the cDNA source used in the amplification 
are shown in Table 4. The forward primers were designed to introduce an NdeI restriction site 
coincident with the ATG start codon, and the reverse primer likewise incorporated an XhoI 
site (for PCR details, see below). The resulting PCR products were digested with XhoI and 
NdeI which were then ligated into the similarly digested pET28b(+) vector (Novagen). This 
expression plasmid incorporates an N-terminal histidine (6 × His) tag to aid purification. The 
constructs were then used to transform E. coli strains DH5α and subsequently BL21(DE3) 
(Novagen) for expression. The nucleotide sequence of the cDNA inserts were confirmed by 
sequencing. 
PCR amplification of the AKR coding regions was performed using Bio-X-ACT (Bioline) 
high-fidelity DNA polymerase. These polymerases have slower synthesis rates than Taq 
polymerases but generate fewer errors. The BIO-X-ACT polymerase mix (Bioline) was used 
according to manufacturer instructions: 
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 10X Optibuffer………….…… 5.0 μl (1X) 
 50 mM MgCl2………….……. 2.5 μl (2.5 mM) 
 100 mM dNTPs………………. 1.0 μl (2 mM) 
 100 μM forward primer………. 0.5 μl (1 μM) 
 100 μM reverse primer……….. 0.5 μl (1 μM) 
 4 U/μl BIO-X-ACT..…………  1.0 μl (0.08 U/μl) 
 Source cDNA (Table 4)……….  1.0 - 5.0 μl 
 Water………………………….. up to 50 μl 
Samples were incubated in an ABI9600 Thermal Cycler with the following program. 96 °C 
for 5 minutes; 58 °C for 5 minutes (70 °C for 1 minute; 95 °C for 30 seconds; 56 °C for 1 
minute) x 35; 70 °C for 10 minutes. The resulting amplified products were separated in 1% 
agarose gel stained with ethidium bromide and visualized in a UV transiluminator. 
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Figure 32 - Strategy for the cloning of AKR coding regions in pET-28b 
The open reading frames (ORFs) of the AKR genes were amplified using primers that introduce a 5’ 
NdeI site and a 3’ XhoI site. These sites were later used to clone the coding regions in the bacterial 
expression vector pET-28b (Novagen). Correct amplification and cloning was confirmed by nucleotide 
sequencing before transforming the vector in the E. coli strain BL21(DE3). 
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Table 4 - Primers used for cloning the murine AKR coding regions. 
 
Gene Forward primer (5'-3') with NdeI site Reverse primer (5'-3') with XhoI site 
Product 
size (bp) 
Source 
cDNA 
Akr1c6 GCAGCATATGGATTCTAAGCAGCAGAC CTGCCTCGAGTTAGTATTCATCCCAAAATG 989 Liver 
Akr1c12 GCAGCATATGAGCTCCAAACAGCACTA CTGCCTCGAGTTAATATTCCTCTGAAAATG 989 BA/F3 
Akr1c13 GCAGCATATGAGCTCCAAACAGCACTG CTGCCTCGAGTTAATATTCCTCCACAAATG 989 BA/F3 
Akr1c14 GCAGCATATGAATTCTGTATCCCCACG CTGCCTCGAGTTAATATTCATCAGTAAATG 989 C2C12 
Akr1c18 GCAGCATATGAATTCCAAAATTCAGAA CTGCCTCGAGTTAATATTCATCGAAGAAT 986 J-774 
Akr1c19 GCAGCATATGAGTTCCAAACAGCAATG CTGCCTCGAGCTAAAATTCATCAGAAAAG 986 BA/F3 
Akr1c20 GCAGCATATGAATTCCAAGCAGCAGAC CTGCCTCGAGTTAGTATTCATCCAAAAATG 989 Liver 
Akr1c21 GCAGCATATGAACTCCAAATGTCATTG CTGCCTCGAGCTAGTATTCATCCAAAAATG 986 Kidney 
 
    Primers were designed to introduce NdeI and XhoI sites at the 5' and 3' end of the coding region, respectively (sites are 
underlined) 
starting codon (ATG) of each gene is highlighted in bold 
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2.3.9 DNA extraction from agarose gels 
PCR products were electrophoresed in 1% agarose gel. The desired band was cut from the gel, 
the slice transferred to a microcentrifuge tube and weighed. For purification the QIAquick gel 
extraction kit (Qiagen) was used. Three volumes of QG buffer (relative to gel slice weight) 
were added to the slice followed by 10 minute incubation at 50⁰C. When the gel was 
dissolved the solution was transferred to a QIAquick column and spun to bind DNA. DNA in 
column was washed with PE buffer and eluted with 30 μl of DNase-free water. 
2.3.10 DNA digestion 
The purified PCR product was digested with NdeI and XhoI. The primers were designed with 
4 extra nucleotides after the restriction site in order to allow maximum digestion efficiency of 
the PCR product (some restriction enzymes can not cut sites very close to the DNA 
extremity). The purified PCR product was incubated with 1 U/μl NdeI (New England 
Biolabs), 1 U/μl XhoI (New England Biolabs) and 1X NEBuffer 2 (New England Biolabs) in 
a 50 μl volume at 37⁰C, overnight.  Approximately 1 μg of pET28b (Novagen) was digested 
under the same conditions. After digestion, 10% of each digestion was run in an analytical 1% 
agarose gel. If the band sizes were as expected the remain of the digestion mixes was run in a 
preparative 1% gel, the bands cut and purified as detailed in section 2.3.9.  
2.3.11 DNA ligation 
After purification both plasmid and insert (AKR ORF) had compatible cohesive termini. 
Ligation reactions were setup in a microcentrifuge tube as follows in a final volume of 10 μl:  
• 1X ligase buffer (Promega) 
• 0.3 U/μl T4 DNA Ligase (Promega) 
• 2 μl plasmid  
• 2 μl insert  
 
The reaction was incubated either for 3 hours at room temperature or left at 4⁰C overnight. 
Preferentially a smaller microcentrifuge tube was used to ensure the maximum interaction 
between the components of the reaction. 
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2.3.12 Transformation of competent DH5α bacteria 
Freshly ligated DNA can be introduced in bacteria where it will be exponentially replicated 
within its host. Readily “competent” E. coli strains are available such as DH5α-T1R 
(Invitrogen). For transformation 50 μl of competent DH5α were carefully transferred into a 
previously chilled microcentrifuge tube, placed on ice. Then, up to 5 μl of ligation mix was 
added to the bacteria and left on ice for 30 minutes. After this, bacteria were heat-shocked by 
placing the tube in a 42⁰C water bath for exactly 30 seconds and then moved back to ice. The 
shock promotes the up-take of DNA by the permeated bacteria. After a few minutes, 250 to 
950 μl of LB broth (Sigma) was added to the bacteria followed by 1 hour incubation at 37⁰C. 
In the case of pET-28b the transformants will become resistant to kanamycin. After 
incubation, 20 to 100 μl of cell suspension were spread in 10 cm Petri dishes with agar-
solidified LB supplemented with 50 μg/ml kanamycin. Only bacteria bearing the plasmid are 
able to survive and proliferate in the plate and because of the solid nature of the broth, 
bacteria grow as colonies. Importantly, these colonies arise from single cells and therefore are 
clonal. 
Plates were left to incubate at 37⁰C overnight with the lid facing down. The following day, for 
each ligation a few colonies were picked (usually between 6 and 20) with a wooden toothpick 
and placed in a 20 ml plastic tube with 5 ml of LB supplemented with 30 μg/ml kanamycin 
(standard concentration of kanamycin for bacterial selection). The cultures were incubated at 
37⁰C in a shaking incubator overnight.  
2.3.13 Plasmid extraction from bacteria 
Wizard Plus SV Miniprep DNA purification kists (Promega) were used to extract plasmid 
DNA. 1 to 5 ml of bacterial cultures was centrifuged and the cell pellets resuspended in 250 
μl cell resuspension solution. Bacteria were lysed by the addition of 250 μl cell lysis solution 
and 10 μl alkaline protease solution and incubated for 5 minutes at room temperature. 
Addition of 350 μl neutralisation solution promotes the precipitation of proteins and genomic 
DNA. The solution was centrifuged for 10 minutes at 14000 rpm in order to separate the 
precipitated material from the supernatant containing the plasmid. The supernatant was 
transferred to a DNA-binding column. The column-bound plasmid DNA was washed with an 
ethanol based washing solution and finally eluted with 100 μl DNase-free water. 
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Also, at this point, 800 μl of bacterial overnight culture were added to 200 μl glycerol, mixed 
and frozen at -80 ºC. Later on, a new culture was started by simply picking the glycerol stock 
directly into liquid or solid LB broth. 
2.3.14 Transformation of BL21 bacteria 
The cloned plasmids were transformed into bacteria that are competent for large scale protein 
expression. BL21(DE3)pLysS (Novagen) is a commercially available strain of E. coli 
compatible with protein expression plasmids like pET-28b. The strain lacks the expression of 
bacterial proteases ensuring high quality protein recovery. Furthermore, these bacteria contain 
an isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible T7 RNA polymerase. This allows 
temporal control of protein expression since pET-28b depends on T7 RNA polymerase to 
express the cloned recombinant protein. The transformation protocol for BL21 was identical 
to the one described in section 2.3.12. After transformation, the bacteria were seeded in solid 
LB plates supplemented with kanamycin and incubated at 37⁰C overnight. The next day three 
colonies were picked, expanded and glycerol stocks made. 
2.3.15 Expression and purification of recombinant murine AKR enzymes 
Overnight 5 ml cultures of the pET28b-AKR1C transformed BL21(DE3) cells were diluted 
1:1000 in fresh LB broth (4 × 200 ml culture) containing 30 μg/ml kanamycin and incubated 
at 37 °C for 5 h (corresponding to an absorbance at 600 nm of  1.0). Expression of 
recombinant protein was induced by adding IPTG to a final concentration of 1 mM and 
incubated at 37 °C overnight with shaking at 220 rpm. Cleared lysates were prepared by 
pelleting bacteria by centrifugation (15 min, 3000g, 4 °C) and disrupting cells in BugBuster 
reagent (Novagen) containing protease inhibitors [Mini-Complete ethylenediaminetetraacetic 
acid (EDTA)-free, Roche Molecular Biochemicals] and Benzonase DNase (Novagen), using 
25 μl of lysis reagent per milliliter of original culture. After incubation at room temperature 
with shaking for 30 min, cell debris was pelleted by centrifugation (30 min, 38,000g, 4 °C). 
The cleared lysate (20 ml) was mixed with 1 ml of nickel-nitrilotriacetic acid (Ni-NTA) “His-
bind” resin (Novagen) followed by gentle shaking on ice for 20–60 min. The mixture was 
loaded onto an empty minicolumn, and unbound protein was removed by washing with 15 ml 
of 50 mM NaPO4 and 300 mM NaCl, pH 8.0. Bound protein was eluted in 1.5 column 
volumes of the same buffer containing 100 mM imidazole. Protein concentration was 
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estimated by Coomassie Blue binding,
 
using a commercial reagent (Bio-Rad Laboratories). 
The imidazole fractions containing protein were subjected to further purification using gel 
filtration on a Superdex 200 HR 10/30 column (GE Healthcare) running in 10 mM potassium 
phosphate, 1 mM EDTA, and 1 mM DTT, pH 7.0. The purity of collected fractions was 
assessed by SDS-PAGE stained with Coomassie Brilliant Blue.  
Activity of the purified recombinant proteins was confirmed by the reduction of 
phenanthrenequinone (PQ), measured as described in page 94. 
2.4 Vector construction and cell transfections 
2.4.1 Construction of a DP2 knockdown vector 
The DP2 knock-down plasmid consists of a vector expressing a short-hairpin RNA (shRNA) 
targeting specifically DP2. The parent vector is a modified pcDNA3.1(+) in which the CMV 
promoter was replaced with the RNAse P H1 gene promoter (driven by RNA polymerase III) 
as described by (Kunath et al., 2003). The parent vector retains the bacterial selection marker 
(Ampicillin) and eukaryotic selection marker (Neomycin). The 5’-Acc65I site and the 3’-XbaI 
site of the vector is used for the ligation of targeted shRNA sequences (Figure 33). 
The BIOPREDsi algorithm (Qiagen) was used to design a 19 bp sequence optimal for DP2 
knockdown (see underlined sequence used for knockdown in Table 5). The selected sequence 
targets the 5’ end of the coding region in the DP2 mRNA. BLAST analysis against the mouse 
transcriptome confirmed specificity against DP2. The targeting sequence was integrated into a 
shRNA context (Figure 33). Sense and anti-sense DP2 targeting sequences were separated by 
a 9 bp stem loop so that when expressed, the RNA molecule folds into a hairpin structure. The 
RNA polIII transcription of the sequence is initiated in adenosine +1 and terminated in a 
thymidine rich region. Two complementary oligonucleotides were ordered so that after 
annealing the sequence would have 5’- Acc65I and 3’- XbaI cohesive ends. A random non-
targeting sequence with the same nucleotide composition as the DP2 targeting sequence was 
generated as a shRNA control. BLAST analysis showed the sequence did not target any 
known mRNA of the mouse transcriptome. This sequence was processed as for the DP2 
targeting sequence 
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For insert generation, 4 μM of each complimentary oligonucleotide pair were mixed in Tris-
EDTA buffer (pH 8.0) to a final volume of 50 μl and incubated at 70⁰C for 10 minutes. After 
that, the oligonucleotides were left at room temperature for 40 – 60 minutes to promote 
annealing. The parent vector (pcDNA-H1) was digested with Acc65I and XbaI. The purified 
vector was ligated with the annealed insert. The ligation products were transformed into 
competent bacteria and seeded on LB plates supplemented with 30 μg/ml ampicillin. 6 
colonies were picked and expanded for plasmid extraction. Cloning was confirmed by 
sequencing the plasmids with a primer binding in the BGH region (primer 56, Table 6). High 
quality plasmid DNA extraction was performed by using Plasmid Maxi Prep kit (Qiagen). 
The resulting plasmids were named pcDNA-shDP2 and pcDNA-shVC (vector control). 
Table 5 - Oligonucleotides used to generate a DP2 silencing vector  
Scrambled 
shRNA 
Sense 5'-GTACCAAGCTTCGCATTGCACGTAGTTTCAAGAGAACTACGTGCAATGCGAAGCTTTTTTTGGAAAT-3' 
Antisense 5'-CTAGATTTCCAAAAAAAGCTTCGCATTGCACGTAGTTCTCTTGAAACTACGTGCAATGCGAAGCTTG-3' 
         
DP2 
shRNA 
Sense 5'-GTACCAAGGCGCTATCCGACTTGTTATTCAAGAGATAACAAGTCGGATAGCGCCTTTTTTTGGAAAT-3' 
Antisense 5'-CTAGATTTCCAAAAAAAGGCGCTATCCGACTTGTTATCTCTTGAATAACAAGTCGGATAGCGCCTTG-3' 
Targeting sequences are underlined 
Sense and antisense oligonucleotides are complimentary 
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Figure 33 - Construction of a DP2 silencing construct 
A DP2 specific targeting sequence was designed using the BIOPREDsi algorithm. (a) The sequence 
was integrated in a short-hairpin RNA context. Sense and anti-sense sequences are separated by a 9 
bp stem loop. Transcription of the sequence is initiated at adenosine +1 and terminated in the 
thymidine rich region. Two complementary oligonucleotides have been designed so that, after 
annealing, Acc65I and XbaI cohesive ends are generated. (b) The annealed double-stranded 
sequence was then cloned in a modified pcDNA vector where the expression is driven by a RNA 
polymerase III promoter (H1 promoter). The resistance cassette for bacterial (ampicillin) and 
eukaryotic (neomycin) selection are retained. Digestion with ScaI linearizes the vector in the ampicillin 
resistance cassette. Vector map was drawn using the pDRAW software. (c) Once transfected in the 
cells, the vector will express the targeting sequence that folds into a short-hairpin RNA conformation. 
This RNA will be processed by the cellular RNA silencing machinery resulting in DP2 mRNA 
degradation. 
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2.4.2 Construction of an Akr1c6 over-expression vector 
The Akr1c6 coding region had been previously cloned into the MSCV-IRES-GFP vector by 
Dr Trong Luong. This vector has the cloned cDNA under regulation of the murine stem cell 
virus (MSCV) promoter. Transcription from this promoter generates a polycistronic mRNA in 
which the Akr1c6 coding region is followed by an internal ribosomal entry site (IRES) 
allowing the simultaneous translation of the green fluorescent protein (GFP). Therefore, 
Akr1c6 expressing cells can be identified by green fluorescence. A vector lacking the Akr1c6 
coding region (but retaining all other components) was used as control. 
2.4.3 Construction of a L-PGDS over-expression vector 
The coding region of murine L-PGDS was cloned using the RT-PCR strategy described in 
page 77. Primers were designed to amplify L-PGDS coding region and introduce a 5’-BamHI 
site (5’-CTAGGGATCCATGGCTGCTCTTCGCATGCTG-3’) and a 3’- EcoRI site (5’-
CATGGAATTCTTACTCTTGAATGCACTTATCCGGTTGGGGCAGG-3’). High-fidelity 
PCR was performed using cDNA from differentiated C2C12 as template. 
The PCR product (590 bp) was initially cloned in pGEM-T Easy Vector (Invitrogen), a 
linearized vector with a single 3´-terminal thymidine at both ends. Since most polymerases 
leave a 5’-terminal adenine, this greatly facilitates ligation into pGEM-T. Also, ligation of 
insert interrupts the bacterial β-galactosidase (β-gal) gene thus allowing for blue/white 
selection of recombinants. After ligation, DH5α competent E. coli strains were transformed 
and plated on LB-agar plates supplemented with 30 μg/ml ampicillin and X-gal. The non-
recombinant colonies growing on the plate will have an intact β-gal that breaks down X-gal 
and generate a blue compound (blue colonies). Colonies harbouring the pGEM-T vector with 
an insert do not have a functional β-gal enzyme and remain white. Six white colonies were 
picked, amplified and plasmid DNA extracted and sequenced using primers 72 and 73 (Table 
6). 
Correctly cloned pGEM-T+L-PGDS plasmids were digested with BamHI and EcoRI and the 
released fragment was ligated to pcDNA3.1(+) vector digested with the same enzymes. 
Ligation clones were sequenced using primers 27 and 56 (Table 6). This construct has the 
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murine L-PGDS coding region under regulation of the CMV promoter. Empty pcDNA was 
used as vector control.  
2.4.4 PPARγ cloning 
PPARγ was cloned from C2C12 cDNA using the RT-PCR strategy described on page 77. 
Primers used for cloning both PPARγ1 and PPARγ2 (γ2 is a splice variant lacking first 30 N-
terminal residues relative to the γ1 amino-acid sequence) are 63, 67 and 65 (65 is common to 
both isoforms; Table 6). High-fidelity PCR was performed as described on page 76 and 
resulted in amplification only of PPARγ1 (1536 bp). The product was cloned into pGEM-T as 
described on page 87 and sequenced using primers 72 and 73 (Table 6). 
2.4.5 Electroporation of cell lines 
Plasmids were transfected into tissue culture cells using the Nucleofector I electroporator 
(Amaxa Biosystems). Plasmid DNA was previously linearised if the electroporation was 
intended to generate stably transfected cells as this greatly improves the chance of random 
integration in the genome (usually a ScaI digestion cuts on a single site, in the middle of the 
ampicillin resistance cassette). Variable amounts of plasmid were used (usually 1 – 10 μg). 
For each transfection reaction, 1 – 2x106 cells were spun down, resuspended in 100 μl Cell 
Line Nucleofector Kit V (Amaxa Biosystems) mixed with plasmid DNA and transferred to an 
electroporation cuvette. Cells were electroporated in a Nucleofector I electroporator with the 
appropriate voltage program (B-32 for C2C12 and CHO; T-16 for J774 and K562). 
Electroporated cells were transferred to a well of a 6-well plate with 3 ml of warm media and 
left to recover for 24 hours. 
2.4.6 G418 selection 
Vectors derived from pcDNA3.1(+) have a neomycin-resistance cassette that confers 
resistance to G418 sulphate (Sigma). In order to produce stably transfected C2C12, selection 
with G418 was used after electroporation with linearised plasmids. 
To determine the optimal G418 concentration for selection with C2C12 cells, a survival curve 
for an increasing concentration of the drug was made. C2C12 cells were seeded in wells of a 
96-well plate (Corning) (1.7 x 10
3
 cells per well) in 200 μl growth media. 24 hours later the 
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media was replaced with 100 μl growth media (see page 71) supplemented with G418 at 0-
1600 μg/ml. Each condition was assayed in six wells. A no-cell control was used as control. 
Cells were cultured with G418 for 7 days with daily media replacement. Cell survival was 
measured with Cell Titre Blue (Promega), a solution containing resazurin (mentioned in page 
96) a molecule that can be reduced by cellular mitochondrial activity generating a fluorescent 
dye (emits fluorescence at 590 nm after excitation at 530 nm). To each well, 10 μl of Cell 
Titre Blue were added and cells incubated at 37 °C for 4 hours. After that, fluorescence was 
measured in KC-4 96-well plate reader (Bio-Tek Instruments). The average fluorescence of 
the no-cell controls was subtracted from all wells. The relative fluorescence was normalised 
against the no-drug control wells (Figure 34). The optimal concentration for G418 selection 
was the lowest dose assayed that assured ~100% cell death (1200 μg/ml). 
 
 
Figure 34 - G418 survival curve for C2C12 cells 
C2C12 cells were grown for 7 days in the presence of increasing concentrations of G418. At day 7, 
cell viability was measured with Cell Titer Blue dye. Cell survival is shown in relation to untreated cells. 
Each circle represents the average survival of 6 replicate wells. Error bars represent standard 
deviation 
.
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Electroporated cells were left to recover for 24 hours before the addition of growth media 
with 1200 μg/ml G418. Cells were cultured in selective media for 9 days (until all mock-
transfected cells had died) and individual colonies were visible. It is very likely that these 
colonies have a single-cell origin (monoclonal). After washing with PBS, sterilized plastic 
cylinders were placed over the colonies. The bottom of the cylinders was coated with vacuum 
grease allowing trypsin-EDTA to be put only on top of the colonies without spilling to the rest 
of the plate. Individually trypsinized colonies were moved to separate 25 cm
2
 tissue culture 
flasks and expanded. Four pcDNA-shDP2 clones and two pcDNA-shVC clones were isolated. 
A fraction of the expanded cells were frozen as viable stocks in liquid nitrogen. The 
remaining cells were kept for RNA and protein analysis. In some experiments the G418-
selected colonies were pooled together (polyclonal). 
2.4.7 H-2Kk sorting 
K562 were co-transfected with 8μg MSCV-Akr1c6-IRES-GFP (or control) and 4 μg H-2Kk 
plasmid (Amaxa). The latter encodes the mouse H-2Kk surface marker that is transiently 
expressed on the cell-surface and is used to positively select transfected cells. 24 hours after 
transfection, cells were pelleted by centrifugation at 263 x g for 10 minutes and washed with 1 
ml cold PBE buffer (PBS with 2 mM EDTA), spun down, resuspended in 320 μl PBE with 80 
μl MACSelect microbeads (Miltenyi Biotec) and incubated for 15 minutes at 4 °C. The 
ferrous microbeads are coated with an antibody against H-2Kk and bind transfected cells. 
After incubation, cold PBE was added to a final volume of 2 ml and the cell suspension 
transferred to a MS column (Miltenyi Biotec) and placed in a magnet. Beads bound to H-2Kk-
positive cells were held by the magnetic field in the column while H-2Kk-negative cells were 
washed away using 4 X 500 μl cold PBE. Selected cells were eluted by removing the column 
from the magnetic field and flushing with more buffer, counted and plated in fresh media at 
the density of 4x10
5
 cells/ml in 24- or 12-well plates. 
Efficiency and enrichment of transfection with MSCV-IRES-GFP plasmids was assessed by 
measuring GFP fluorescence by flow cytometry (detailed in page 91). 
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2.5 Assessing HPC-7 differentiation 
2.5.1 Jenner-Giemsa staining 
To analyse cell morphology during differentiation, 60 μl of cell suspension were spun against 
a microscope slide using a Cytopsin3 cytocentrifuge (Shandon), fixed with 100% methanol 
for 5 minutes and left to air dry for 10 minutes. Jenner staining solution (VWR) diluted 1/3 in 
1 mM sodium phosphate buffer pH5.6 was incubated on the slides for 5mins and then washed 
off with distilled water. Slides were then incubated with Giemsa stain (VWR) diluted 1/20 in 
1 mM sodium phosphate buffer pH5.6 for 10mins at room temperature before washing again 
with water.  Slides were dried and then mounted onto coverslips using DePex (VWR, UK). 
Stained cytospins were photographed using an Olympus Camedia C-5050 Zoom Camera 
adapted for inverted microscopes. 
2.5.2 Flow cytometry analysis of surface markers 
To analyse the expression of surface markers during differentiation, 100 μl of cell suspension 
were transferred to flow cytometry tubes (BD Biosciences) and incubated for 15 minutes at 
room temperature with 1 – 3 μl fluorochrome-conjugated antibody. Anti-mouse FITC-CD34 
and PE-Sca1 were kindly supplied by the group of Prof Frampton (IBR, University of 
Birmingham, UK). After incubation 3 ml of cold PBS were added and tubes centrifuged at 
1500 rpm for 5 minutes. Stained cells were resuspended in 300 μl FACS-fix solution (PBS 
with 1% formaldehyde and 2% FBS) and kept in the dark at 4° C. Analysis was performed on 
a BD FACSCalibur flow cytometer (BD Biosciences) using Cell Quest Pro software (Becton 
Dickinson). 
2.6 Assessing C2C12 differentiation 
2.6.1 Fusion index measurement 
A standard method for quantifying C2C12 differentiation is to measure the fusion index (FI), 
that is, the fraction of myoblasts that have fused to generate myotubes. To assess this, C2C12 
cultures in 6-well plates were washed and fixed with 100% methanol for 5 minutes at the 
desired time points. After fixation, cells were stained using the Jenner-Giemsa protocol (see 
page 91). Each sample was photographed in 4 randomly selected regions using a digital 
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Olympus Camedia C-5050 Camera adapted to an inverted microscope. Protein-rich myotubes 
can be identified by a darker purple color while nuclei stain pink. For each field the number of 
nuclei incorporated in myotubes and the total number of nuclei was scored. FI was calculated 
as the percentage of total nuclei incorporated in myotubes. 
2.6.2 Creatine kinase assay 
Creatine kinase (also creatine phosphokinase, CK) is a dimeric enzyme that is highly 
expressed in differentiated muscle tissue.  CK catalyzes the conversion of creatine to 
phosphocreatine, consuming ATP, as well as the reverse reaction. In tissues where ATP can 
be rapidly consumed (such as skeletal muscle) phosphocreatine serves as an energy reservoir 
for the rapid buffering and regeneration of ATP. Thus, CK plays a key role in maintaining 
ATP levels in this tissue. 
The following protocol was adapted from (Khurana and Dey, 2002) and its principle is 
detailed in Figure 35. Cells growing in 6-well plates were washed twice with ice-cold PBS 
before adding 50 μl of 0.05 M glycilglycin, pH 6.75 (lysis buffer). Plates were left overnight 
with lysis buffer at -20 °C. After thawing, the wells were scraped and the contents centrifuged 
at 16000 x g for 10 minutes in a microcentrifuge at 4 °C. Finally, the supernatant containing 
the soluble internal proteins was collected and stored at 4° C (to avoid freezing and thawing). 
Protein content was determined with the Protein Assay kit (BioRad). 
The assay solution was prepared in 0.1 M glycilglycin (pH 6.75) as follows: 
 10 mM glucose 
 2.5 mM magnesium acetate 
 0.5 mM ADP (Calbiochem) 
 5.0 mM AMP (Calbiochem) 
 0.4 mM NADP+ (Sigma) 
 10 mM Phosphocreatine (Calbiochem) 
 1.0 U/ml hexokinase (Roche) (added immediately before assaying) 
 0.5 U/ml glucose-6-p dehydrogenase (Roche) (added immediately before assaying) 
 1.54 mg/ml DTT (added immediately before assaying) 
Both hexokinase and glucose-6-p dehydrogenase are supplied as a 2:1 enzyme mix. For the 
assay, 100 μl assay solution was transferred to a quartz cuvette and set as zero absorbance at 
340 nm in a spectrophotometer. Then 5 μl of sample was added and the increase in 
absorbance per minute recorded. If the solutions are correctly prepared, addition of CK 
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positive samples will result in a linear increase of absorbance for at least the first 5 minutes. 
The rates are subsequently normalised to the amount of protein measured previously in each 
respective sample. 
 
Figure 35 - Mechanism of creatine kinase assay. 
The creatine kinase (CK) assay relies on three sequential reactions. First, the creatine kinase from the 
sample converts phosphocreatine and ADP to creatine and ATP, respectively. Secondly, the 
generated ATP is used to convert glucose to glucose-6-phosphate by hexokinase present in the assay 
solution. Lastly, glucose-6-phosphate-dehydrogenase uses glucose-6-phosphate to reduce NADP
+
 to 
NADPH. The final product (NADPH) can be measured in a spectrophotometer at 340 nm and its 
production is proportional to the amount of CK added from the sample (all other reagents and 
enzymes exist at constant concentration). 
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2.6.3 Expression of myogenic markers 
The expression of three myogenic markers was measured in C2C12, MyoD, Myog (myogenin) 
and Acta1 (α-actin 1). At the desired time points, cells were released from the wells by adding 
trypsin-EDTA, washed and stored at -20 °C for later RNA extraction. RNA extraction, cDNA 
synthesis and Taqman QRT-PCR are described from page 73 onwards. Primers and probes 
used to quantify expression of these genes are present in Table 6 and Table 7, respectively. 
2.7 Enzymatic assays 
Several assays were used to determine AKR enzymatic activity. Reaction rates (v) were 
calculated as nanomoles of substrate turned over per minute per miligram of enzyme 
(nmol.min
-1
.mg
-1
) or as number of substrate molecules turned over by a molecule of enzyme 
per minute; kcat (min
-1
). 
2.7.1 Spectrophotometric assay 
In the spectrophotometric assay the reaction is monitored by measuring the consumption of 
co-factor in real time. NADPH absorbs at 340 nm (but not its oxidized form NADP
+
) and its 
concentration can be calculated using the NADPH extinction coefficient (ε = 6220 M-1.cm-1). 
Importantly, substrates that also absorb at 340 nm cannot be used in this assay as they 
interfere with the measurement of NADPH. 
Reaction mixtures were prepared in a plastic cuvette to a final volume of 1 ml in 50 mM 
KH2PO4 (pH 6.5) buffer with 150 μM NADPH (Sigma), 0 – 100 μM substrate and 15 μg/ml 
recombinant enzyme. The cuvette was placed in a spectrophotometer kept at 37 °C and 
absorbance measured at 340 nm. Reaction was initiated by adding purified recombinant 
enzyme and NADPH consumption was monitored for 3 to 5 minutes in order to determine 
reaction rates. The intervals at which absorption was measured depended on the speed of the 
reaction. The rate of spontaneous NADPH reduction was also measured by preparing a 
mixture without substrate. This was the minimum measurable rate (background). 
2.7.2 Radiometric assay 
For the radiometric assay the obtained substrates were radioactively labeled with tritium (
3
H) 
so that the reaction products could be visualized after separation in thin layer chromatography 
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(TLC). This method is useful for substrates that absorb in the same wavelength of NADPH 
(340 nm; see above) and informs about the type of products formed. It is also a more sensitive 
method able to detect slower activities. 
For prostaglandin turn-over, reaction mixtures were prepared in borosilicate glass tubes (13 x 
100 mm) (Corning) in a final volume of 0.2 ml in 50 mM KH2PO4 (pH 6.5) buffer with the 
following: 
 150 μM NADPH 
 0.2 μCi radio labeled substrate ([3H]-PGD2, [
3H]-PGE2, [
3H]-PGH2) (GE Healthcare) 
 0 – 250 μM “cold” substrate (PGD2, PGE2, PGH2) (Cayman Chemical) 
For 5α-dihydrotestosterone (5α-DHT) turn-over, a similar set-up was used but with the 
following mixture: 
 150 μM NADPH 
 25 μM 5α-DHT (Sigma) 
 1 μCi [3H]-5α-DHT (GE Healthcare) 
 0 – 250 μM “cold” substrate (PGD2, PGE2, PGH2) (Cayman Chemical) 
Reactions were initiated by adding purified recombinant enzyme (35 μg/ml) and stopped after 
a desired time either by flash-freezing with liquid nitrogen or initiating the extraction 
protocol. 
2.7.3 Extraction of prostanoids 
For extraction, 500 μl methanol and 2.5 μl 10% formic acid (Sigma) were added to each 
sample and vortexed for 1 minute before the addition of 1 ml chloroform and 50 μl 4.2% KCl 
(Sigma). After vortexing for a further 3 minutes the reaction mixtures were spun down at 
2500 rpm for 10 minutes and the resulting aqueous and proteinaceous layers removed by 
aspiration. The prostanoid containing chloroform fraction was evaporated to dryness at 35°C 
under a steam of nitrogen and and prostaglandins were resuspended in 40 μl chloroform.  
2.7.4 Extraction of steroids 
For extraction, 500 μl methanol and 2.5 μl 10% formic acid were added to each sample and 
vortexed for 1 minute before the addition of 1 ml dichloromethane. After vortexing for a 
further 3 minutes the reaction mixtures were incubated at room temperature for 2 hours. 
Samples where then spun down at 2500 rpm for 10 minutes and the resulting aqueous and 
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proteinaceous layers removed by aspiration. The steroid containing chloroform fraction was 
then evaporated to dryness under a steam of nitrogen and at 35°C and the steroids were 
resuspended in 40 μl chloroform. 
2.7.5 Separation of prostanoids and steroids by thin layer chromatography (TLC) 
Extracted prostaglandins and steroids were spotted on to TLC plates (Fluka), 2 cm above the 
bottom edge and each sample separated laterally by 1.5 cm. As a control, 0.2 μCi of radio-
labeled substrate were also spotted along with cold standards.  Prostaglandins were separated 
using chloroform/methanol/acetic acid/distilled water (90:8:1:0.8). Steroids were separated 
using chloroform/ethyl acetate (4:1). The solvents were placed in a chromatography tank for 
at least 2 hours for equilibration before inserting the TLC plates. Chromatography was run for 
1 to 2 hours. After running, the plates were dried for 10 minutes at room temperature before 
being scanned in a Bioscan Plate Reader to detect the location of the radioactive label. Cold 
standards were visualized after a short incubation with iodine vapour. For optimal separation 
of 5α-DHT reduction products plates were run three times consecutively in the same solvent 
solution. 
2.7.6 Resazurin/Diaphorase assay 
The Resazurin/Diaphorase assay is a quick method to measure the consumption of NADPH at 
a certain timepoint in a reaction. The assay is based on two sequential reactions: first the 
normal reaction (enzyme, substrate and NADPH) followed by addition of resazurin (a blue 
non-fluorescent dye) and diaphorase (a cytochrome reductase). Upon addition, the diaphorase 
quickly consumes the remaining NADPH to catalyze the reduction of resazurin to resorufin (a 
pink dye that emits fluorescence at 590 nm after excitation at 530 nm). Fluorescence levels 
are proportional to the amount of NADPH remaining in the well. This assay can be performed 
in 96-well plate format allowing for large scale screens. 
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Reaction mixtures were prepared in 96-well plates (Costar) in a final volume of 0.2 ml in 50 
mM KH2PO4 (pH 6.5) buffer with the following final concentrations: 
 150 μM NADPH 
 0 – 500 μM substrate 
 35 μg/ml recombinant enzyme 
The reaction was left to incubate at 37 °C for the desired period of time followed by the 
addition of 5 μl of the second reaction mixture (concentration in mixture / final 
concentration): 
 1.1 mM / 26.8 μM resazurin (Sigma) 
 22.2 U/ml / 0.54 U/ml diaphorase (Sigma) 
After pipette-mixing the second mixture, the reaction was left to incubate at 37 °C for further 
10 minutes. Fluorescence in the 96-well plate was read using a KC 4 microplate reader with 
excitation at 530 nm, emission at 590 nm and sensitivity of 50. Because AKRs are also 
reductases, a control experiment without substrate was performed for all enzymes to check for 
diaphorase-independent conversion of resazurin to resorufin. 
2.7.7 Determination of enzyme kinetic parameters 
For determination of the enzyme kinetic parameters Km and kcat, the reaction velocity was 
measured using different substrate concentrations. The results were fitted to a Michaelis-
Menten curve using the VisualEnzymics software (SoftZymics). 
2.8 Prostanoid synthesis and turn-over by tissue culture cells 
2.8.1 Prostaglandin turn-over by tissue culture cells 
This assay was used to measure if intact live cells (from tissue culture cell lines) were able to 
metabolise prostaglandins. For adherent cells (like C2C12), cells were seeded in 6-well plates 
and grown to the desired confluence. Then, cells were washed with warm PBS and left in 1 ml 
PBS or serum-free DMEM with 0.2 μCi radio labeled prostaglandin ([3H]-PGD2, [
3
H]-PGE2) 
for 9 hours or overnight. For non-adherent cells (like HPC-7 or K562), 1 – 2x106 cells were 
spun down and resuspended in 0.2 ml PBS with 0.2 μCi radio labeled prostaglandin for 9 
hours or overnight at 37 °C, 5% CO2. After incubation, PBS or serum-free DMEM were 
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collected after centrifugation and prostaglandins extracted, separated and detected as detailed 
in page 95. 
2.8.2 Measuring prostaglandins in tissue culture supernatant 
Levels of secreted prostaglandins were measured in the culture supernatant of C2C12 cells 
using kits from Cayman Chemical (PGD2-MOX EIA kit and PGF2α EIA kit) according to 
manufacturer’s instructions. Media was harvested at different time points during C2C12 
differentiation, flash-frozen with liquid nitrogen and stored at -80 °C. Both are Enzyme-linked 
Immunosorbent Assays (EIA) and are based on the competition between prostaglandin from 
the sample and a fixed amount of prostaglandin-acetylcholinesterase (AChE) conjugate for a 
limited number of prostaglandin-specific antiserum binding sites, coating the inside of a well 
(Figure 36). The more prostaglandin present in the sample, the less prostaglandin-AChE is 
retained in the well after the washings. In the end, a reagent is added containing a compound 
that is converted by AChE into a yellow substance that strongly absorbs at 412 nm. The assay 
is performed in a 96-well plate (each sample read in triplicate) alongside a calibration curve 
with known prostaglandin concentrations. The PGD2-MOX EIA kit has one extra step, 
converting the unstable PGD2 into the more stable PGD2 methoxyme (PGD2-MOX) 
 
Figure 36 - Prostaglandin enzyme-linked immunosorbent assay  
Diagram of the enzyme-linked immunosorbent assay (EIA) for the detection of prostaglandins in tissue 
culture supernatant. Taken from Cayman Chemical website.
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2.8.3 Arachidonic acid metabolism by tissue culture cells  
Arachidonic acid (AA) is the precursor of all eicosanoids and radio-labeled AA can be used to 
trace which prostanoids can be synthesized by a certain cell type. Also, this method can be 
used to detect changes or inhibition in synthesis of certain prostanoids. Tissue culture cells 
were exposed to 0.25 μCi [1-14C] arachidonic acid (GE Healthcare), as detailed in page 97 
and incubated overnight at 37 °C, 5% CO2. Eicosanoids were extracted and separated as in 
page 95. For visualization of AA products, a light-sensitive film was exposed to the TLC 
plate for 3 days at -80 °C before being developed. Cold standards were run in the TLC as 
references. 
2.9 Analysis of cell motility 
C2C12 cells were seeded in 6-well plates (5 x10
4
 per well) and left overnight to adhere. On 
the following day, 2 ml of fresh media with either 10 μM PGD2 or vehicle was added to the 
cells. Each treatment was done in triplicate. The plates were placed on a microscope stage 
equipped with an incubator where they were kept at 37 °C and 5% CO2. Time-lapse imaging 
began 20 minutes after addition of PGD2 with a Nikon Eclipse TE200-U microscope with 20x 
phase contrast objective, capturing 1 frame every 2 minutes over a period of 3 hours. 
Cell movement was tracked using the Manual Track software plug-in for ImageJ. For each 
condition, the movement of 30 cells (10 from each replicate) was tracked and used to generate 
a dispersion plot. 
2.10 Measuring generation of mitochondrial superoxide 
To measure the generation of mitochondrial superoxide, C2C12 cells were seeded in 6-well 
plates (5 x10
4
 cells per well) and left to incubate for 48 hours in growth media. After this, 
growth media was replaced with differentiation media with either100 μM hydrogen peroxide 
(H2O2), 10 μM PGD2, 10 μM 15d-PGJ2 or vehicle (in triplicate) and incubated for 24 hours. 
After incubation, cells were washed twice with PBS and were incubated with 1 ml PBS with 5 
μM MitoSOX red (Invitrogen). MitoSOX red exhibits red fluorescence when oxidized by 
mitochondrial superoxide (absorption/emission ~510/580 nm). Cells were incubated for 20 
minutes with MitoSOX red before imaging. 
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For each well, three fields were photographed using a digital camera associated with an 
Axiovert 135 TV microscope (Zeiss). For each field a contrast-phase and a red-fluorescence 
picture was taken. For each field MitoSOX red fluorescence was quantified using ImageJ 
software and normalised to the cell number. 
2.11 Murine embryonic stem cell (mESC) manipulation 
2.11.1 Culture of G4 murine embryonic stem cells 
The G4 embryonic stem cell line was derived from a male blastocyst originating from the 
natural mating of a 129S6/SvEvTac female with a C57BL/6Ncr male (Nagy et al., 1993). G4 
ES cells are commonly used for in vitro manipulation (gene knock-out, over-expression, etc.) 
and can be used to derive transgenic mouse strains. 
Embryonic stem cell growth is supported in vitro by a layer of mouse embryonic fibroblasts 
(feeder cells). These fibroblasts are obtained from 13.5 day old embryos and treated with 0.01 
mg/ml mitomycin C for two hours. After treatment cells remain viable but are unable to 
proliferate, thus supporting stem cell growth without competing for nutrients.   
Before culturing G4 cells, 60 mm plastic Petri dishes (Costar) were coated with 0.1% gelatin 
solution (Sigma) and a layer of mitomycin C treated feeder cells was seeded on top of it (1 x 
10
6
 per dish). Feeder cells were allowed to attach and form a monolayer overnight. G4 
mESCs were then seeded on top of the feeder layer (1 – 3 x 106 cells per dish) and cultured 
with DMEM (Gibco) with 4500 mg/ml glucose (without sodium pyruvate) and supplemented 
with 15% mESC-tested fetal calf serum (FBS), 2 mM glutamine, 500 U/ml penicillin, 500 
μg/ml streptomycin, 1% non-essential amino acids (Gibco), 100 µM β-mercaptoethanol 
(Sigma), 1% nucleosides and 100 U/ml murine Leukemia Inhibitory Factor (LIF) (Gibco) and 
kept at 5% CO2 at 37°C. Media was changed daily and cells passaged every two or three days 
(before reaching confluence). 
2.11.2 Electroporation and selection of G418-resistant colonies 
For electroporation, 1 x 10
7
 G4 cells were resuspended in 0.8 ml PBS and transferred to an 
electroporation cuvette (Gene Pulser Cuvette, Bio-Rad) with 25 µg of targeting construct 
(previously generated by M Scholze, Max Planck Institute for Molecular Genetics, Berlin, 
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Germany) and electroporated using a Gene Pulser electroporator (Bio-Rad) at 240 V and 500 
µF. After electroporation cells were plated in four 60 mm plastic Petri dishes over neomycin-
resistant feeder cells. Media was changed the following day to remove dead cells. Selection 
began 36 hours after electroporation by changing to selective media with 350 ng/ml G418 
sulphate (Geneticin) (Sigma). Media was changed daily until colonies were clearly visible. 
Neomycin resistant colonies were picked using a stereomicroscope and plated in 96 well 
plates coated with gelatin and a layer of neomycin resistant feeder cells (1 x 10
4
 cells per 
well). Cells were grown in selection media for 3 days and the colonies were replicated 
(keeping the relative position in the plate) into 2 other plates. After 2 more days of culture one 
of the plates was frozen (keeping cells viable) by adding to each well 140 μl of bicarbonate-
free DMEM supplemented with 10mM Hepes, 20% mESC-tested FBS and 20% DMSO and 
storing at -80⁰C. This was the master plate from where the clones would be propagated before 
generating chimeric mice. The remaining two replica plates were grown to confluence for 
DNA extraction (4 – 5 days). 
2.11.3 DNA extraction for mESCs growing in 96-well plates 
Cells growing in 96 well plates were washed with PBS and lysed overnight at 60°C with 50 μl 
lysis buffer (10 mM Tris•Cl, 10 mM EDTA, 10 mM NaCl, 0.5% sacrosyl and 1 mg/ml 
proteinase K) per well. DNA was precipitated by adding 150 μl NaCl and ethanol mix (150 μl 
5 M NaCl in 10 ml cold absolute ethanol) and incubating for 30 minutes at room temperature. 
The DNA precipitated as a filamentous network attached to the bottom of the well. The 
solution was removed by carefully inverting the plate and the DNA washed 3 times with 150 
μl 70% ethanol. 
2.11.4 Colony screening by southern blotting 
Genomic DNA in the 96 well plates was digested in a humid chamber at 37 ⁰C overnight with 
30 μl per well of 330 U/ml genomic tested EcoRV (Promega), 1X EcoRV digestion buffer 
(Promega), 1X bovine serum albumin (BSA) (Promega), 100 μg/ml RNase (Promega) and 1 
mM spermidine (Sigma). The contents of the well were only mixed after 2 – 4 hours of 
digestion to avoid mechanical breakage of genomic DNA. Next day, loading buffer was added 
to the wells and digested DNA electrophoresed in a 0.7% TBA agarose (Invitrogen) gel with 
ethidium bromide (Sigma) at 4 V/cm. After 2 – 3 hours the gel was analysed under UV light. 
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A DNA smear was visible. DNA in the gel was depurinated for 10 minutes with 0.25 M HCl 
and then denatured with 0.5 N NaOH for a further 45 minutes. A Zetaprobe GT membrane 
(BioRad) was pre-wet with H2O for 2 minutes and then soaked in 0.5 N NaOH for 2 minutes. 
DNA in the agarose gel was transferred onto the membrane by capillary blotting overnight. 
Next day, membrane and DNA were cross linked then  neutralized with 2x SSC (0.3 M NaCl, 
0.03 M sodium citrate, 0.1 mM EDTA) for 20 minutes. After that, the membrane was 
incubated with a specific 
32
P dCTP labeled probe in hybridization solution (5X SSC, 5X 
Denhardt's solution, 40% formamide, 0.5% SDS) overnight at 60⁰C. The following day, 
membranes were washed with 2x SSC + 1% SDS, exposed to Phospho Image plate (Fujifilm) 
and scanned with Phospho Image Scanner (Fujifilm). 
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Table 6 - Sequence of primers used for RT-PCR, QRT-PCR, cloning and sequencing 
Primer Name Sequence (5’-3’) # Gene Comment 
18S QRT F GCCGCTAGAGGTGAAATTCTTG 1 18S For mouse and human (taqman) 
18S QRT R CATTCTTGGCAAATGCTTTCG 2 18S For mouse and human (taqman) 
AKR1C12 QRT F TTTGTGATGTGGCCAAAAGG 3 Akr1c12 Designed for mouse gene (taqman) 
AKR1C12 QRT R GGCACAATCCCACGTTGAA 4 Akr1c12 Designed for mouse gene (taqman) 
AKR1C13 QRT F ATCATGGCTTCTGCCTGATGT 5 Akr1c13 Designed for mouse gene (taqman) 
AKR1C13 QRT R ACAAGTCCATCCAACAGTCCATCT 6 Akr1c13 Designed for mouse gene (taqman) 
AKR1C14 QRT F CTACGGATGATTGTGAATCACCAT 7 Akr1c14 Designed for mouse gene (taqman) 
AKR1C14 QRT R GGCACTTGCTGCTCTAACAGAA 8 Akr1c14 Designed for mouse gene (taqman) 
AKR1C18 QRT F GCCCTTGCCACGAGTTCTATTA 9 Akr1c18 Designed for mouse gene (taqman) 
AKR1C18 QRT R GGAGGCGGTGTGTCGAGTT 10 Akr1c18 Designed for mouse gene (taqman) 
AKR1C19 QRT F AGCAATGAGTTCCAAACAGCAA 11 Akr1c19 Designed for mouse gene (taqman) 
AKR1C19 QRT R CTGGTTTGTAGGTGCCAAAGC 12 Akr1c19 Designed for mouse gene (taqman) 
AKR1C20 QRT F AACGCCTGCGCTGATTG 13 Akr1c20 Designed for mouse gene (taqman) 
AKR1C20 QRT R GAAACTCTTGGCTAGGACCACAA 14 Akr1c20 Designed for mouse gene (taqman) 
AKR1C21 QRT F 
CCATGGCAAAAAAATATAATCGAA
CT 
15 Akr1c21 Designed for mouse gene (taqman) 
AKR1C21 QRT R GACCACAATCCCACGCTGTA 16 Akr1c21 Designed for mouse gene (taqman) 
AKR1C6 F CGTCCAGAACTCGTACGG 17 Akr1c6 Designed for mouse gene (taqman) 
AKR1C6 R GAGGTACAGGTCCACATAGTCCAA 18 Akr1c6 Designed for mouse gene (taqman) 
AKR1C6 QRT F 
GATGACCTGAATAAAAATATCCGA
TACA 
19 Akr1c6 Designed for mouse gene (taqman) 
AKR1C6 QRT R 
CCTCCAGTTAGTATTCATCCCAAA
A 
20 Akr1c6 Designed for mouse gene (taqman) 
ACTA1 QRT F CGACGGGCAGGTCATCA 25 α-actin1 Designed for mouse gene (taqman) 
ACTA1 QRT R CGATAAAGGAAGGCTGGAAGAG 26 α-actin1 Designed for mouse gene (taqman) 
CMV FOR CGCAAATGGGCGGTAGGCGTG 27 
CMV 
promoter 
For sequencing 
COX1 QRT F CCAGAACCAGGGTGTCTGTGT 28 Cox-1 Designed for mouse gene (taqman) 
COX1 QRT R GTAGCCCGTGCGAGTACAATC 29 Cox-1 Designed for mouse gene (taqman) 
COX2 QRT F TGACCCCCAAGGCTCAAATA 30 Cox-2 Designed for mouse gene (taqman) 
COX2 QRT R CCCAGGTCCTCGCTTATGATC 31 Cox-2 Designed for mouse gene (taqman) 
DP1 QRT F GTGGCCGCCTTCTGCTT 32 DP1  Designed for mouse gene (taqman) 
DP1 QRT R AGTACTGCACGAACTTCCCAAAA 33 DP1  Designed for mouse gene (taqman) 
DP1 SCREEN F GAAGTTCGTGCAGTACTGTCCAG 34 DP1  For DP1 receptor screening 
DP1 SCREEN R TCCACTATGGAAATCACAGAC 35 DP1  For DP1 receptor screening 
DP1 RT F TCTACCAAAGGCACGTCACCTT 36 DP1  For DP1 receptor screening 
DP1 RT R CGAACTTCCCAAAACCAGCA 37 DP1  For DP1 receptor screening 
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Primer Name Sequence (5’-3’) # Gene Comment 
DP2 QRT F ATGCCCCGACATGTTGTACA 38 DP2  Designed for mouse gene (taqman) 
DP2 QRT R TCTTCTACCAGCACGCTTTCAA 39 DP2  Designed for mouse gene (taqman) 
DP2 SCREEN F CATGTGCTACTACAACTTGC 40 DP2  For DP2 receptor screening 
DP2 SCREEN R GCAGACTGAAGATGTGGTAGG 41 DP2  For DP2 receptor screening 
GAPDH QRT F GACGGCCGCATCTTCTTGT 42 Gapdh Gapdh control (Taqman) 
GAPDH QRT R CACACCGACCTTCACCATTTT 43 Gapdh Gapdh control (Taqman) 
GAPDH FWD TCAAGAAGGTGGTGAAGCAG 44 
Gapdh / 
GAPDH 
Gapdh control (human and mouse) 
GAPDH REV ACCACCCTGTTGCTGTAGCC 45 
Gapdh / 
GAPDH 
Gapdh control (human and mouse) 
H PGDS QRT F TTTAAAGCCTGGCTTGTTGGA 46 H-Pgds Designed for mouse gene (taqman) 
H PGDS QRT R AATGGCAGGGATAGCTTGGA 47 H-Pgds Designed for mouse gene (taqman) 
L PGDS QRT F CACTCGGGCAGCATCCA 48 L-Pgds Designed for mouse gene (taqman) 
L PGDS QRT R TGAATAGCAGAGCGTACTCGTCAT 49 L-Pgds Designed for mouse gene (taqman) 
MYOD QRT F TGGTTCTTCACGCCCAAAAG 50 MyoD Designed for mouse gene (taqman) 
MYOD QRT R TCTGGAAGAACGGCTTCGAA 51 MyoD Designed for mouse gene (taqman) 
MYOG QRT F GACCCTACAGACGCCCACAA 52 Myogenin Designed for mouse gene (taqman) 
MYOG QRT R CATATCCTCCACCGTGATGCT 53 Myogenin Designed for mouse gene (taqman) 
POLYA R GGGTCCATGGTGATACAAGG 56 PolyA seq. For sequencing 
PPARG QRT F TGCCAGTTCGATCCGTAGAA 61 PPARγ Designed for mouse gene (taqman) 
PPARG QRT R 
TCAAGGTTAATGAAACCAGGGATA
TT 
62 PPARγ Designed for mouse gene (taqman) 
PPARG1 CL F 
ATTACCATGGTTGACACAGAGATG
CCATT 
63 PPARγ Designed for mouse gene (cloning) 
PPARG1 SCR F GGACCGAGTGTGACGACAAGAT 64 PPARγ1 
Designed for mouse gene 
(screening) 
PPARG CL R 
TTTCCTGCTAATACAAGTCCTTGT
AGATC 
65 PPARγ1/2 Designed for mouse gene (cloning) 
PPARG1/2 SCR R AGCTGATTCCGAAGTTGGTGG 66 PPARγ 1/2 
Designed for mouse gene 
(screening) 
PPARG2 CL F 
TTTATGCTGTTATGGGTGAAACTC
TGGGA 
67 PPARγ 2 Designed for mouse gene (cloning) 
PPARG2 SCR F TTCTCCTGTTGACCCAGAGCAT 68 PPARγ 2 
Designed for mouse gene 
(screening) 
SP6 PROMOTER ATTTAGGTGACACTATAG 71 
SP6 
promoter 
For sequencing 
T7 PROMOTER TAATACGACTCACTATAGGG 72 
T7 
promoter 
For sequencing 
T7 TERMINATOR GCTAGTTATTGCTCAGCGG 73 
T7 
terminator 
For sequencing 
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 Table 7 - Sequence and modifications of probes used for Taqman QRT-PCR 
Gene Sequence 
Mod 3' 
(quencher) 
Mod 5' 
(fluorochrome) 
Forward 
primer 
Reverse 
Primer 
18S TCTGGTCCGTCTTGCGCCGG 5-TAMRA VIC 1 2 
Akr1c12 AAGCCCTGCCCTAATTGCACTTCGAT 5-TAMRA 6-FAM 3 4 
Akr1c13 TGTGTGTGGACAGTGATGCTGGCAATATG 5-TAMRA 6-FAM 5 6 
Akr1c14 TGGGCACTGGGAGCCAAACCTAAGT 5-TAMRA 6-FAM 7 8 
Akr1c18 TTGTGTGATGCTGGACTCTCAGATGCC 5-TAMRA 6-FAM 9 10 
Akr1c19 ATGGCAACTTCATCCCTGCGCTG 5-TAMRA 6-FAM 11 12 
Akr1c20 CCTTCGCTACCAGGTGCAACGTGG 5-TAMRA 6-FAM 13 14 
Akr1c21 CAGCCTTGATTGCCCTTCGCTACCA 5-TAMRA 6-FAM 15 16 
Akr1c6 AAGTGGTTCTAGCTTTAAGGACCATCCTGATTTTCC 5-TAMRA 6-FAM 19 20 
COX-2 TTGCCCAGCACTTCACCCATCAGTT 5-TAMRA 6-FAM 30 31 
DP2 CGCTCGCTACGCGCGGTG 5-TAMRA 6-FAM 38 39 
Gapdh CAGTGCCAGCCTCGTCCCGTAGA BHQ-1 6-JOE 42 43 
H-PGDS ATCTACCCCAAACTGGTGTCATTACGGAACAAA 5-TAMRA 6-FAM 46 47 
L-PGDS TCCGTGTCAGTGGTGGAGGCCA 5-TAMRA 6-FAM 48 49 
MyoD TGAAGCTTAAATGACACTCTTCCCAACTGTCC 5-TAMRA 6-FAM 50 51 
Myogenin CTGCACTCCCTTACGTCCATCGTGG 5-TAMRA 6-FAM 52 53 
PPARγ CCGTGCAAGAGATCACAGAGTATGCCAA 5-TAMRA 6-FAM 61 62 
α-actin AGCGTTTCCGTTGCCCGGAGA 5-TAMRA 6-FAM 25 26 
            
5-TAMRA, 5-tetramethylrhodamine 
6-FAM, carboxyfluorescein 
BHQ-1, black hole quencher 
6-JOE, 6-Carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein 
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3 CHAPTER THREE: Screening for PGD2-
reductase activity amongst the mouse AKR1C 
enzymes 
In humans, AKR1C3 is the only isoform of the AKR1C subfamily capable of catalysing the 
11β-ketoreduction of PGD2 to 11β-PGF2α. In myeloid leukaemia cells, this activity promotes 
proliferation and resistance to differentiation making AKR1C3 a novel therapeutic target (see 
section 1.3.7). Mice however have eight AKR1C isoforms and it is not known which, if any, 
is the homologue of AKR1C3. 
3.1 Phylogenetic analysis of the AKR1C subfamily 
3.1.1 Comparison of human and murine AKR1C gene clusters 
According to the AKR superfamily nomenclature system, members of the same subfamily, 
such as the AKR1C subfamily, share a minimum of 60% amino-acid sequence identity. All 
AKR1C isoforms from human and mouse are coded in gene clusters on chromosomes 10 and 
13, respectively (scale comparison of both clusters is shown in Figure 38). In both clusters, all 
AKR1C genes have an identical exon-intron organization. However, the phylogenetic 
relationship between enzymes of both species can not be inferred by merely analysing the 
organization of the gene clusters. 
3.1.2 Amino-acid sequence alignment of human and murine AKR1C enzymes 
Higher conservation of amino-acid sequence often reflects a conserved function between two 
proteins. The loci syntenic to that of the human AKR1C gene cluster was analysed in the 
genomes of chimpanzee (Pan troglodytes), macaque (Macaca fuscata), bull (Bos taurus), 
horse (Equus ferus), dog (Canis familiaris), rat (Rattus norvegicus) and mouse (Mus 
musculus) using the Ensembl database (Hubbard et al., 2009). The amino-acid sequence of all 
known and predicted AKR proteins coded in the loci was obtained. The rabbit (Oryctolagus 
cuniculus) genome was not annotated in the Ensembl database but one AKR1C enzyme (-
1C5) had been previously described and is listed on the AKR homepage database 
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(Wintergalen et al., 1995). A total of 62 sequences were obtained from which only 24 had 
been previously described at the AKR homepage (Table 8). The AKR amino-acid sequences 
were aligned using the ClustalW algorithm and a phylogram was generated from this 
alignment using the TreeView X software (Figure 37).   
Interestingly, not all AKR sequences in these clusters belonged to AKR1C subfamily. All 
species have at least one gene in their cluster encoding an AKR1E member (less than 60% 
sequence identity with the remaining) from which only mouse AKR1E1 and human AKR1E2 
had been previously reported (Sakuma and Kubota, 2008). Note that from the three AKR 
genes in the dog (Cf) cluster, two encode enzymes of the AKR1E subfamily (AKR1CL2 and 
AR1). On the other hand, the remaining species have only one AKR1E and several AKR1C 
enzymes. 
Closely related to the AKR1E isoforms is a group of AKR1C enzymes that has been poorly 
described. This includes rat (Rn) AKR1C15, three horse (Ef) enzymes (XP_001500212.1, 
XP_001500201.2 and XP_001500793.2) and AKR1CL1 from human (Hs), chimpanzee (Pt) 
and macaque (Mf). Apart from the cloning of rat AKR1C15 (Qin and Cheng, 1994) no other 
reports have focused on these enzymes. Bull (Bt) and mouse (Mm) do not have any enzyme in 
this group. As mentioned previously, human AKR1CL1 is labeled as a pseudogene in the 
NCBI database. 
The four human isoforms (AKR1C1-1C4) have an average of 88% amino-acid sequence 
identity amongst them hence the proximity in the phylogram. In fact, AKR1C isoforms from 
human, chimpanzee and macaque are all closely related suggesting a recent common ancestor 
in the primate order. Chimpanzee and macaque have 3 AKR1C isoforms while humans have 
4. This is most likely due to a gene duplication occurring in humans that gave rise to 
AKR1C1 and -1C2 (97% sequence similarity). For AKR1C3 and -1C4 there seems to be a 
closely related homologue in the three primate species.  
In contrast to the close kinship of the human AKR1C enzymes, murine isoforms appear to be 
far more diverse. Rodent enzymes have high variability amongst them suggesting that their 
enlarged array of AKR1C proteins has multiple ancestral origins (Figure 37). In most cases, 
mouse enzymes have one-to-one homologues with rat isoforms, for example rat AKR1C8 and 
mouse AKR1C18, which are believed to be functional homologues (Miura et al., 1994, Maho 
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Ishida, 1999). Nevertheless, some mouse and rat-specific gene duplications are observed. 
Importantly, this analysis did not reveal any clear evolutionary homologues between 
individual human and murine AKR1C enzymes.  
As in primates, all AKR1C isoforms found in bull and horse are closely related with isoforms 
of the same species. This suggests that duplication and diversification of AKR1C genes has 
occurred after radiation of the several mammalian orders. 
Another interesting finding is that the positioning of the AKR1C genes in the human and 
mouse genomic cluster strikingly recapitulates the phylogeny of the coded enzymes (Figure 
38). Genes coding for AKRs with higher sequence identity were found to sit in close 
proximity, a likely record of the gene duplication history in the origin of the clusters. 
In conclusion, this analysis revealed high evolutionary divergence amongst mammalian 
AKR1C enzymes. Human enzymes appear to have arisen from gene duplication events 
occurring after the divergence between primates and rodents and thus, one-to-one homologies 
can not be identified.  
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Table 8 - List of AKR proteins encoded in the AKR1C gene cluster of several mammalian species. 
Species Designation in Ensembl Alternative designations 
Described  
in AKR 
homepage? 
Subfamily 
     
Bos taurus AKR1C3 
 
no 1C 
Bos taurus NP_001030444.1 
 
no 1C 
Bos taurus DDBX_BOVIN AKR1C11 yes 1C 
Bos taurus NP_001033673.1 
 
no 1C 
Bos taurus PGFS2_BOVIN AKR1C7 yes 1C 
Bos taurus IPI00903711.1 
 
no 1C 
Bos taurus IPI00837681.2 
 
no 1C 
Bos taurus Q8HZ63_BOVIN 
 
no 1C 
Bos taurus LOC785996 
 
no 1C 
Bos taurus IPI00697013.4 
 
no 1E 
     
Canis familiaris AKR1C3 
 
no 1C 
Canis familiaris AKR1CL2 
 
no 1E 
Canis familiaris AR1 
 
no 1E 
     
Equus ferus AK1CN_HORSE AKR1C23 yes 1C 
Equus ferus XP_001500212.1 
 
no 1C 
Equus ferus XP_001500201.2 
 
no 1C 
Equus ferus XP_001500793.2 
 
no 1C 
Equus ferus XP_001500932.2 
 
no 1C 
Equus ferus XP_001916998.1 
 
no 1C 
Equus ferus XP_001500971.1 
 
no 1C 
Equus ferus XP_001500834.1 
 
no 1C 
Equus ferus XP_001501068.1 
 
no 1C 
Equus ferus XP_001501043.1 
 
no 1C 
Equus ferus XP_001500336.1 
 
no 1C 
Equus ferus AK1CO_HORSE 
 
no 1C 
Equus ferus AKR1CL2 
 
no 1E 
     
Homo sapiens AKR1C1 
 
yes 1C 
Homo sapiens AKR1C2 
 
yes 1C 
Homo sapiens AKR1C3 
 
yes 1C 
Homo sapiens AKR1C4 
 
yes 1C 
Homo sapiens AKR1CL1 
 
no 1C 
Homo sapiens AKR1CL2 AKR1E2 yes 1E 
     
Species Designation in Ensembl Alternative designations 
Described  
in AKR 
homepage? 
Subfamily 
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Macaca fuscata AKR1C3 
 
no 1C 
Macaca fuscata AKR1C4 AKR1C25 yes 1C 
Macaca fuscata AKR1CL1 
 
no 1C 
Macaca fuscata AKR1CL2 
 
no 1E 
     
Mus musculus AKR1C14 
 
yes 1C 
Mus musculus AKR1C20 
 
yes 1C 
Mus musculus AKR1C6 
 
yes 1C 
Mus musculus AKR1C12 
 
yes 1C 
Mus musculus AKR1C13 
 
yes 1C 
Mus musculus AKR1C19 
 
yes 1C 
Mus musculus AKR1C18 
 
yes 1C 
Mus musculus AKR1C21 
 
yes 1C 
Mus musculus AKR1E1 
 
yes 1E 
     
Oryctolagus cuniculus n/a AKR1C5 yes 1C 
     
Pan troglodytes XM_001143407.1 
 
no 1C 
Pan troglodytes AKR1C3 
 
no 1C 
Pan troglodytes AKR1C4 
 
no 1C 
Pan troglodytes AKR1CL1 
 
no 1C 
Pan troglodytes AKR1CL2 
 
no 1E 
     
Rattus norvegicus NP_001103370.1 AKR1C15 yes 1C 
Rattus norvegicus NP_001028869.1 AKR1C1 no 1C 
Rattus norvegicus AKR1C12 AKR1C16 yes 1C 
Rattus norvegicus NP_001129216.1 AKR1C17 yes 1C 
Rattus norvegicus NP_001014262.3 AKR1C24 yes 1C 
Rattus norvegicus NP_001094046.1 AKR1C19 no 1C 
Rattus norvegicus AK1CH_RAT AKR1C8 yes 1C 
Rattus norvegicus AK1CL_RAT AKR1C21 no 1C 
Rattus norvegicus DIDH_RAT AKR1C9 yes 1C 
Rattus norvegicus AKCL2_RAT AKR1CL2 no 1E 
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Figure 37 - Phylogeny of the AKR proteins coded in the AKR1C 
gene cluster of several mammalian species. 
The amino-acid sequences of all AKR genes found in the AKR1C 
gene clusters of several mammalian species were aligned using 
ClustalW and a tree was generated using TreeView X software. The 
species analyzed were: human (Homo sapiens, Hs, red arrows), 
chimpanzee (Pan troglodytes, Pt), macaque (Macaca fuscata, Mf), 
bull (Bos taurus, Bt), horse (Equus ferus, Ef), dog (Canis familiaris, 
Cf), mouse (Mus musculus, Mm, blue arrows) and rat (Rattus 
norvegicus, Rn). The rabbit genome (Oryctolagus cuniculus, Oc) was 
not annotated on the Ensembl database. The only rabbit enzyme 
analyzed (AKR1C25) was described in the AKR homepage database. 
PGD2 11β-ketoreductases are marked with a green circle. The names 
shown for each protein are described on Table 8. 
 
AKR1E 
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Figure 38 – Relationship between phylogeny and gene positioning of the human and mouse AKR1C 
cluster. 
Position of AKR1C genes in chromosome reflects phylogenetic relationships. Scale representation of 
murine (chromosome 13) and human (chromosome 10) AKR1C gene clusters. Grey boxes represent 
individual genes. 
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3.2 Production of recombinant murine AKR1C proteins 
The phylogenetic analysis of the AKR1C subfamily revealed high evolutionary divergence 
between human and murine isoforms. Nevertheless, this does not rule out the existence of a 
PGD2 11β-ketoreductase amongst the murine enzymes since bovine isoforms AKR1C7 and -
1C11 with low identity with AKR1C3 also have this activity. In order to test if the mouse 
AKR1C enzyme can reduce PGD2, purified His-tagged recombinant proteins were generated 
for the eight mouse isoforms. 
The open reading frames of the eight AKR1C isoforms were amplified from a panel of mouse 
tissues and cell line cDNAs (see Table 4). The amplified coding regions were cloned into the 
expression vector pET28b. Figure 39 shows the cloning process of Akr1c14 and is 
representative of the remaining isoforms. Correct cloning was confirmed by nucleotide 
sequencing before over-expression of the protein in E. coli strain BL21. The expressed 
recombinant protein was isolated by affinity column purification taking advantage of a 6xHis 
tag introduced in the N-terminus of the protein. To achieve a greater level of purity, the 
protein was further purified by fast protein liquid chromatography (FPLC). Purity of the 
recombinant proteins was assessed by SDS-PAGE as shown in Figure 40. Cloning and 
production of human recombinant AKR1C proteins had been previously performed by Dr N 
Davies and Dr J Ride.   
Amplification of the Akr1c18 coding region resulted in two products:  the expected product 
containing the full coding region and a product lacking exon 4 (as confirmed by nucleotide 
sequencing). The apparent splice variant lacking exon 4 did not yield any recombinant protein 
after over-expression suggesting it formed an unstable product. The complete coding region 
of Akr1c18 resulted in production of reasonable levels of recombinant protein. However, the 
total amount of AKR1C18 produced was much what was obtained for the remaining 
recombinant AKRs for reasons that were not determined. 
To test for activity, recombinant proteins were incubated with NADPH and 
phenanthrenequinone (PQ), a synthetic compound with two carbonyl groups, commonly used 
to detect AKR-mediated reduction (Penning et al., 2000, Byrns et al., 2008, Suzuki et al., 
1999, Chen et al., 1992). Consumption of NADPH was monitored spectrophotometrically as 
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shown in Figure 41. All recombinant AKRs consumed NADPH in the presence of PQ. This 
assay was routinely used to assess the integrity of the recombinant enzymes. 
 
 
Figure 39 - Cloning AKR1C14 open reading frame into pET28b 
This scheme is representative for the cloning of all AKRs. The open reading frame (ORF) of Akr1c14 
was amplified by PCR from total C2C12 cDNA. The ~1 kb product was purified, digested (NdeI, XhoI) 
and purified. The expression vector pET28-b was linearised (NdeI, XhoI) and gel purified.  Purified 
vector and insert have compatible cohesive ends and were ligated. Ligation products were 
transformed into competent bacteria (DH5α), colonies were picked, expanded and plasmid DNA 
extracted. Correct cloning was firstly analysed by restriction pattern. In this example, digestion with 
SphI, EcoRI and XhoI allowed the identification of three clones with the expected pattern (red arrows). 
The selected plasmids were sequenced to confirm correct cloning of the AKR ORF. 
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Figure 40 - SDS-PAGE of purified recombinant AKR1C proteins 
Purity of recombinant AKR1C proteins was assessed by SDS-PAGE followed by Coomassie Blue 
staining. 3 μg of recombinant AKR was loaded in each lane before separation in a 12% SDS-
polyacrylamide gel. L: ladder. 
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Figure 41 - Recombinant AKR1C enzymes have activity against phenanthrenequinone (PQ) 
Purified recombinant AKR1C enzymes were incubated with NADPH and phenanthrenequinone (PQ), 
a synthetic compound with two carbonyl groups that is reduced by AKR enzymes. Reduction of PQ 
was assessed by monitoring the consumption of NADPH in a spectrophotometric assay. Absence of 
PQ resulted in no consumption of NADPH (red line). 
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3.3 Activity of murine AKR1C enzymes against PGD2 
The purified recombinant enzymes were then used to determine which of the murine 
isoforms, if any, has PGD2 reductase activity. Recombinant AKRs were incubated with 
NADPH and [
3
H]-PGD2 at 37 ºC for four hours. The products were extracted and separated 
by thin layer chromatography (TLC) along with known standards for PGD2, 15d-PGJ2 and 
11β-PGF2α (as detailed on page 95). Each lane of the TLC plate was scanned to identify the 
position of the radio-labeled products. A representative set of traces is shown in Figure 42. 
A trace of non-incubated radio-labeled substrate (hot standard) shows a major peak, co-
migrating with PGD2, and a smaller peak co-migrating with 15d-PGJ2, which is the result of 
spontaneous dehydration. Incubation of PGD2 in buffer without enzyme results in increased 
spontaneous generation of 15d-PGJ2. Human AKR1C3 was used as positive control, as this 
enzyme was able to efficiently convert PGD2 to a product co-migrating with 11β-PGF2α and 
prevent further 15d-PGJ2 generation. When PGD2 was incubated with the murine AKR1C 
enzymes no 11β-ketoreduction or any other type of modification was observed. This result 
was obtained with different batches of recombinant enzymes. An alternative assay measuring 
the consumption of NADPH (detailed on page 96) also showed that, unlike AKR1C3, murine 
AKR1C enzymes do not use PGD2 as a substrate (data not shown). 
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Figure 42 - Murine AKR1C enzymes do not reduce PGD2 
Human AKR1C3 and murine AKR1C6, -1C12, -1C13, -1C14, -1C18, -1C19, -1C20 and -1C21 were 
incubated with NADPH and [
3
H]-PGD2 at 37 °C for 4 hours. Reaction products were separated by thin 
layer chromatography and the lanes were scanned to detect radio-labeled species. The hot standard 
lane represents [
3
H]-PGD2 separated without incubation. Incubation of [
3
H]-PGD2 in the absence of 
AKR enzymes (no AKR) resulted in spontaneous dehydration into 15d-PGJ2 (J2). Human AKR1C3 
converted PGD2 (D2) into 11β-PGF2α (F2α) preventing the spontaneous generation of J2. None of the 
murine AKR1C enzymes was able to reduce PGD2 or modify it in any other way. This experiment was 
repeated several times with identical results. 
 
123 
 
3.4 Activity of murine AKR1C enzymes towards PGH2 and PGE2 
Production of PGF2α can be achieved by two other routes, the 9,11-endoperoxide reduction of 
PGH2 and the 9-ketoreduction of PGE2 (Figure 18). These two routes generate 11α-PGF2α 
(simply denominated PGF2α), a stereoisomer of 11β-PGF2α capable of activating the FP 
receptor with similar affinity. All these reductions are considered PGF synthase activities and 
are commonly performed by members of the AKR superfamily. Recently, the first three 
murine PGF synthases have been described. Two of the AKR1B subfamily (Kabututu et al., 
2008) and one of the thioredoxin-like superfamily (Moriuchi et al., 2008). Because human 
AKR1C3, bovine AKR1C7 and AKR1C11 and rabbit AKR1C5 have PGF synthase activity 
the ability of murine AKR1C enzymes to reduce PGH2 or PGE2 was interrogated. 
Incubation of murine enzymes with [
3
H]-PGH2 did not result in reduction or any other 
modification (data not shown). Incubation with [
3
H]-PGE2 revealed that only mouse AKR1C6 
was able to perform the 9-ketoreduction to generate a product co-migrating with PGF2α 
(Figure 43 A). These results were confirmed with the NADPH consumption assay (data not 
shown). This as yet undescribed PGF synthase activity of AKR1C6 occurred at a slow rate 
and was incomplete, as only ~ 40% of PGE2 was reduced after 4 hours at which point the 
reaction reached equilibrium (Figure 43 B). This was not due to product inhibition since 0.05, 
0.5, 5 and 50 μM PGF2α did not impair AKR1C6-mediated reduction of PQ. Analysis of 
enzyme kinetics revealed that the AKR1C6-mediated reduction of PGE2 was not only slow 
(kcat = 0.24 ± 0.03 min
-1
) but also occurred with low affinity (Km = 73.1 ± 19.9 μM) (Figure 
43 C). These parameters, however, are comparable to those described for another PGE2 9-
ketoreductase, rabbit AKR1C5 (Wintergalen et al., 1995). 
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3.4.1 K562 cells overexpressing AKR1C6 do not acquire PGE2 reductase activity. 
Given that AKR1C6 reduces PGE2 with low efficiency in vitro it was interrogated if the 
artificial over-expression of AKR1C6 could confer PGE2-reductase activity to cells. For over-
expression an MSCV-IRES vector that produces a bicistronic mRNA with AKR1C6 and GFP 
was used (detailed on page 87). The co-expression of GFP with the gene of interest allows for 
the determination of transfection efficiency using flow cytometry. The cell line of choice was 
K562, since these cells are of human origin and therefore have no expression of AKR1C6, are 
easy to transfect and do not metabolise PGE2 (Figure 44). Nevertheless, PGE2 seems to be 
able to cross the membrane and enter the cytoplasm of K562 cells as radio-labelled product 
was identified inside cells (Figure 44, bottom pannel). 
K562 cells were co-transfected with a vector coding for a truncated membrane protein H-2Kk 
and either MSCV-GFP (vector control) or MSCV-AKR1C6-GFP. Transient expression of H-
2Kk allowed for the enrichment of transfected cells, as described on page 90. After 
enrichment, the proportion of GFP positive cells was 91% and 83% for MSCV-GFP and 
MSCV-AKR1C6-GFP, respectively (Figure 45 A). The over-expression of AKR1C6 was 
confirmed by RT-PCR, using mouse liver as a positive control (Figure 45 B). However, cells 
over-expressing AKR1C6 did not metabolise radio-labeled PGE2 (Figure 45 C). 
3.5 Discussion 
In human AML cells AKR1C3 promotes cell proliferation and prevents differentiation by 
depleting PGD2 from the cytosol. In order to produce an animal model to study the 
physiological role of AKR1C3 I have searched for a mouse AKR1C enzyme with PGD2 11β-
ketoreductase activity.  
To date, 24 sequences are attributed to the AKR1C subfamily. In order to have a more 
comprehensive overview of the AKR1C phylogeny, all known and predicted AKR sequences 
coded in the human, chimpanzee, macaque, rat, horse and bull AKR1C gene clusters were 
aligned in order to generate a phylogenetic tree (Figure 37). The 38 additional AKR1Cs are 
predicted sequences that were obtained by screening the Ensembl database for AKR-coding 
genes in the loci homologous tho the human AKR1C gene cluster. The phylogenetic analysis 
revealed significant diversity amongst mammalian AKR1C enzymes. Isoforms were more 
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closely related to others of the same mammalian order (primate, rodent, etc.) suggesting the 
AKR1C enzymes have diversified later in mammalian evolution. Thus, this analysis failed to 
identify phylogenetic homologues between human and mouse AKR1C isoforms. 
Nevertheless, PGD2 reductase activity seems to have evolved independently in at least two 
phylogenetic branches: the primate (AKR1C3) and the bovine (AKR1C7 and AKR1C11).  
Therefore, the murine isoforms were screened for PGD2 reductase activity using purified 
recombinant enzymes. Surprisingly, none of the murine AKR1C enzymes reduced PGD2 
suggesting this activity is absent in mice or is performed by an enzyme of another family 
(AKR or non-AKR). This result has strong implications in the modeling of AKR1C3 in mice 
since there is no apparent functional homologue that could be targeted for a knock-out. This 
also raises the question of how conserved are the remaining AKR1C functions, such as steroid 
metabolism and its implications in prostate, breast and endometrial tissues. 
We have also identified that AKR1C6 has PGF synthase activity by catalysing the 9-
ketoreduction of PGE2. To date, the only AKR described as a PGE2 reductase was AKR1C5, 
an enzyme expressed in the corpus luteum of rabbits  (Wintergalen et al., 1995). Because 
AKR1C5 acted both as a PGF synthase and an inactivator of progesterone it was speculated 
that the enzyme plays a role in promoting the regression of the corpus luteum. In order to 
ascertain if AKR1C6 has a similar role in mouse physiology it is essential to determine its 
exact tissue expression pattern as well as its steroid metabolism properties. 
The results so far have shown that human and murine AKR1C enzymes are highly divergent 
in sequence and prostaglandin metabolizing properties. The next stage was to fully 
characterize these enzymes for their steroid substrate preference and tissue expression.  
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Figure 43 - Mouse AKR1C6 reduced PGE2 to PGF2α 
A: [
3
H]-PGE2 was incubated with NADPH for 6 hours at 37 ºC in the presence or absence of murine 
purified recombinant AKR1C enzymes. Products were extracted, separated by TLC and visualized as 
described on page 94. Non-incubated PGE2 (hot standard) shows a peak co-migrating with PGE2 (E2). 
Incubation of PGE2 without AKR does not result in spontaneous generation of other products. 
Incubation of PGE2 with AKR1C6, but not other mouse or human AKR1C enzymes, resulted in 
generation of a product co-migrating with PGF2α (F2α). B: Reduction of PGE2 to PGF2α by AKR1C6 
was incomplete reaction with only 40% of conversion at equilibrium after 4 hours incubation. C: 
Michaelis-Menten curve for the reduction of PGE2 by AKR1C6. Incubation with increasing 
concentrations of PGE2 was stopped 1 hour after addition of enzyme and reaction rates were 
calculated. Data was fitted to a Michaelis-Menten curve using Visual Enzymics. Dots represent 
biological replicates for each concentration.  
127 
 
 
 
 
Figure 44 - K562 cells do not metabolise PGE2 
5x10
6
 K562 cells were resuspended in 200 μl PBS with 5 μCi [
3
H]-PGE2 and incubated at 37 ºC 
overnight. Prostanoids were extracted from supernatant and cells and analysed by TLC. Although 
K562 did not metabolise PGE2, the radio-label was found inside the cells suggesting PGE2 can enter 
the cytoplasm of K562. 
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Figure 45 - Ectopic expression of AKR1C6 in K562 does not confer PGE2 reductase activity 
A: K562 cells were co-transfected with plasmids encoding for the membrane protein H-2Kk and with 
MSCV-GFP or MSCV-AKR1C6-GFP. Transfected cells were purified by affinity column taking 
advantage of the transient expression of the H-2Kk protein (detailed on page 90). Transfection 
efficiency was assessed by measuring GFP fluorescence in a flow cytometer. Purple filled curve: 
untransfected K562. Green line: MSCV-GFP (91% GFP
+ve
). Pink line: MSCV-AKR1C6-GFP (83% 
GFP
+ve
). B: Expression of AKR1C6 was measured by RT-PCR. Mouse liver cDNA was used as a 
positive control. C: Transfected K562 were incubated with radio-labeled PGE2 overnight and analysed 
by TLC. Over-expression of AKR1C6 did not confer PGE2 metabolizing activity to K562. 
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4 CHAPTER FOUR: Unveiling the differences 
between human and murine AKR1C enzymes 
4.1 Activity of human and murine AKR1C enzymes towards steroids 
Most AKR1C enzymes have hydroxysteroid dehydrogenase (HSD) activity, reducing 
carbonyl groups at position 3 (3α/β-HSD), 17 (17β-HSD) or 20 (20α-HSD). These enzymes 
are responsible for the tissue-specific activation or inactivation of steroids, thus regulating the 
transcriptional activity of steroid hormone receptors. In order to find functional homologies, 
human and murine AKR1C enzymes were characterised for their ability to reduce 
androstanedione, 5α-dihydrotestosterone (5α-DHT), estrone and progesterone.  
4.1.1 Screen for steroid reducing activities 
A spectrophotometric assay was used to measure the real-time consumption of NADPH 
(described on page 94), an indirect measure of the reduction reaction. However, using this 
assay, the reaction products can not be identified. The possible products for each reaction are 
shown in Figure 46. Androstanedione, a steroid precursor, has two carbonyl groups in 
positions 3 and 17. Reduction at position 3 yields androsterone, a weak androgen, whilst 
reduction at position 17 yields 5α-DHT, a potent androgen. Reduction at both sites results in 
androstanediol, a weak androgen or an estrogen depending upon wether the hydroxyl group is 
in the α or β orientation, respectively. Reduction of progesterone at position 20 to 20α-
dihydroxyprogesterone results in its inactivation. Estrone when reduced at position 17 yields 
17β-estradiol, a potent estrogen. These steroids were incubated with the human and murine 
recombinant AKR1C enzymes to detect reduction activity. Results are summarized in Table 
9. 
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Figure 46 - Steroid reduction reactions. 
A panel of steroids was used as test substrates for human and murine AKR1C enzymes. 
Androstanedione, an inactive steroid precursor, can be converted to the weak androgen androsterone 
(3α-HSD) or the potent androgen 5α-DHT (17β-HSD). Progesterone can be inactivated to 20α-
dihydroxyprogesterone (20α-HSD). Estrone can be converted to the potent estrogen 17β-estradiol 
(17β-HSD). The potent androgen 5α-DHT can be inactivated to the weak androgen 3α-androstanediol 
or the estrogen 3β-androstanediol (3α/β-HSD). 
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Androstanedione (adione) was reduced by all human enzymes, with AKR1C2 and AKR1C4 
being the most efficient (kcat/Km = 795 and 627 min
-1
.mM
-1
, respectively). Murine AKR1C6 
and AKR1C21 were the only isoforms with detectable androstanedione reduction activity. 
However, the kinetic profile of AKR1C21 did not fit a Michaelis-Menten curve, with reaction 
velocities increasing until ~ 6 μM adrostanedione (~ 4 min-1) followed by a decrease. 
Reduction of estrone to 17β-estradiol was not detected amongst the human enzymes with this 
assay. However, murine AKR1C6 and AKR1C18 were able to reduce estrone with relatively 
high efficiency (kcat/Km = 452 and 652 min
-1
.mM
-1
, respectively).  
Reduction of progesterone to its 20α-hydroxy form was detected with AKR1C4, -1C3 and -
1C1, the latter being the most efficient (kcat/Km = 421 min
-1
.mM
-1
). Amongst the murine 
isoforms, AKR1C6, -1C18 and -1C20 were able to reduce progesterone with different 
efficiencies (kcat/Km = 192, 1080 and 138 min
-1
.mM
-1
, respectively). It should be noted that in 
spite of its relatively low affinity (Km = 105.7 µM) AKR1C18 showed rapid turn over of 
progesterone (114.12 min
-1
).  
Reduction of 5α-DHT was detected for all human isoforms except AKR1C3. Efficiency was 
highest with AKR1C4, followed by -1C2 and -1C1 (kcat/Km = 1096, 472 and 146 min
-1
.mM
-1
, 
respectively). Murine AKR1C18 was capable of reducing 5α-DHT with extremely high 
efficiency (kcat/Km = 5746 min
-1
.mM
-1
). AKR1C6 and AKR1C21 also showed activity 
towards 5α-DHT but, once again, the kinetic profile of AKR1C21 did not fit a Michaelis-
Menten curve with reaction velocity peaking at ~ 15 μM (~ 4 min-1) followed by a decrease 
with higher substrate concentrations. 
These results show that despite androstanedione, progesterone, estrone and 5α-DHT being 
used by human and murine enzymes there are no clear functional homologues in terms of 
substrate preference.  
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Table 9 - Kinetic parameters for the NADPH-dependent reduction of steroid hormones by purified recombinant 
murine AKR isoforms 
 
Enzyme 
Km 
(μM) 
kcat 
(min-1) 
kcat/Km 
(min-1.mM-1) 
 
Enzyme 
Km 
(μM) 
kcat 
(min-1) 
kcat/Km 
(min-1.mM-1) 
Adione 
    
Estrone 
   
AKR1C1 35.9 ± 4.4 5.24 ± 0.36 146  AKR1C1 na na na 
AKR1C2 1.9 ± 0.7 1.51 ± 0.10 795  AKR1C2 na na na 
AKR1C3 3.8 ± 1.0 0.79 ± 0.05 210  AKR1C3 na na na 
AKR1C4 7.4 ± 2.1 4.64 ± 0.39 627  AKR1C4 na na na 
         
AKR1C6 19.1 ± 4.5 10.33 ± 1.06 541  AKR1C6 11.4 ± 3.5 5.15 ± 0.58 452 
AKR1C12 na na na  AKR1C12 na na na 
AKR1C13 na na na  AKR1C13 na na na 
AKR1C14 na na na  AKR1C14 na na na 
AKR1C18 na na na  AKR1C18 8.9 ± 4.4 5.8 ± 0.95 652 
AKR1C19 na na na  AKR1C19 na na na 
AKR1C20 na na na  AKR1C20 na na na 
AKR1C21 nmm nmm nmm  AKR1C21 na na na 
Progesterone 
    
5α-DHT 
   
AKR1C1 4.2 ± 1.0 1.77 ± 0.13 421  AKR1C1 46.9 ± 6.5 6.85 ± 0.45 146 
AKR1C2 na na na  AKR1C2 4.3 ± 0.6 2.03 ± 0.08 472 
AKR1C3 0.9 ± 0.3 0.14 ± 0.01 156  AKR1C3 na na na 
AKR1C4 9.4 ± 3.5 0.74 ± 0.09 79  AKR1C4 6.7 ± 1.9 7.34 ± 0.66 1096 
         
AKR1C6 25.1 ± 5.6 4.81 ± 0.87 192  AKR1C6 5.8 ± 2.2 0.93 ± 0.10 160 
AKR1C12 na na na  AKR1C12 na na na 
AKR1C13 na na na  AKR1C13 na na na 
AKR1C14 na na na  AKR1C14 na na na 
AKR1C18 105.7 ± 29.1 114.12 ± 19.2 1080  AKR1C18 3.9 ± 0.5 22.41 ± 0.82 5746 
AKR1C19 na na na  AKR1C19 na na na 
AKR1C20 3.7 ± 1.2 0.51 ± 0.05 138  AKR1C20 na na na 
AKR1C21 na na na  AKR1C21 nnm nnm nnm 
         
adione; androstanedione 
5α-DHT; 5α-dihydrotestosterone 
na; no detectable activity 
nmm; data does not fit a Michaelis-Menten curve 
 
4.1.2 Validation of 5α-DHT reduction using radio-labeled substrate  
The spectrophotometric assay used to characterize the steroid preference of human and 
murine AKR1C enzymes is an easy and convenient method. However, its sensitivity is 
limited and slow enzymatic activities (with low Km and kcat) may not be detected. Therefore, a 
radiometric assay was used to measure the turn-over of 5α-DHT in order to compare the two 
methods. 
Enzymes were incubated with 25 μM 5α-DHT for 30 and 90 minutes before extraction of 
reaction products and separation by TLC (Figure 47). All enzymes apart from AKR1C19 and 
-1C20 reduced 5α-DHT. The majority converted 5α-DHT to 3α-androstanediol (3α-adiol) 
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whilst AKR1C2 produced mainly 3β-androstanediol, AKR1C4 produced both stereoisomers 
and mouse AKR1C21 yielded a product that did not co-migrate with 3α- or 3β-
androstanediol. The percentage of substrate reduced to product was determined at 30 and 90 
minutes (Figure 48). In agreement with the spectrophotometric assay, AKR1C1, -1C2, -1C4, -
1C18 and -1C21 were the most efficient in reducing 5α-DHT (between 50 and 100% substrate 
reduction at 30 minutes). AKR1C6 showed an intermediate efficiency whilst AKR1C3, -
1C12, -1C13, -1C14 reduced 5α-DHT at a slow rate.  
Both methods identified AKR1C1, -1C2, -1C4, -1C6, -1C18 and -1C21 as the most efficient 
in reducing 5α-DHT (Table 9 and Figure 48). However, the lower activities of AKR1C3, -
1C12, -1C13 and -1C14 against 5α-DHT were only detected using the radiometric method. 
This result exposes the limitations of the spectrophotometric assay but does not contradict the 
results obtained in the previous section. 
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Figure 47 - Reduction of 5α-DHT by human and murine AKR1C enzymes. 
Murine and human recombinant AKR1C enzymes were incubated with 25 μM 5α-DHT spiked with 
radio-labeled 5α-DHT and NADPH for 90 minutes. Steroids were extracted, separated by thin layer 
chromatography (TLC) and visualized by scanning the lanes for radioactive products. Hot standards 
for 5α-DHT and 3α-androstanediol (3α-adiol) ran as shown on top two panels of left column.  Most 
enzymes that reduced 5α-DHT produced 3α-adiol (3α) except AKR1C1 that produced mainly 3β-adiol 
(3β), AKR1C4 produced a mixture of both stereoisomers and AKR1C21 that produced an unknown 
species (?). These are representative traces. Experiment was repeated thrice. 
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Figure 48 – Fraction of 5α-DHT reduced to 3α/β-androstanediol by human and murine AKR1C enzymes. 
Human and murine AKR1C enzymes were incubated with radio-labeled 5α-DHT for 30 or 90 minutes 
and reaction products were analysed as shown in Figure 47. Bars represent the average percentage 
of 5α-DHT converted to 3α/β-androstanediol at those time points, obtained from three replicates. 
Errors bar represent standard deviation. Note that AKR1C21 quickly converted 5α-DHT to a product 
that did not co-migrate with either 3α- or 3β-androstanediol. 
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4.2 Tissue-expression pattern of murine AKR1C enzymes 
The four human AKR1C enzymes have distinct tissue expression patterns (Penning et al., 
2000) which correlate with their enzymatic preferences (androgens and estrogens in prostate 
and breast; PGD2 in haemopoietic cells) and their implication in cancer (Figure 8). In order to 
assertain the relationship between enzymatic activity and tissue distribution the expression of 
the 8 murine AKR1C enzymes was measured in mouse spleen, liver, lung, stomach, small 
intestine, colon, kidney, prostate, testes, uterus (from pregnant animals) and ovary (from 
pregnant and non-pregnant animals). 
For this analysis all tissues were obtained in triplicate (from three different animals) from our 
collaborators (Dr H. Schrewe and P. Rocha) at the Max Planck Institute for Molecular 
Biology in Berlin, Germany. RNA was extracted, cDNA prepared and gene expression 
measured using Taqman QRT-PCR (detailed in page 75). Sequences of primers and probes 
used are shown in Table 6 and Table 7, respectively. Two “housekeeping” genes were used as 
loading controls, Gapdh and 18S. The expression levels of 18S were more consistent between 
tissues than Gapdh. Therefore, expression of AKR1C genes in each sample was normalized to 
18S expression. Variability between tissue replicates was identical for Gapdh and 18S.  
Normalized expression of the 8 murine AKR1C genes and Gapdh is shown in Figure 49. 
Most AKR1C genes were found to be expressed in the liver, particularly Akr1c6 and -1c20 
which were detected exclusively in this tissue. Tissue specificity was also observed for 
Akr1c21 which was detected only in the kidney. Progesterone-inactivating Akr1c18 was 
highly expressed in the ovaries of non-pregnant mice but was absent in ovaries of pregnant 
mice. The closely related Akr1c12, -1c13 and -1c19 showed a similar expression pattern, 
being detected mainly in gastrointestinal tissues (stomach, small intestine and colon). Akr1c14 
showed the broadest tissue distribution being detected in liver, lung, stomach, colon, kidney, 
uterus and ovary. Surprisingly, tissues that are highly responsive to sex-steroids (prostate, 
testes and uterus) showed very low or no expression of AKR1C isoforms. As mentioned 
previously, Gapdh was expressed in all tissues but at variable levels. 
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Figure 49 - Tissue expression of the eight murine AKR1C enzymes. 
RNA was extracted from several tissues from CD1 mice (in triplicate), cDNA generated and gene 
expression quantified by Taqman QRT-PCR. Expression levels were normalized to 18S expression 
using the following formula: (2
-(CTgene - CT18S)
) x10
6
 and Gapdh expression was measured as control of 
cDNA quality. P; extracted from pregnant mice. Bars represent average expression of three biological 
replicates and error bars represent standard deviation.  
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4.3 Expression of AKR1C enzymes in a murine haemopoietic stem cell line 
(HPC-7) 
Since AKR1C1, -1C2 and -1C3 are expressed in human haemopoietic stem cells we 
interrogated which AKR1C genes are similarly expressed in mouse. However, haemopoietic 
stem cells comprise a very small fraction of the bone marrow cell content (0.1 - 0.01%) and 
harvesting large amounts of these cells is difficult and requires the sacrifice of many animals. 
Therefore we used a mouse cell line with haemopoietic stem cell properties (HPC-7) to 
measure the expression of AKR1C genes in haemopoietic lineages. 
4.3.1 Differentiation of HPC-7 
The HPC-7 cell line was generated in 1998 by transducing mouse embryonic stem cells with 
the coding region of LH2, a transcription factor expressed in foetal liver at the time of active 
haemopoiesis (Pinto do et al., 2002, Pinto do et al., 1998). This resulted in the generation of a 
multipotent haemopoietic precursor cell line that requires stem cell factor (SCF) for growth 
and expresses appropriate haemopoietic progenitor markers. Furthermore, HPC-7 cells can be 
induced to differentiate into various mature myeloid lineages upon addition of other factors. 
The SCF required for expansion of HPC-7 was obtained by harvesting the conditioned media 
from CHO cells over-expressing SCF (method detailed on page 70). HPC-7 cells were 
cultured with 10% SCF-conditioned media. The expression of AKR1C genes was measured 
in both differentiated and undifferentiated HPC-7. 
When cultured in the presence of SCF, HPC-7 cells retained their blast morphology and grew 
at a steady rate (Figure 50). Removal of SCF resulted in a quick decrease in cell number with 
culture death occurring 2 days after factor-deprivation (Figure 50 B). Exposure to 4 U/ml 
human erythropoietin (hEPO) induced a notable increase in cell proliferation after 2 days 
followed by stabilization of cell number after 4 days (Figure 50 B). Treatment with hEPO also 
induced differentiation into the erythroid lineage, with red blood cells appearing after 4 days 
in culture (Figure 50 A). The cell pellets of hEPO-treated cultures, collected every two days, 
became increasingly red, probably due to the production of haemoglobin.  
Previous reports using another mouse haemopoietic progenitor cell line (EML) showed that a 
combination of SCF, interleukin-3 (IL-3) and all-trans retinoic acid (ATRA) is able to induce 
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the initiation of promyelocytic differentiation (Tsai et al., 1994, Weiler et al., 1999, Du et al., 
2000). HPC-7 cells were cultured in the presence of SCF, 100 ng/ml mouse IL-3 and 100 nM 
ATRA for 72 hours and changes in cell number, cell morphology and surface expression of 
the markers CD34 and Sca-1 monitored. After 72 hours no differences were observed in cell 
number and morphology between SCF-treated and SCF+IL3+ATRA-treated cultures. Surface 
expression of CD34 and Sca-1 was measured by flow cytometry and found to be significantly 
upregulated in cells cultured with SCF, IL-3 and ATRA relative to cells cultured with SCF 
only (Figure 51). The upregulation of these markers was interpreted as an initial commitment 
to differentiation. Cells from undifferentiated, hEPO and SCF + IL3 + ATRA treated cultures 
were harvested for RNA extraction and gene expression analysis. 
4.3.2 AKR1C expression 
Expression of murine AKR1C genes was measured in undifferentiated HPC-7 cells as well as 
in cells cultured with hEPO or the combination of SCF, IL-3 and ATRA. Gene expression 
was assessed by Taqman QRT-PCR using the primers and probes shown in Table 6 and Table 
7. In undifferentiated HPC-7 cells only very low levels of Akr1c13 mRNA but no other 
AKR1C genes were detected. Culture of HPC-7 cells with hEPO resulted in a small increase 
of Akr1c13 expression but no other AKR1C gene. Similarly, culture with SCF, IL-3 and 
ATRA had no effect on Akr1c13 expression nor did it cause the upregulation of other AKR1C 
genes.  
Also, expression of the inducible cyclooxygenase isoform (COX-2), the enzyme responsible 
for prostaglandin production, was not detected in differentiated or factor-treated cells. In 
agreement with this, HPC-7 cells were unable to convert radio-labeled arachidonic acid into 
any prostanoid species (Figure 52). 
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Figure 50 - Erythropoietin induces erythrocyte differentiation of HPC-7 
HPC-7 cells were cultured in the presence of 10% conditioned medium with stem cell factor (SCF), 
4U/ml human erythropoietin (hEPO) or no factor for seven days. A: Cells were harvested every two 
days, cytospun preparations fixed with methanol and stained with Jenner-Giemsa stain. Cells cultured 
with SCF retained the initial blast morphology while exposure to hEPO induced the differentiation of 
erythrocytes. Notice in day 6 the appearance of cells in different stages of erythropoiesis (with and 
without nuclei). B: Cells in culture were counted daily using a haemocytometer. SCF-treated cells 
showed a constant linear growth while hEPO induced cell proliferation. Absence of SCF resulted in 
death of all cells after 2 days in culture. Dots represent the average of two biological replicates and 
error bars represent the standard deviation. 
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Figure 51 - Combination of ATRA, IL-3 and SCF causes upregulation of surface markers CD34 and Sca-1 
in HPC-7 cells 
HPC-7 cells were cultured in the presence of 10% conditioned medium with stem cell factor (SCF) 
alone or in combination with 100 nM all-trans retinoic acid (ATRA) and 100 ng/ml interleukin-3 (IL-3) 
for 72 hours. A: representative flow cytometry analysis histogram for the expression of the surface 
marker Sca-1. Red curve: unstained cells; blue line: SCF alone; green line: SCF + ATRA + IL-3. B: 
fraction of CD34 and Sca-1 positive cells were calculated. Bars represent the average of three 
biological replicates and error bars represent standard deviation. *; P < 0.05. 
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4.4 Discussion 
Results in the previous chapter demonstrated that human and murine AKR1C enzyme amino 
acid sequences are divergent and that none of the murine enzymes had PGD2 reductase 
activity. This discrepancy in phylogeny and function prompted further elucidation of the 
functional differences between human and mouse AKR1C enzymes. 
Firstly, we compared the preference of human and mouse enzymes for steroid substrates.  All 
four human AKR1C enzymes showed ample steroid reductase activity. Amongst the mouse 
isoforms, AKR1C6 and -1C18 were active towards the most steroid substrates, followed by -
1C20 and -1C21. Interestingly, the remaining isoforms, AKR1C12, -1C13, -1C14 and -1C19, 
were unable to reduce any of the tested steroids. In addition to reducing PGE2 (see page 120), 
AKR1C6 was active towards androstanedione, estrone, 5α-DHT and progesterone (3-, 17- and 
20-HSD). Such substrate promiscuity suggests the catalytic pocket of AKR1C6 might 
accommodate a variety of molecules and could possibly relate to a function in xenobiotic 
detoxification. Previous reports had already shown that AKR1C18 is an efficient inactivator 
of progesterone, an activity related to the termination of pregnancy in mice (Miura et al., 
1994, Maho Ishida, 1999, Piekorz et al., 2005). The present work showed that, in addition, 
AKR1C18 can inactivate 5α-DHT (anti-androgenic activity) and activate estrone to 17β-
estradiol. This combination of activities implies that AKR1C18 acts in the ovary and uterus 
by promoting an estrogenic environment whilst inactivating androgenic and gestational 
steroids.  Interestingly, AKR1C21 showed potent activities towards androstanedione and 5α-
DHT but the respective enzyme kinetics did not fit a Michaelis-Menten curve. Also, 
AKR1C21 reduced 5α-DHT to a product other than 3α- or 3β-androstanediol. This different 
behavior of AKR1C21 may be related to its ability to bind steroids differently, as reported 
previously (Faucher et al., 2007). These results further expose the difference between human 
and mouse AKR1C enzymes, since no functional homologue in terms of steroid substrate 
preference could be identified. 
Contrary to previous reports, estrone reductase activities amongst the human enzymes 
(Penning et al., 2000, Penning and Byrns, 2009) was not detected. In these reports radiometric 
assays were used that allow the detection of slower and less efficient AKR activities. The 
results obtained for the reduction of 5α-DHT with the spectrophotometric assay were 
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validated using a radiometric assay. Results from both methods were in agreement for the 
most efficient enzymes (AKR1C1, -1C2, -1C4, -1C6, -1C18 and -1C21) but exposed the lack 
of sensitivity of the spectrophotometric assay by revealing the slower activities of AKR1C3, -
1C12, -1C13 and -1C14. This result should be taken into consideration when analysing the 
data shown on Table 9, where lower activities towards progesterone, estrone and 
androstanedione might have been undetected.  
The eight mouse AKR1C genes were also characterised in their tissue expression profile. 
Tissues were harvested from male and female animals and gene expression measured by 
Taqman QRT-PCR. Although some of the murine isoforms show steroid metabolizing 
activities, expression of these enzymes in prostate, uterus, ovary and testes was very low or 
not detected. For instance, AKR1C6 reduced androstanedione, estrone, 5α-DHT and 
progesterone, yet its expression was restricted to the liver. Similarly, AKR1C20 was able to 
inactivate progesterone but was not detected outside the liver, further suggesting a hepatic 
detoxification role. The exception is perhaps AKR1C18, an efficient inactivator of 
progesterone and 5α-DHT and potentiator of estrone, expressed in the ovary of non-pregnant 
animals but repressed during pregnancy. As mentioned above, the progesterone-inactivating 
role of AKR1C18 has been previously linked to its expression in ovary and role in induction 
of parturition (Piekorz et al., 2005). The anti-androgenic and pro-estrogenic activities 
described here are in agreement with its expression in estrogen-sensitive tissues.  
Conversely, AKR1C12, -1C13, -1C14 and -1C19 showed a broad tissue distribution but were 
unable to reduce any of the tested steroids. These AKRs, which have no close phylogenetic 
relation with the human isoforms, are found in gastrointestinal tissues (stomach, small 
intestine and colon) suggesting a possible function in metabolizing dietary compounds. This 
comparison revealed a discrepant tissue-expression pattern between human and murine 
AKR1C enzymes involved in estrogen and androgen metabolism. 
Because three of the four human AKR1C isoforms are expressed in haemopoietic stem cells 
(Birtwistle et al., 2008) we used the mouse haemopoietic progenitor cell line HPC-7 to 
measure AKR1C expression. HPC-7 cells were induced to differentiate using EPO or a 
combination of SCF, IL-3 and ATRA. The differentiation was assessed by monitoring 
changes in cell morphology and surface marker expression, respectively. A more extensive 
characterisation of these lineage commitments would be necessary, such as expression of 
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lineage-specific transcription factors and other surface markers. Surprisingly, only very low 
levels of Akr1c13, but no other AKR1C gene, was detected. This pattern of expression was 
not altered by EPO or the SCF, IL-3 and ATRA combination. This lack of AKR1C expression 
in HPC-7 is further evidence of the functional divergence between human and mouse 
enzymes. 
 
 
Figure 52 - HPC-7 cells do not convert arachidonic acid into prostanoids. 
HPC-7 cells were resuspended in serum-free media supplemented with 0.25 μCi [1-
12
C]-arachidonic 
acid with or without 20 μM indomethacin (COX inhibitor) and incubated at 37ºC for 3 hours. Cell-free 
incubation was used as control (Media). Prostanoids were extracted, separated by TLC and exposed 
to light-sensitive film. The following cold standards were run between sample lanes: PGD2 (D), PGE2 
(E), TXA2 (Tx) and PGF2α (F). Top large band: arachidonic acid. Note that non-incubated arachidonic 
acid (Hot) is contaminated with products co-migrating with PGD2 and other unidentified species. 
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5 CHAPTER FIVE: Targeting aldo-keto 
reductases in embryonic stem cells 
Previous amino-acid sequence analysis had revealed higher sequence identity between murine 
AKR1C6 and human AKR1C3. Therefore, at the beginning of this project the Akr1c6 gene 
was targeted in murine embryonic stem cells in order to generate a knock-out mouse strain. 
This work was performed before the lack of homology between human and mouse AKR1C 
enzymes was exposed. 
5.1 Production of Akr1c6 floxed murine embryonic stem cell line 
Generation of a knock-out mouse strain requires specific targeting of the genomic locus of the 
gene of interest in embryonic stem cells. For this, specific DNA sequences known as LoxP 
sites are introduced in introns flanking one or more key exons of the gene. Introduction of 
these sites does not alter gene expression and the targeted cells behave normally. The 
manipulated stem cells are used to derive transgenic mice where the gene of interest is flanked 
by LoxP sites. The strain, which has wild type expression of the gene, is then crossed with 
mice expressing the Cre recombinase, a bacterial enzyme that recognizes LoxP sites. In the 
cells of the progeny, the Cre recombinase recognizes the LoxP sites in the gene of interest and 
promotes recombinantion between them. This results in excision of the key exons rendering 
the gene inactive (knock-out). Also, strains expressing Cre recombinase in a tissue-specific 
manner can be used to produce tissue-specific knock-out animals. 
The procedure used to target the Akr1c6 gene in murine embryonic stem cells is detailed in 
Figure 53. The Akr1c6 gene is composed of 9 exons and 8 introns. A targeting construct for 
Akr1c6 had been previously built by M Scholze and Dr H Schrewe (Max Planck Institute for 
Molecular Genetics, Berlin, Germany). The construct has a large region of homology with the 
Akr1c6 genomic locus (spanning exons 1 to 3), a neomycin resistance cassette (conferring 
resistance to G418) and three LoxP sites (LoxP1-LoxP3).  
After electroporation, the region of homology between the vector DNA and genomic DNA 
allows for homologous recombination and introduction of the Neomycin cassette and LoxP 
sites in the chromosome locus. Recombinant embryonic stem cell colonies were selected with 
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G418, clonally picked and expanded. Southern blotting was used to assess the correct 
integration of the construct. Genomic DNA was extracted from the amplified clones and 
digested with the restriction enzyme EcoRV. The digested DNA was separated by agarose gel 
electrophoresis, transferred onto a membrane and probed with a 5’ probe (Figure 53, in red). 
Digestion of the wild-type Akr1c6 locus results in a 6.2 kb fragment detected by the probe. On 
the other hand, correct integration of the targeting construct introduces an EcoRV site 
between exons 1 and 2, resulting in a 3.0 kb fragment. Therefore, clones in which the Akr1c6 
locus was correctly targeted yielded both a wild-type 6.2 kb fragment and a modified 3.0 kb 
fragment (usually only one of the chromosomes is successfully targeted) whilst clones with 
incorrect integration yielded the 6.2 kb fragment only. An example screening blot is presented 
in Figure 54, with two positive clones identified by red arrows. 
The selected clones were expanded and correct integration re-confirmed by Southern blotting. 
These Akr1c6 
floxed-neo
 cells (exons flanked by LoxP sites) were stored at the Max Planck 
Institute but were never used to generate transgenic animals due to the results described in 
chapters 2 and 4 showing the lack of PGD2 reductase activity of AKR1C6 and the remaining 
mouse isoforms. However, if used, these cells would generate animals expressing AKR1C6 at 
wild-type levels since no exon is disrupted. These animals could then be crossed with Cre-
expressing strains to achieve total or tissue-specific knock-out.  
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Figure 53 – Strategy for the generation of an Akr1c6floxed-neo mouse embryonic stem cell line. 
The Akr1c6 gene is located on mouse chromosome 13 and is composed of 9 exons, the first 4 of 
which are represented here (Ex1-Ex4). The targeting construct contains a large region of homology 
with the Akr1c6 locus (in green) including exons 1 to 3, three LoxP sites (orange triangles) and a 
neomycin resistance cassette (red box). The vector is introduced in G4 murine embryonic stem cells 
by electroporation and integrates the locus via homologous recombination. Treatment with G418 
selects colonies with an inserted neomycin
R
 cassette. To identify clones with homologous 
recombination, genomic DNA from G418-resistant colonies is screened by southern blotting with the 5’ 
probe (in red) after digestion with EcoRV (sites in blue). A 3 kb fragment will be generated instead of 
the 6.2 kb (wild-type). These Akr1c6
floxed-neo
 cells are expanded and used to generate transgenic 
animals (Akr1c6 expression is not affected as all exons are intact). Akr1c6
floxed
 mice can later be 
crossed with animals expressing the bacterial Cre recombinase in a tissue-specific manner. In these 
tissues, Cre recombinase will act on the LoxP sites removing the DNA between. The resulting 
genomic locus lacks exons 2 and 3 and the respective mRNA leads to expression of a truncated non-
functional protein (knock-out). 
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Figure 54 - Southern blot screen for homologous recombination in mESCs 
Genomic DNA was extracted from G418-resistant mESC colonies, digested with EcoRV and analysed 
by southern blotting using a 5’ probe (see Figure 53 for details). Colonies with correct insertion of 
targeting construct yield two bands: 6.2 kb (wild type allele) and 3.0 kb (modified allele). Red arrows 
point to clones with correct integration of target construct. 
 
5.2 Production of a murine inducible knock-down system 
Gene function can also be studied in vivo by over-expressing modified microRNAs (miRNAs) 
to silence gene expression in mouse tissues. Expression of these miRNAs can be regulated 
using inducible systems that enable temporal control of gene silencing. An inducible knock-
down system was developed at the Max Planck Institute for Molecular Genetics (Berlin) as 
described in Figure 55. Because this system was of potential use for the study of AKR1C 
enzymes in mice, the collaboration effort was extended to the development of the pDONOR 
vector (Figure 55). 
Previously, Dr M Morkel and co-workers had manipulated the ROSA26 locus in murine 
embryonic stem cells as shown in Figure 55. The murine ROSA26 locus is a constitutively 
open chromatin region in the mouse genome and, for this reason, is often used in transgene 
over-expression studies (Soriano, 1999). The locus was modified by inserting a gene encoding 
the tetracycline-responsive transcription silencer (tTS), two LoxP sites (with different 
sequence and orientation) and a promoterless gene conferring resistance to puromycine.  
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The pDONOR vector was designed to be compatible with the modified ROSA26 locus. The 
vector contains the enhanced GFP (eGFP) gene interrupted by an intron. The intron harbors 
the modified mir30 sequence (an endogenous miRNA) with the targeting sequence for the 
gene of interest. The eGFP-mir30 gene is under regulation of a CMV or a tissue-specific 
promoter. Furthermore, the activity of this promoter is under influence of a tetracycline 
responsive element (TRE). A PGK promoter is located at the 3’ end of the construct. All these 
elements are flanked by two LoxP sites compatible with the LoxP sites present in the 
ROSA26 locus. Importantly, the pDONOR vector was designed so that the CMV promoter 
and the mir30 targeting sequence can be quickly exchanged, allowing for quick customization 
of the system. 
Upon co-transfection with a Cre-recombinase expressing vector, the pDONOR elements 
integrate the ROSA26 locus via homologous recombination of the LoxP sites. This brings the 
puromycin-resistance cassette under control of the PGK promoter, rendering the cells resistant 
to this antibiotic and allowing for positive selection. The specificity of the Cre-Lox 
recombination and the puromycin selection make the knock-in process highly efficient. 
In the recombinant cells, the tTS protein binds to the TRE and silence the eGFP-mir30 gene. 
Exogenously added tetracycline binds the tTS releasing it from the TRE leading to expression 
of the eGFP-mir30 gene. Upon translation the nascent eGFP-mir30 mRNA is spliced 
releasing the mir30 sequence. This results in production of eGFP (green fluorescence can be 
used as reporter) and a miRNA specific against the target-gene that is processed by the 
cellular silencing machinery. These stem cells can be used to generate transgenic mice and, at 
the desired timepoint, silence expression of target gene by adding tetracycline to the animal’s 
drinking water. 
This inducible knock-down system is currently being optimized at the Max Planck Institute. 
However, and despite the contribution in building the pDONOR vector, the system was not 
used to study the role of AKR1C enzymes. 
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Figure 55 - Construction of an inducible knock down system. 
The ROSA26 locus is a constitutively open chromatin region of the mouse genome. Two loxP sites 
(orange triangles), the tetracycline-responsive transcription silencer (tTS) gene and a promoterless 
coding region for puromycine resistance (Puro
R
) have been introduced in the ROSA26 locus. The 
pDONOR construct has loxP sites homologous to those in ROSA26 above flanking a Tet-responsive 
element (TRE)  in the vicinity of a promoter (CMV or a tissue-specific promoter), the coding sequence 
of the enhanced green fluorescence protein (eGFP) interrupted by an intron coding for a modified 
mir30 shRNA targeting a gene of interest and a PGK promoter. Upon transient Cre recombinase 
expression, the pDONOR construct is integrated in the ROSA26 locus. The PGK promoter will drive 
puromycine resistance, facilitating the selection of homologous recombination events. The expression 
of the eGFP-shRNA gene depends on the promoter cloned upstream and on the tTS. In the absence 
of tetracycline the tTS recognizes the TRE and promotes chromatin condensation in the promoter 
region blocking eGFP-shRNA expression. Added tetracylin blocks tTS activity allowing gene 
expression.  Under these conditions the RNA for eGFP-mir30 is transcribed and processed, 
generating GFP and a shRNA. The shRNA will be processed by the RNAi silencing machinery 
resulting in target gene repression while GFP is used as a marker of shRNA production. 
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6 CHAPTER SIX: Inhibition of myogenesis by 
PGD2 
6.1 Introduction to the myogenesis project 
During the early stages of the project, whilst searching for the murine PGD2 11β-
ketoreductase, a panel of mouse cell lines was screened for AKR1C gene expression. These 
cell lines were later used as a source for cloning the open reading frames of the AKR1C genes 
(see Table 4). The C2C12 cell line, which was part of the panel, was derived from adult 
mouse myoblasts in 1977 (Yaffe and Saxel, 1977) and can undergo in vitro myogenesis 
generating long multinucleated myotubes (muscle fibers) and has become a widely used 
model for the study of adult myogenesis. A previous study had shown that C2C12 
differentiation was sensitive to 15d-PGJ2 (Hunter et al., 2001). This project was dedicated to 
elucidating the effect of PGD2 in C2C12 differentiation, a widely used model for the study of 
adult myogenesis. 
6.2 Differentiation of C2C12 myoblasts 
If kept below confluence and in serum-supplemented media, C2C12 cells retain their 
myoblast properties and rapidly proliferate. In order to induce myogenic differentiation, 
C2C12 cells are allowed to reach confluence and, at that point, are changed to low-serum 
conditions to induce terminal myogenic differentiation (day 0). In most C2C12 protocols, 
differentiation is performed with media supplemented with low levels of horse rather than 
bovine serum (Hunter et al., 2001, Ardite et al., 2004). In this study C2C12 cells were 
differentiated with 5% horse serum (HS)-supplemented media and the process followed over 
the period of 4 days (Figure 56). The change was made after the cells reached 80 to 90% 
confluence. Twenty four hours after the addition of low-serum media, some cells detached 
from the plate suggesting cell death had occurred. At day 2 the first signs of cell fusion were 
observed, with large di- or polynucleated structures arising. These structures became larger 
over the remaining days and began to take on a fiber-like morphology. At day 4, long 
multinucleated myotubes could be observed (Figure 56). 
153 
 
Longer differentiation assays of up to 10 days were also performed. Myotubes continued to 
increase until day 6-7 after which cell fusion had largely ceased. A single addition of 
differentiation media at day 0 resulted in a slight increase in myotube formation when 
compared with cultures that hadthe media refreshed every two days. 
 
 
 
 
Figure 56 - Myogenic differentiation of C2C12. 
C2C12 cells were seeded in six-well plates in DMEM supplemented with 10% foetal bovine serum 
(FBS). When cultures reached 80-90% confluence media was replaced with DMEM supplemented 
with 5% horse serum (HS). This is considered day 0. Media was refreshed every 2 days. Cultures 
were monitored daily using an inverted microscope. Cells begin to fuse around day 2 to form 
multinucleated structures, the myotubes. By day 4 the myotubes are multinucleated. Pictures taken at 
20X amplification. 
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6.3 Development of an assay to measure myotube density 
There are several methods to measure in vitro myogenic differentiation that can be applied to 
C2C12. The most widely used method consists of staining the cultures with antibodies against 
myotube-specific proteins (myogenin; myosin heavy chain), staining the nuclei (Hoechst; 
propidium iodide) and scoring the number of nuclei inside and outside myotubes. The fusion 
index, the proportion of myotube-integrated nuclei relative to the total nuclei count is 
calculated. Other dying methods, such as the Jenner-Giemsa stain, can also be used as long as 
nuclei and myotube structures are distinguishable. This method (detailed on page 91) is 
labour-intensive and is biased by the operator’s decisions of whether a nucleus is inside or 
outside the myotube or whether a certain structure is indeed a myotube.  
A less biased method is the measurement of creatine kinase (CK) activity (detailed on page 
92). CK is an enzyme highly expressed in muscle tissue where, according to the energetic 
demands, it regulates ATP levels by transferring phosphate groups between ADP and creatine 
(phospho-kinase activity). For this method, cells are washed thoroughly with PBS to remove 
traces of CK that might have leaked from dead cells. Afterwards, the cells are lysed and the 
soluble cytoplasmic proteins purified by centrifugation. The protein extract is incubated with 
a reaction mix (Figure 35) and the activity measured is proportional to the amount of CK in 
the sample. The activity is normalized to the protein content of the sample. Despite being a 
quick and unbiased assay, measurement of CK activity does not inform about the overall 
aspect, protein content and myotube size of the cultures. Therefore this assay is often used as 
an additional method that complements the fusion index. 
I have developed a simple and quick method that uses an unbiased analysis of stained cells to 
measure the density of the cultures i. e. the amount of protein-rich myotubes. C2C12 cells 
were differentiated over the period of 7 days and, at days -1, 0, 1, 3, 5 and 7, cultures were 
fixed and stained using Jenner-Giemsa dyes (staining detailed in page 91). The staining was 
done simultaneously for all samples in order to minimize technical variation between dyed 
samples. The Jenner-Giemsa dyes contain methylene blue and eosin. The former stains nuclei 
with a light pink color while the latter stains muscle fibers and collagen with a dark purple 
color. Therefore, with this staining it is possible to follow myotube formation during C2C12 
differentiation, as show in Figure 57 A. 
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Figure 57 - Analysis of C2C12 differentiation using image histograms. 
C2C12 cells were differentiated for a period of 7 days (day 0; change to differentiation media). At days 
-1, 0, 1, 3, 5 and 7 cells were fixed, stained with Jenner-Giemsa dyes and photographed (four fields 
per well). A: Representative pictures of stained cultures during differentiation (20X amplification). Note 
that protein-rich structures, such as the myotubes, are stained darker. B: Pictures of stained cultures 
were analysed with ImageJ. For each picture an image histogram was acquired. In the image 
histogram, the colour tones of the picture are divided into 255 units (0 being the darkest and 255 being 
the lightest) and the number of pixels attributed to each tone is shown (axis only up to 210). Lines 
represent the average pixel count of three biological replicates and error bars represent the standard 
deviation. Note that as cultures become myotube-rich more pixels are distributed to the darker tones. 
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For each time point, three biological replicates were fixed and four different fields 
photographed in each replicate well. Each picture was analysed with the ImageJ software and 
the respective image histograms were obtained. In an image histogram the spectrum of color 
tones is divided into 255 units with 0 being the darkest and 255 the lightest. The histogram 
shows how the pixels of the picture are distributed across the tone range. In Figure 57 B the 
average image histograms from cultures of the several time points are plotted. The error bars 
represent the standard deviation of the three biological replicates for each tone unit. The 
histogram for day -1 shows that most pixels have lighter tones as shown by the peak around 
tone 175. As cells reach confluence in day 0, the pixels become more distributed to the darker 
tones. At day 1 the amount of pixels in darker tones reduces slightly. At days 3, 5 and 7, a 
progressive increase in the amount of pixels allocated to the darker tones is observed, in 
agreement with the growth and maturation of myotubes.  
This measurement of differentiation was then compared with the fusion index (FI). The same 
photographs of stained cultures were used to count the total number of nuclei and the fraction 
residing inside the myotubes (Figure 59 A). In this method, nuclei are considered inside 
myotubes irrespective of how dark those structures stain. The total number of nuclei per field 
increased steadily until day 1 and decreased slowly afterwards. However, the proportion of 
nuclei inside myotubes increased between days 1 and 3 and stabilized until the end of the 
experiment, implying that the fusion rate decreased after day 3. This also suggests that the 
decrease in total nuclei is related to death of un-fused cells. Therefore, the calculated fusion 
index showed a quick increase between day 1 and 3 that decelerated until day 7 (Figure 59 B).  
For quantification of the culture density the sum of the pixels allocated to the darkest tones 
was compared (Figure 58). In this experiment, the number of pixels allocated to tones 
between 0 and 50 (darkest) was added and used as a measure of culture density. The choice of 
these values is arbitrary and depends on the histogram distribution, which varies depending on 
the magnification of the photograph, light exposure and staining process. As shown in Figure 
59 C, the culture density remained low until day 1, from which point a rapid and constant 
increase occurred that lasted until day 7.  
This analysis shows three events that occur in sequence during C2C12 differentiation. First 
the rapid increase of cell number (between days -1 and 1) followed by cell fusion (between 
days 1 and 3) and, finally, the increasing maturation of myotubes as these become more 
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protein-rich (between days 1 and 7). This newly developed method measures a phenomenon 
different to the one measured by the fusion index. Nevertheless, this measurement can also be 
used to quantify C2C12 differentiation. This assay was used in the following experiments as 
an unbiased complementary analysis to the fusion index. 
 
 
Figure 58 - Calculation of culture density from picture histograms. 
In order to quantify the culture density, the pixels attributed to the darkest tones in the picture 
histogram are added. The threshold tone is chosen arbitrarily (in this experiment the tones 0 to 50 
were added) depending on the distribution of the histogram. 
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Figure 59 - Fusion index and culture density during C2C12 differentiation. 
C2C12 cells were differentiated over a period of 7 days. At days -1, 0, 1, 3, 5 and 7 cells were fixed, 
stained with Jenner-Giemsa dyes and photographed (four fields per well). A: Number of total nuclei 
and nuclei inside myotubes per field. B: Fusion index, the fraction total nuclei inside myotubes. C: For 
each image histogram, the number of pixels attributed to tones 50 or less (darkest) was added. Each 
circle corresponds to one biological replicate and is the average measure of four pictures taken. Lines 
represent the average of the three biological replicates and are linked by the dotted line (trend over 
time). 
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6.4 PGD2 inhibits C2C12 myogenesis  
C2C12 cells were differentiated in the presence of 0.001, 0.01, 0.1, 1, 2.5, 5 and 10 μM PGD2 
or vehicle (Figure 60). Myotube formation was inhibited at micromolar doses (1-10 μM), as 
assessed by the fusion index and culture density. The effect was dose-dependent and had an 
IC50 of approximately 5 μM. Importantly, this effect was specific to PGD2, since equimolar 
doses of PGE2 and PGF2α did not affect C2C12 myotube formation even at 10 μM (Figure 
61), despite the structural similarity of these molecules. Inhibition of differentiation by PGD2 
was identical whether it was administered only once at the beginning of the experiment or 
every two days, suggesting the myogenic block occurs at an early stage. 
The time-course of PGD2 inhibition of myogenesis was also analysed (Figure 62). Reduced 
fusion index and creatine kinase activity relative to vehicle control were observed as early as 
day 2 post-confluence. Also, suppression of myotube formation was still evident at day 7 with 
no recovery occurring post day 4. 
Because inhibition of myotube formation by PGD2 could be due to a C2C12-specific artifact, 
the effect of PGD2 was tested in another widely used in vitro model of myogenesis, the rat L6 
cell line. Like C2C12, L6 were isolated from primary muscle samples and behave as 
myoblasts, fusing at high confluence to form long syncytial myotubes (Yaffe, 1968). When 
exposed to micromolar doses of PGD2, the number and size of myotubes was reduced in L6 
cells relative to controls (Figure 63 A). However, with L6 cells, the staining did not allow for 
clear distinction of nuclei and therefore the fusion index could not be calculated. Instead, CK 
activity was measured in these cultures and shown to be impaired in a dose-dependent manner 
(Figure 63 B). 
These results show that PGD2, but not PGE2 or PGF2α, impairs in vitro myogenesis of two 
myoblast cell lines. The inhibition seems to occur in the early stages of differentiation and no 
recovery was observed after 7 days of culture.  
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Figure 60 - PGD2 inhibits C2C12 differentiation in a dose-dependent manner. 
C2C12 cells were differentiated for 4 days in the presence of PGD2 (0.001, 0.01, 0.1, 1, 2.5, 5 and 10 
μM) or vehicle. A: representative staining of cultures treated with vehicle, 5 μM or 10 μM PGD2 
(amplification: 20X). B: myotube formation in PGD2-treated cells was quantified by measuring the 
fusion index relative to vehicle-treated cells. PGD2 inhibits the fusion index in a dose-dependent 
manner with an IC50 of ~5 μM. C:  Culture densities of PGD2-treated cultures. All measurements are 
the average of three biological replicates and error bars represent standard deviation. *; P < 0.05 
relative to vehicle control. 
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Figure 61 - PGD2 but not PGE2 and PGF2α inhibit myotube formation. 
C2C12 cells were differentiated for 4 days in the presence of 10μM PGD2, PGE2, PGF2α or vehicle. A: 
representative pictures of Jenner-Giemsa stained cultures (amplification: 20X). Myotube formation is 
reduced in PGD2-treated cultures only. B: myotube formation in PG-treated cells was quantified by 
measuring the fusion index relative to vehicle-treated cells. C:  Culture densities of PG-treated 
cultures. All measurements are the average of three biological replicates and error bars represent 
standard deviation. *; P < 0.05 relative to vehicle control. 
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Figure 62 – Time course analysis of PGD2-mediated inhibition of C2C12 differentiation. 
C2C12 cells were differentiated for 4 days in the presence of 10μM PGD2. Fusion index (A) and 
creatine kinase activity (B) were measured at days 0, 2 and 4.  The inhibition caused by PGD2 is 
evident as early as day 2. All measurements are the average of three biological replicates and error 
bars represent standard deviation. *; P < 0.05 relative to respective vehicle control. 
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Figure 63 - PGD2 inhibits differentiation of the rat L6 myoblast cell line. 
L6 myoblasts were differentiated for 6 days in the presence of PGD2 (1, 5 or 10 μM) or vehicle. A: 
Pictures of three biological replicates of Jenner-Giemsa stained L6 cultures (amplification: 10X). B: L6 
differentiation was measured by creatine kinase activity. All measurements are the average of three 
biological replicates and error bars represent standard deviation. *; P < 0.05 relative to respective 
vehicle control. 
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6.5 PGD2 alters gene expression during C2C12 myogenesis 
Expression levels of the myogenic markers MyoD, myogenin and α-actin were measured 
using quantitative real-time PCR (QRT-PCR) during C2C12 differentiation in the presence or 
absence of 10 M PGD2. RNA was harvested at pre-confluence (day -1) and every 24 hours 
until day 4 post-confluence (Figure 64).  
MyoD, a myogenic master regulator and a marker of activated satellite cells (Buckingham, 
2006), was found to be expressed in pre-confluent C2C12, increased during differentiation 
until day 2 and decreased thereafter. In PGD2-treated cultures the increase in MyoD 
expression was delayed reaching a maximum only at day 4. Myogenin is part of a second 
wave of regulators expressed in cells that have ceased dividing and committed to terminal 
differentiation (Buckingham, 2006). In control cultures, myogenin mRNA levels quickly 
increased after day 0 and remained high until day 4. However, this strong upregulation was 
markedly attenuated in cells exposed to PGD2. Skeletal muscle α-actin is one of the most 
abundant proteins in mature myotubes as a key component of the contractile machinery. 
Expression of α-actin increased markedly during C2C12 differentiation and, as observed for 
myogenin, the upregulation was diminished in PGD2-treated cells.  
Altogether, these data demonstrate that PGD2 disrupts normal transcriptional changes during 
myogenesis, even in early events such as MyoD upregulation. 
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Figure 64 - PGD2 disrupts transcriptional changes during C2C12 myogenesis. 
Cells were differentiated in the presence of 10 μM PGD2 or vehicle. Expression of MyoD, myogenin 
and α-actin was measured by Taqman QRT-PCR on RNA extracted every 24h from day -1 to day 4 
post-confluence. Data are normalized to GAPDH expression and represent the average of three 
biological replicates ± standard deviation. *, P <0.05 versus equivalent vehicle timepoint. 
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6.6 PGD2 alters C2C12 cell cycle resulting in increased cell number 
Upon commitment to terminal differentiation, myoblasts cease to proliferate and initiate the 
process of cell fusion. Disrupting this withdrawal from cell cycle can affect the subsequent 
steps of myogenic differentiation. We exposed C2C12 to 10 μM PGD2 and determined cell 
number and cell cycle profiles at 24 and 48 hours post treatment. PGD2 treatment induced a 
~30% increase in cell number relative to control (Figure 65 A). Cell counts did not change 
between 24 and 48 hours in either condition. Cell cycle analysis at 24 hours post addition of 
PGD2 revealed a decrease in the proportion of cells in G1 phase relative to control (65.6% 
versus 75.8%, respectively) while, concomitantly, a higher proportion of cells in S and G2 
phase was observed (Figure 65 B and Figure 65). At 48 hours, the proportion of cells in G1 
phase increased in both treatments as expected in a cell population ceasing to proliferate 
(Figure 65 C and Figure 65). However, at this time point, no differences were observed 
between PGD2-treated and control cultures.  
Interestingly, PGD2 induced an increase in cell number even in conditions of extreme serum 
deprivation as cultures incubated for 3 days in media with 0.5% serum and 10 μM PGD2 had 
~35% more cells than controls (Figure 67).  
These results suggest that PGD2 may affect C2C12 myogenesis by altering the cell cycle 
profile of the myoblast population at the onset of differentiation 
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Figure 65 - PGD2 causes an increase in cell number at the onset of C2C12 differentiation. 
C2C12 cells were cultured in the presence or absence of 10 μM PGD2. At 24 and 48 hours post-
treatment, cells were trypsinized and counted (A) and stained with propidium iodide for cell cycle 
analysis with a flow cytometer (B and C). Flow cytometry histograms shown in Figure 66. Data are the 
average of three biological replicates ± standard deviation. *, P <0.05 versus equivalent vehicle 
control. 
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Figure 66 - Altered cell cycle of PGD2-treated cells after 24 hours. 
C2C12 cells were cultured in the presence or absence of 10 μM PGD2. At 24 and 48 hours post-
treatment, cells were trypsinized, stained with propidium iodide for cell cycle analysis with a flow 
cytometer. The histograms shown are representative of three biological replicates. 
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Figure 67 - PGD2 induces an increase in cell number even in extreme low serum conditions. 
C2C12 were differentiated for 3 days using media with 0.5% horse serum supplemented with either 10 
μM PGD2 or vehicle. Cultures were fixed and stained (A) and number of nuclei per field determined by 
counting (B; total and inside myotubes). Data are the average of three biological replicates ± standard 
deviation. *, P < 0.05 versus vehicle control. 
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6.7 Levels of exogenous PGD2 in supernatant decrease after 24 hours 
When in biological solutions, PGD2 undergoes a series of spontaneous dehydration steps 
giving rise to the J-series prostaglandins (Straus and Glass, 2001). The end product of these 
non-enzymatic reactions is 15d-PGJ2, also present in inflammatory tissues (Rajakariar et al., 
2007). In order to measure the rate of conversion to J-series prostaglandins confluent C2C12 
cultures were incubated with 10 μM PGD2 spiked with radio-labeled PGD2. After 3, 6 and 24 
hours the media was harvested, prostaglandins extracted and separated in TLC. Levels of 
PGD2 decreased to ~50% of the initial values in the first 6 hours of incubation (~30% after 24 
hours). J-series intermediates and 15d-PGJ2 were detected after 3 hours but remained 
unchanged during the time course. Instead, the total levels of radio-labeled PGs decreased in 
the supernatant as measured by total counts, suggesting an uptake by the cells. It is not clear 
whether it is PGD2 or the dehydration products that are assimilated by the cells. Nevertheless, 
this data shows that PGD2 has a transient presence in the supernatant and that J-series 
prostaglandins are generated and may have an effect on C2C12 myogenesis (data not shown). 
6.8 PGD2 treatment does not induce mitochondrial superoxide 
A previous study demonstrated that high dose 15d-PGJ2 can also inhibit C2C12 myogenesis 
(Hunter et al., 2001). However, even at the highest PGD2 doses used in our assays (10 μM), it 
seems unlikely that the generated levels of 15d-PGJ2 would be comparable to those used by 
Hunter et al. Nevertheless, 15d-PGJ2 is a highly-reactive PG that is able to generate toxic 
reactive oxygen species and could affect myoblast behavior in low doses.  
In order to measure if exposure to PGD2, or its dehydration products, induces generation of 
reactive oxygen species in C2C12 the formation of mitochondrial superoxide was measured 
using the fluorescent Mitosox Red dye (Figure 68). Untreated C2C12 showed basal 
superoxide levels that were increased by approximately 2-fold after a 24h incubation with 100 
μM H2O2 used as a positive control for the assay. Similarly and as expected, treatment with 
15d-PGJ2 generated mitochondrial superoxide. However in marked contrast, treatment with 
10μM PGD2 not only resulted in no increase in superoxide generation but lead to a small, yet 
significant, decrease. Interestingly, both 15d-PGJ2 and H2O2 treatments resulted in a ~50% 
decrease in cell number relative to control.  
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These results suggest that the inhibition of myogenesis by PGD2 is not mediated by 
conversion to high concentrations of 15d-PGJ2 and subsequent mitochondrial superoxide 
generation. 
 
 
 
Figure 68 - Treatment with PGD2 does not generate reactive oxygen species. 
C2C12 were incubated with either 100 μM H2O2, 10 μM PGD2 or 10 μM 15d-PGJ2 for 24h. Generation 
of mitochondrial superoxide species was detected using Mitosox Red dye as described in page 99. A: 
Merged phase-contrast (grey) and Mitosox Red fluorescence (red) showing superoxide generation in 
cells. B: Mitosox Red fluorescence was normalized to cell number. Data are the average of three 
biological replicates ± standard deviation. *, P <0.05 versus equivalent vehicle control. 
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6.9 PPARγ is not required for PGD2 inhibition of C2C12 myogenesis  
Another mechanism of action attributed to 15d-PGJ2 is the activation of the peroxisome 
proliferator-activated receptor (PPARγ), a member of the nuclear receptor family of 
transcription factors expressed in C2C12 and essential for myogenesis (Singh et al., 2007, 
Forman et al., 1995). Although an accumulation of 15d-PGJ2 was not observed in culture 
media there was an overall decrease in the PGD2 pool. Therefore it is possible that PGD2 
represses myogenesis via generation of 15d-PGJ2 inside the cells resulting in activation of 
PPARγ.  
We investigated whether PPAR was involved in PGD2-mediated inhibition of differentiation. 
Stimulation of PPARγ with the synthetic ligand ciglitazone did not affect myotube formation 
but these structures stained more lightly than controls, suggesting less accumulation of protein 
(Figure 69). Furthermore, pre-treatment with a PPARγ antagonist (GW9662) did not block the 
PGD2 effect on myotube formation. Thus, PPARγ activation does not seem to be required for 
PGD2 inhibition of C2C12 myogenesis. This observation further suggests that the suppression 
of myogenesis by PGD2 is independent of 15d-PGJ2. 
Upon transition to differentiation media, PPARγ was found to be down-regulated and 
remained low until day 4 ( 
Figure 70). Interestingly, treatment with PGD2 caused an up-regulation of PPARγ expression 
that remained high throughout differentiation. Given that activation or inhibition of PPARγ 
does not seem to affect C2C12 myogenesis we speculate this event is an effect of PGD2 
inhibition rather than an immediate cause. 
Previous studies showed that upregulation or knockdown of PPARγ affects C2C12 
differentiation (Singh et al., 2007). However, the present study shows that treatment with 
PPARγ specific agonist (ciglitazone) or antagonist (GW9662) does not alter myotube 
formation. This could be due to C2C12 expressing a mutated form of PPARγ that exerts 
ligand-independent effects. Therefore, PPARγ mRNA was cloned from C2C12 and sequenced 
(as described in page 88). The sequence obtained from 8 individual clones was that of wild-
type PPARγ. 
 
173 
 
 
 
 
 
 
Figure 69 - PGD2 inhibition of myogenesis does not require PPARγ activation. 
C2C12 were differentiated for 4 days in the presence of 10 μM PGD2, 10 μM Ciglitazone (synthetic 
PPARγ agonist), 1 μM GW9662 (PPARγ antagonist) and 1 μM GW9662 + 10 μM PGD2. The PPARγ 
antagonist was added 30 minutes before PGD2. Myotube formation was determined by fusion index 
(A) and culture density (B). Note that although ciglitazone did not affect fusion index it induced a small 
decrease in the culture density. Data are the average of three individual wells ± standard deviation. *, 
P <0.05 versus vehicle control. 
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Figure 70 - PGD2 induces upregulation of PPARγ during C2C12 differentiation. 
Cells were differentiated in the presence of 10 μM PGD2 or vehicle. Expression of PPARγ was 
measured by Taqman QRT-PCR on RNA extracted every 24h from day -1 to day 4 post-confluence. 
Data are normalized to GAPDH expression and represent the average of three biological replicates ± 
standard deviation. *, P <0.05 versus equivalent vehicle timepoint. 
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6.10 Altered cell motility in PGD2-treated C2C12 
During inflammation, PGD2 acts as potent chemoattractant for leukocytes (Kostenis and 
Ulven, 2006). Also, migration of primary mouse myoblasts was shown to be modulated by 
PGI2, resulting in enhanced cell fusion (Bondesen et al., 2007). Therefore, we speculated that 
PGD2 may have an effect on C2C12 motility. 
C2C12 cells were seeded in growth media which was replaced after 24 hours with 
differentiation media with 10 μM PGD2 or vehicle. Cells were monitored using time-lapse 
imaging over the course of 3 hours and their motility was tracked (Figure 71). The dispersion 
plots shown in Figure 71 A represent the relative movement of 30 cells per treatment. It is 
noticeable that PGD2-exposed cells are less mobile than untreated cells. The average velocity 
was reduced to ~60% in PGD2-exposed cells relative to controls (Figure 71 B). The histogram 
in Figure 71 C shows the distribution of velocities of all monitored cells, with PGD2-treated 
cells being clearly slower. This experiment was repeated twice with identical results. 
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Figure 71 - PGD2 reduces C2C12 cell motility. 
C2C12 cells were seeded with growth media and, 24 hours later, changed to differentiation media with 
10 μM PGD2 or vehicle (three biological replicates per treatment). Cells were placed on a microscope 
stage equipped with an incubator and kept at 37 °C and 5% CO2. Time-lapse imaging began 20 
minutes after addition of PGD2 capturing 1 frame every 2 minutes over a period of 3 hours. Cell 
movement was tracked using the Manual Track software plug-in for ImageJ. A: for each condition, the 
movement of 30 cells (10 from each replicate) was tracked and used to generate a dispersion plot. B: 
cell velocities of vehicle and PGD2-treated cells. Data are the average of three individual wells ± 
standard deviation. *, P <0.05 versus vehicle control. C: histogram showing the velocity distribution of 
vehicle and PGD2-treated cells.  
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6.11 PGD2 inhibits C2C12 myogenesis in a DP1 and DP2-independent 
manner 
Secreted prostanoids elicit many of their downstream effects on neighbouring cells via 
specific surface receptors of the G-protein coupled receptor (GPCR) superfamily. 
Extracellular PGD2 can interact with two high-affinity receptors known as DP1 and DP2 (or 
CRTH2) (Kostenis and Ulven, 2006).  
To test for DP receptor-mediated function, C2C12 myoblasts were differentiated in the 
presence of the DP1 and DP2 selective agonists BW245c and 15R-methyl- PGD2, 
respectively. Both synthetic compounds selectively activate DP receptors with EC50 in the 
low nanomolar range (Monneret et al., 2003, Boie et al., 1995).  As shown in Figure 72 A, 10 
μM 15R-methyl- PGD2, but not 10 μM BW245c, was able to mimic PGD2 inhibition of 
culture density, cell fusion, creatine kinase activity and α-actin expression after 4 days of 
differentiation, suggesting a DP2-mediated effect. However, as observed for PGD2, 15R-
methyl- PGD2 only exerted these effects at high micromolar doses (Figure 73), a 
concentration much higher than the described EC50 for DP2-mediated eosinophil activation 
(1.7 nM) (Monneret et al., 2003). 
Expression of PGD2 surface receptors was analysed by RT-PCR in pre-confluent 
undifferentiated and in differentiated C2C12 (Figure 74). Surprisingly, no mRNA was 
detected for DP1 or DP2 at either differentiation stage despite the DP2 agonist having 
mimicked PGD2 in inhibiting myotube formation. Using Taqman QRT-PCR, very low levels 
of DP2 expression were detected (approximately 100 000x lower than GAPDH). Attempts, to 
knock-down DP2 expression in C2C12 using both transient and stable over-expression of a 
specific shRNA against this gene were unsuccessful (method detailed in pages 84 and 88).   
To confirm if DP2 signaling is indeed absent, cells were pre-incubated with CAY10471 (DP2 
selective antagonist) before addition of PGD2 (Royer et al., 2007). CAY10471 failed to 
prevent the suppression of α-actin up-regulation at 0.5, 5 or 10 μM (Figure 72 C). Altogether, 
these data point to a non-DP mediated action of both PGD2 and 15R-methyl- PGD2. 
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Figure 72 - Effects of DP1 and DP2 agonists and antagonists. 
C2C12 were differentiated for 4 days in the presence of 10 μM PGD2, 10μM BW245c (DP1 agonist), 
10μM 15R-methyl-PGD2 (DP2 agonist) or vehicle. A: Myogenic differentiation was measured by 
culture density, fusion index, creatine kinase activity and α-actin expression. B: Structures of PGD2, 
BW245c and 15R-methyl-PGD2 (15(R)-PGD2). C: Cells were pre-incubated for 30 minutes with 0.5, 5 
and 10 μM CAY10471 (DP2 antagonist) before the addition of 10 μM PGD2. At day 4 post-confluence 
RNA was extracted and expression of skeletal α-actin 1 assessed by QRT-PCR. Data are the average 
of three biological replicates ± standard deviation. *, P <0.05 versus vehicle control. 
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Figure 73 - DP2 agonist, 15R-methyl-PGD2, inhibits myogenesis at high micromolar doses. 
C2C12 were differentiated in the presence of 1 and 10 μM 15R-methyl-PGD2 or vehicle. Differentiation 
is shown by phase-contrast photography of cultures. 
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Figure 74 - C2C12 do not express DP1 or DP2. 
Representative gel showing expression of DP1 and DP2 in differentiated and undifferentiated C2C12 
using RT-PCR. As positive controls, cDNA from mouse DP1 (KmDP53) and DP2 (KmB20) transfected 
cells were used. Positive controls and GAPDH: 30 cycles. C2C12 samples and negative controls: 38 
cycles. 
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6.12 Production of prostanoids by C2C12 
Since PGD2 has modulatory effects on C2C12 myogenesis we inquired if these cells are able 
to secrete endogenous PGD2 as a form of autocrine and paracrine signalling. Firstly the 
expression of enzymes involved in the production of PGD2 was analysed: COX-2 and the two 
PGD2-synthases H-PGDS and L-PGDS (pathway in Figure 19). As shown in Figure 75, 
COX-2 mRNA levels were high in undifferentiated cells (day -1) but quickly dropped in the 
following days, suggesting PG production is reduced during myogenesis. Both PGDS 
enzymes were expressed at low levels in undifferentiated cells. However, L-PGDS was 
strongly upregulated during differentiation in a similar fashion to that observed for α-actin 
(Figure 64). Levels of H-PGDS remained unchanged. 
In order to identify which PGs are produced by C2C12, undifferentiated (day 0) and 
differentiated (day 4) cultures were incubated with trace amounts of radio-labeled [
14
C]-
arachidonic acid (AA). Total prostanoids were extracted from culture supernatants and 
separated using thin layer chromatography. As shown in Figure 76 A, myoblasts produced 
several arachidonic acid-derived products, the most predominant of which co-migrated with 
PGE2. Lower levels of products co-migrating with PGD2 and PGF2α were also detected. 
Inhibition of COX activity with 20 μM indomethacin blocked the formation of these products 
(Figure 76 A). In differentiated C2C12 cultures PG synthesis dramatically decreased (Figure 
76 B) in agreement with COX-2 being downregulated at the onset of differentiation. PGE2 
was still detected in differentiated cultures but a large fraction of the radioactive label was 
retained in the origin, suggesting that arachidonic acid was being converted to more 
hydrophilic species. Production of an unidentified AA product was also reduced in 
differentiated C2C12.  
Secretion of PGD2 to culture media was also measured by an ELISA-based method. In 
agreement with the AA incubation assay, low levels of PGD2 were detected in supernatant of 
undifferentiated cells which were further reduced to near undetectable levels in later stages of 
differentiation (Figure 76 C). These results show that, despite the upregulation of L-PGDS, 
the levels of PGD2 secreted by C2C12 are unlikely to exert an autocrine or paracrine effect on 
differentiation. 
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Figure 75 - Expression of COX-2, L-PGDS and H-PGDS during C2C12 differentiation. 
C2C12 cells were differentiated for a period of 4 days. Expression of COX-2, L-PGDS and H-PGDS 
was measured by Taqman QRT-PCR on RNA extracted every 24h from day -1 to day 4 post-
confluence. Note that L-PGDS and H-PGDS expression is presented at the same scale. Data are 
normalized to GAPDH expression and represent the average of three biological replicates ± standard 
deviation. 
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Figure 76 - Metabolism of arachidonic acid and production of PGD2 by C2C12 cells. 
A: Undifferentiated C2C12 were incubated with [
14
C]-arachidonic acid (AA) for 3 hours in the presence 
or absence of 20 μM indomethacin. PGs were extracted from the supernatant and separated by thin 
layer chromatography (TLC) along with cold standards for PGD2, PGE2 and PGF2α. Three biological 
replicates are shown for each condition. B: Undifferentiated (day 0) and differentiated (day 4) cells 
were incubated with 
1
C-arachidonic acid (AA) for 3 hours. PGs were extracted and separated as 
mentioned above. C: PGD2 levels in the supernatant were measured during C2C12 differentiation 
using an ELISA-based assay as described in page 98. Dots represent average of six biological 
replicates and error bars represent standard deviation. 
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6.13 L-PGDS is upregulated during C2C12 myogenesis 
The data in the previous section demonstrated that L-PGDS is markedly upregulated during 
C2C12 differentiation despite no increase in PGD2 production being observed. This protein 
has a dual function, acting as a PGD2 synthase in the cytoplasm and as a high affinity 
transporter for retinoids if secreted to the extra-cellular space (Urade and Hayaishi, 2000a).  
Using a monoclonal antibody, the expression of L-PGDS protein was analysed during C2C12 
differentiation in cells and in supernatant. L-PGDS protein was not detected inside cells at any 
time-point during myogenesis (data not shown). In contrast, L-PGDS was detected in the 
supernatant of cells from day 0 (addition of low-serum media) until day 4 (Figure 77). The 
two detected species migrated with a molecular weight of ~50 and ~60 kDa, much higher than 
the ~21 kDa predicted for the wild type protein. Such discrepancy in molecular weight might 
be due to post-translational modifications such as N-glycosylation, known to occur at two 
sites in L-PGDS (Ragolia et al., 2007). Pure recombinant GST-fused L-PGDS was used as a 
positive control and migrated according to the predicted molecular weight (~46 kDa).This 
result and the absence of PGD2 production by C2C12 cells suggest that L-PGDS is not acting 
as a PGD2 synthase. 
I then tested if the change to differentiation media (5% serum) was sufficient to induce 
upregulation of L-PGDS. Also, because the regulatory region of the L-PGDS gene contains 
thyroid hormone responsive elements (TRE) and indeed thyroid hormone (T3) is able to 
induce L-PGDS expression in mouse neuronal cells (Garcia-Fernandez et al., 2000, Urade and 
Hayaishi, 2000b) the effect of 100 nM T3 on L-PGDS expression was examined. As shown in 
Figure 78, increased expression of L-PGDS, myogenin and α-actin were observed in cells 
incubated for 48h in differentiation media (5% HS) relative to cells kept in growth media 
(10% FBS). Addition of 100 nM T3 did not result in any change in expression of L-PGDS, 
myogenin or α-actin in any type of media. Like L-PGDS, the genes coding for myogenin and 
α-actin are flanked by thyroid hormone responsive elements and, in contrast to the results 
shown here, have been shown to be induced by T3 in C2C12 cells (Baumgartner et al., 2007). 
This suggests that the experimental conditions used in this experiment may not have been 
suitable.  
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In order to further elucidate the role of L-PGDS in C2C12 myogenesis the L-PGDS coding 
region was cloned and a pcDNA3.1-based over-expression plasmid was generated (see page 
87). Using site-directed mutagenesis a C65A mutatation was introduced in the L-PGDS 
vector, thus coding for an enzymatically inactive protein (see page 76). Both plasmids were 
used to generate stably-transfected CHO cells that can be used to produce conditioned media 
with post-translationally modified L-PGDS protein. Unfortunately, due to time restriction 
these tools were not validated or used in experiments with C2C12. Therefore, the function and 
cause of L-PGDS upregulation in C2C12 remains unknown.  
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Figure 77 - C2C12 secrete L-PGDS into the supernatant after incubation with differentiation media. 
C2C12 cells were differentiated for four days. At days -1, 0, 1, 2, 3 and 4, cells were washed, 
transferred to serum-free media and left to incubate for 24 hours. For each day, 30 μl of supernatant 
were separated in SDS-PAGE alongside purified recombinant mouse L-PGDS (+). Proteins were then 
transferred onto a membrane and probed with a monoclonal antibody against L-PGDS. Each lane 
contains proteins secreted by C2C12 over the period of 23 hours. Note that the recombinant L-PGDS 
used here as a positive control was produced in bacteria with a GST-tag and has a predicted 
molecular weight of 46 kDa. For visualization of total proteins, gels were silver stained. Values on the 
left correspond to the protein ladder (in kDa).  
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Figure 78 - Differentiation media induces upregulation of L-PGDS, myogenin and α-actin. 
C2C12 were seeded in growth media and, after 24 hours changed to growth media (10% FBS) or 
differentiation media (5% HS) supplemented with 100 nM T3 or vehicle. Cells were harvested 48 
hours later and used for RNA extraction. Expression of L-PGDS, myogenin and α-actin were 
measured using Taqman QRT-PCR. Bars represent the average of three biological replicates and 
error bars represent standard deviation. 
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6.14 Discussion 
Disruption of myofibers, caused by either injury or exercise, activates two cellular processes 
essential for local tissue regeneration. Firstly, the transition of quiescent satellite cells to 
proliferating myoblasts and secondly the activation of resident mast cells followed by 
sequential infiltration of neutrophils and macrophages. Activated mast cells release large 
amounts of PGD2 that is known to act as a chemoattractant for circulating leukocytes. Given 
that myoblasts share this pro-inflammatory microenvironment I questioned if high doses of 
PGD2 can affect myoblast behaviour, particularly in their ability to form myotubes. 
C2C12: tools of the trade 
The C2C12 cell line, immortalised myoblasts derived from adult mice that retain the 
capability to undergo myogenic differentiation in vitro, were used as model for adult 
myogenesis. Although this system does not mimic all the aspects of the injured and inflamed 
muscle it offers the possibility of studying the myogenic process in isolation whilst adding the 
desired stimuli, like PGD2, in a controlled fashion. C2C12 differentiation was induced by 
culturing confluent cultures in low-serum media (5% horse serum). This resulted in 
withdrawal from cell cycle, followed by cell fusion to form long syncytial myotubes. 
Differentiation was accompanied by increased expression of MyoD, myogenin and α-actin as 
well as increased creatine kinase activity.  
A quick, cheap and easy method to quantify C2C12 myogenesis 
I have also developed an unbiased and less labour-intensive method for quantifying C2C12 
differentiation based on photographs of Jenner-Giemsa stained cultures. Protein-rich mature 
myotubes stain darker and this maturation can be assessed by obtaining the picture histograms 
and measuring the amount of pixels in the darkest tones. The method requires simultaneous 
staining using a single batch of dyes and simultaneous photography to minimize variability 
between pictures. The threshold of darkest tones is arbitrary and, in the experiment shown in 
Figure 59, the sum of tones 0 to 50 (tones range from 0 to 255) were chosen for comparison. 
In other experiments thresholds of 75 or even 100 were used, depending on the shape of the 
histograms. Nevertheless, for each individual experiment the same threshold was used. The 
data showed that the increase in culture density measured with this method is a different 
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phenomenon to that measured by the fusion index. In C2C12 in vitro differentiation, cells fuse 
quickly after serum-reduction to form long myotubes while accumulation of protein in these 
structures happens afterwards. The sequence of these two events, preceded by an increase in 
cell number, is shown in Figure 59. Measurement of fusion index, the most widely used 
method to assess in vitro myogenesis, requires the scoring of nuclei as inside or outside 
myotubes in a large number of photographs, increasing the chance of human error and biased 
assessment. The histogram method was used as an unbiased complement to the fusion index 
analysis for photographs of stained cultures. 
PGD2 inhibits C2C12 and L6 myogenesis 
The experiments presented here show that micromolar doses of PGD2 inhibit myotube 
formation in a dose dependent manner as measured by fusion index and culture density. The 
inhibition had an IC50 of ~ 5 μM, a level that is likely to occur in inflamed tissues according 
to previous studies (Rajakariar et al., 2007, Anhut et al., 1979, Irikura et al., 2009). These 
doses are however, far higher than those required to activate the surface receptors DP1 and 
DP2 (Ulven and Kostenis, 2006). Importantly, equimolar doses of PGE2 and PGF2α did not 
inhibit C2C12 differentiation despite being structurally very similar to PGD2 (Figure 79). 
These molecules differ only in the configuration of the carbon ring: 9-hydroxyl, 11-keto for 
PGD2; 9-keto, 11-hydroxyil for PGE2 and 9,11-hydroxyl for PGF2α, suggesting this might be 
the moiety in PGD2 responsible for inhibiting myotube formation. 
Inhibition of cell fusion and creatine kinase activity could be observed as early as day 2 post-
confluence. Also, one single administration of PGD2 at day 0 exerted the same effect as 
refreshing PGD2 every 2 days, suggesting the block occurs at an early stage in differentiation. 
Expression of myogenic markers during differentiation was deregulated by PGD2 including 
the early upregulation of MyoD and the long-term upregulation of myogenin and α-actin. 
Altogether, these data suggest myogenesis is being blocked at an early stage by PGD2. 
Importantly, myogenic differentiation of the rat myoblast cell line, L6, was also inhibited by 
PGD2 in an identical dose range. This strongly suggests that the PGD2 effect is not a cell line-
specific artifact. However, both cell lines are immortalised and of rodent origin, an important 
bias that should be taken into account. Future studies should therefore make use of isolated 
primary myoblasts to test the inhibitory effects of PGD2. This, alongside in vivo studies with 
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regenerating muscle, would be the ultimate confirmation of the role of PGD2 in adult 
myogenesis. 
Exposure to PGD2 caused an increase in cell number 24 hours after treatment accompanied by 
a higher proportion of cells in S and G2/M phase. Differences in cell cycle profile dissipated 
after 48 hours as cells in both treatments progressed almost exclusively to G1/G0 phase. 
Therefore, when myoblasts are induced to exit cell cycle in low-serum conditions, PGD2 
appears to keep cells in a proliferative state for longer, delaying the subsequent myogenic 
commitment. The increased cell number might be a consequence rather than the cause of the 
inhibition. 
Previous reports had shown that micromolar doses of 15d-PGJ2, the end product of PGD2 
spontaneous dehydration, were able to block C2C12 myogenesis (Hunter et al., 2001). We 
have observed that PGD2 levels quickly decrease in culture media and dehydration products, 
including 15d-PGJ2, are generated early on. However, the total levels of these dehydration 
products remained unchanged suggesting that either PGD2 or the products themselves were 
being taken up by the cells. Nevertheless, generation of this reactive prostaglandin is specific 
to PGD2 and does not occur with PGE2 or PGF2α.  
Treatment with PGD2 did not induce mitochondrial superoxide levels instead bringing a small 
but significant decrease. In contrast, exogenous 15d-PGJ2 caused a 1.5 fold increase in 
superoxide levels, comparable to the effect of H2O2, a known inducer of reactive oxygen 
species. Furthermore, cells treated with 15d-PGJ2 appeared stressed and cell numbers 
decreased after 24 hours of treatment as opposed to the increase in cell numbers observed 
with PGD2. Furthermore, inhibition of differentiation by PGD2 did not seem to require 
PPARγ, a nuclear receptor activated by 15d-PGJ2. Curiously, ciglitazone (PPARγ agonist) 
reduced culture density without affecting myotube formation suggesting activation of PPARγ 
may be involved in protein production during maturation. Also, whilst PPARγ was down-
regulated during C2C12 differentiation, treatment with PGD2 caused an upregulation instead. 
A previous study showed that over-expression or knock-down of PPARγ in C2C12 ablated 
myogenic differentiation. Therefore, the PGD2-induced upregulation of PPARγ might be the 
downstream mechanism leading to the inhibition of myogenesis. These results imply that 
although PGD2 generates 15d-PGJ2 in culture, the inhibition is not likely to be mediated by 
the dehydration product. 
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Time-lapse imaging was also used to quantify changes in cell motility and found that PGD2-
treated cells are less motile than untreated cells. During inflammation, PGD2 acts as a 
chemotractive signal for leukocytes and this phenomenon is mediated by DP2. However, the 
data shown here revealed that that C2C12 do not express DP2 (or DP1) at any time during 
differentiation. During myogenesis, myoblasts align with each other in parallel before fusion. 
This alteration in cell motility can therefore affect the process of fusion as cells fail to position 
themselves correctly. 
As mentioned above, expression of the PGD2 high-affinity surface receptors DP1 and DP2 
was not detected using RT-PCR. Quantitative RT-PCR detected very low levels of DP2 but 
these measurements were too close to the detection limit of the method. Nevertheless a vector 
over-expresing a shRNA targeted against DP2 mRNA was built and used to attempt to knock-
down gene expression. These attempts were without success as DP2 levels remained close to 
the detection limit of the QRT-PCR. It was concluded that DP2 expression is absent or too 
low to have any biological significance. 
Despite the lack of DP2 expression, the selective agonist 15R-methyl- PGD2 was able to 
mimic PGD2 in blocking myogenesis. On the other hand, BW245c, a DP1 agonist, exerted no 
effect. Like PGD2, 15R-methyl- PGD2 only blocked differentiation at micromolar doses that 
are far higher than the published concentrations needed to activate DP2. This suggests that 
both PGD2 and 15R-methyl- PGD2 are acting independently of DP2 but hitting the same, yet 
unknown, biological target. Indeed, 15R-methyl- PGD2 shares the same 9-hydroxyl, 11-keto 
configuration in the carbon ring as PGD2 (Figure 79), further implying that this is the moiety 
responsible for the inhibition of differentiation. Also, it can not be ruled out that, like PGD2, 
15R-methyl- PGD2 may suffer spontaneous dehydration and generate a reactive prostaglandin 
like 15d-PGJ2. 
COX-2 expression was markedly down-regulated at the onset of differentiation, therefore 
limiting the production of prostanoids. However, L-PGDS (but not H-PGDS) was strongly 
upregulated during differentiation, suggesting the PGD2 production capability might be 
increased. Incubation of C2C12 with arachidonic acid revealed that undifferentiated cells 
produce several types of prostaglandins, mainly PGE2 and to a lesser extend PGD2 and PGF2α. 
In agreement with COX-2 down-regulation, differentiated (day 4) cells showed a marked 
decrease in prostaglandin production. Production of PGD2 did not increase during 
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differentiation, despite L-PGDS up-regulation. Levels of PGD2 were also measured with and 
ELISA-based assay yielding the same results. This suggests that C2C12 do not produce large 
enough amounts of PGD2 to exert an autocrine or paracrine effect on differentiation. 
L-PGDS: what role in myogenesis? 
The scale of L-PGDS up-regulation mirrored that of α-actin suggesting that the expression of 
this protein to be important in terminal differentiation. L-PGDS is a bifunctional protein that 
can act as a PGD2 synthase when retained in the cytosol or as a ligand-carrier protein for bile 
acids and retinoids when secreted (Urade and Hayaishi, 2000a). Because no increase in PGD2 
production was observed during differentiation and because L-PGDS protein was detected in 
the supernatant but not in cell lysates of differentiated cells it is reasonable to propose that it 
does not act as a synthase in C2C12 but has an extracellular function.  L-PGDS expression 
and secretion was induced at the onset of differentiation and may induce myoblasts to exit the 
proliferative state as was previously observed in isolated vascular smooth muscle cells 
(Ragolia et al., 2004). L-PGDS may also be involved in muscle nutrient uptake as it has been 
shown to promote glucose transport in L6 cells (Ragolia et al., 2008) and L-PGDS knock-out 
mice develop glucose-intolerance (Ragolia et al., 2005). Culturing C2C12 cells in 5% horse 
serum caused a 5.5-fold increase in L-PGDS expression relative to cells cultured in 10% FBS. 
Despite previous reports showing that thyroid hormone induces L-PGDS expression, no 
change in mRNA levels after treatment with 100 nM T3 was observed. The reported 
myogenin and α-actin up-regulation in C2C12 after T3 exposure were also not observed 
perhaps suggesting the experimental conditions (e.g. T3 quality) were not ideal. CHO cell 
lines over-expressing wild type and C65A mutated L-PGDS were generated and will be used 
for future studies. However, due to time limitation I could not entirely explain the 
physiological relevance of L-PGDS in myogenic differentiation. 
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Figure 79 - Structure and inhibitory actions of PGs and PG-like molecules. 
PGD2 and 15R-mehtyl-PGD2 (15R-m-PGD2) blocked myotube formation in C2C12 at micromolar 
doses. However, structurally similar molecules PGE2 and PGF2α had no effect in differentiation at the 
same doses. Also, BW245c failed to block C2C12 myogenesis. 
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7 CHAPTER SEVEN: General discussion 
7.1 Divergence between mouse and human AKR1C enzymes 
7.1.1 Different phylogeny, substrate preference and tissue distribution  
Enzymes of the AKR1C subfamily have been implicated in the progression of human prostate 
and breast carcinomas as well as leukaemias due to their steroid hormone and prostaglandin 
reductase activities. In this project I attempted to identify the homologue of AKR1C3 (PGD2 
11β-ketoreductase; 17β-HSD; 20α-HSD) amongst the eight murine AKR1C isoforms with the 
objective of generating a knock-out mouse strain and studying its role in leukaemogenesis. 
A subfamily on the verge of a breakdown  
When speciation occurs, the divergent copies of a given gene in the resulting species are said 
to be orthologous. Many human genes have a single corresponding orthologue (“one-to-one”) 
in the mouse genome and their function is often conserved. In some cases, after speciation, 
the orthologues undergo gene duplication and a “one-to-one” comparison is no longer 
possible. This is the case for AKR1C genes of mice and humans. 
Sequence alignment of known and predicted mammalian AKR1C amino-acid sequences 
revealed new aspects of the subfamily (Figure 37). Firstly, the number and sequence of 
AKR1C enzymes is highly variable across the different mammalian orders. Thus, AKR1C 
enzymes are only conserved in closely related species of the same order (primates, rodents, 
etc.).  Human AKR1C enzymes have “one-to-one” orthology with isoforms from chimpanzee 
and macaque but not with isoforms of non-primate species. Similarly, bovine, equine and 
rodent enzymes have higher identity with enzymes of the same order. However, even in some 
species of the same order the number of AKR1C genes is not conserved. This is the case for 
AKR1C1 and -1C2, two genes existing in humans but not in chimpanzee or macaque. 
Likewise, rat and mouse have several species-specific duplications.  
Nevertheless, previously described orthologues were identified such as human AKR1C4 and 
macaque AKR1C25, both liver-restricted enzymes with identical substrate preference and 
inhibitor sensitivity (Higaki et al., 2002). Also, murine AKR1C18 and rat AKR1C8 are 
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known homologues for their ability to inactivate progesterone in the ovary and uterus (Miura 
et al., 1994, Maho Ishida, 1999). Such parallelisms were not observed between human and 
mouse enzymes. Overall, this analysis implies that AKR1C enzymes have diverged 
significantly between mice and humans since their latest common ancestor. This analysis also 
suggests that the AKR1C isoforms have changed in number and sequence according to the 
evolutionary needs of each mammalian order, family or even genus. 
Lack of a PGD2 11β-ketoreductase amongst the mouse AKR1C enzymes 
Surprisingly, none of the murine isoforms mimicked AKR1C3 in reducing PGD2 (page 118) 
supporting the idea of a divergent function of the subfamily in the two species. The absence of 
a PGD2 reductase also suggests that the roles of PGD2 and 15d-PGJ2 in mouse haemopoiesis 
may not be conserved and that their pro-differentiative effects are human or primate-specific. 
Murine haemopoietic progenitors may rely on a different molecule to regulate differentiation, 
such as PGE2, recently shown to promote proliferation of haemopoietic stem cells in zebrafish 
and mouse (Lord et al., 2007, North et al., 2007). However, the bone-marrow of rodents, like 
that of humans, is a PGD2-rich environment (Ujihara et al., 1988b). Alternatively, if the 
function of PGD2 and 15d-PGJ2 is conserved in mouse haemopoiesis, the reduction to 11β-
PGF2α may be performed by an enzyme of another AKR subfamily or a non-AKR enzyme 
(Figure 80). This hypothesis is further supported by the absence of AKR1C expression in the 
murine haemopoietic progenitor cell line HPC-7 (page 136). The absence of homology with 
the human isoforms reported here compromised the primary objective of this project, the 
creation of a mouse strain lacking the AKR1C3-homologue but, on the other hand, prompted 
further investigation on the divergence of AKR1C functions of mice and humans. 
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Figure 80 - Regulation of HSC proliferation by PGD2 is not conserved between humans and mice. 
In human haemopoietic stem cells (HSC) and leukaemic cells, AKR1C3 prevents differentiation by 
converting PGD2 to 11β-PGF2α and protecting from the generation of 15d-PGJ2. However, mice lack 
an AKR1C with PGD2 reductase activity suggesting an alternative mechanism. Either a non-AKR1C 
enzyme converts PGD2 to 11β-PGF2α or an alternative factor (X) regulates the balance proliferation 
and differentiation. 
 
AKR1C6: a novel PGE2 9-ketoreductase? 
An as yet unreported PGE2 reductase activity of mouse recombinant AKR1C6 was also 
shown here (page 120) similar to that observed with rabbit AKR1C5 (Wintergalen et al., 
1995). AKR1C6 and -1C5 have high sequence identity (80%) and identical kinetic parameters 
towards PGE2. In addition, both enzymes have 20α-HSD activity towards progesterone (page 
130). These enzymatic activities are particularly important during female estrous cycle and 
parturition, where increased PGF2α levels signaling via FP and inactivation of progesterone 
induce degeneration of the corpus luteum and uterine contraction, respectively (Unezaki et al., 
1996). However, whilst AKR1C5 is expressed in the ovaries of rabbits, AKR1C6 was found 
to be expressed exclusively in the liver (Figure 49) suggesting these enzymes may not be 
functional homologues.  
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Steroid hormone metabolism and tissue expression 
Despite some mouse enzymes being able to reduce androstanediol, 5α-DHT, estrone and 
progesterone, their expression was not detected in the usual sex steroid-sensitive tissues. For 
instance, AKR1C6 and AKR1C21 perform the pro-androgenic conversion of androstanediol 
to 5α-DHT and the anti-androgenic inactivation of 5α-DHT but their expression is restricted 
to liver and kidney, respectively. Conversely, only very low levels of AKR1C12 and -1C14 
expression were detected in prostate ant testes, respectively, but these enzymes had no activity 
towards androgens (Figure 49). Similarly, AKR1C6 and AKR1C20 were able to reduce 
progesterone (20α-HSD activity) but no expression was detected in the ovary or uterus of 
mice. This discrepancy between enzymatic activity and tissue expression further accentuates 
the lack of homology between human and mouse AKR1C isoforms. 
The only exception was AKR1C18, which is highly expressed in the mouse ovaries and 
inactivates progesterone. As reported previously (Piekorz et al., 2005), expression of 
AKR1C18 was found to be suppressed during pregnancy, when progesterone remains active 
in the serum to support the gestational tissues (Figure 49).  The results shown here report for 
the first time two additional activities of AKR1C18 with possible relevance in female 
reproductive tissues: potentiation of estrone to 17β-estradiol (pro-estrogenic) and inactivation 
of 5α-DHT (anti-androgenic). AKR1C18 performed these three steroid reductase activities 
with efficiency several times higher than that observed with the human isoforms (Table 9). 
Judging by its distant phylogenetic relationship, enzymatic efficiency towards substrates and 
tissue expression it is reasonable to affirm that AKR1C18 has no functional homologue 
amongst the human isoforms. 
Interestingly, very low or no steroid reductase activity was observed for AKR1C12, -1C13, -
1C14 and -1C19. Given that steroids and prostaglandins are the substrate hallmarks of this 
subfamily, and possibly a characteristic of the AKR1C ancestor, it is likely that these enzymes 
have specialised in reducing other types of substrates. These AKR1C isoforms are mostly 
expressed in the gastro-intestinal tract and may be involved in metabolism of dietary 
compounds. 
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Overall, this analysis showed that despite some mouse AKR1C enzymes having ketosteroid 
reductase activities, the combination of these activities with their tissue-expression pattern 
does not resemble what occurs in humans. 
7.1.2 Implications for modeling AKR1C enzymes in cancer 
Due to the increasing range of tools available to manipulate it’s genome, the mouse has 
become a powerful and commonly used tool to query gene function and model human disease 
(Jackson-Grusby, 2002). However, direct comparison between the two mammalian organisms 
requires conservation of orthologous genes. The results shown here have exposed a significant 
lack of phylogenetic and functional conservation between human and mouse AKR1C 
enzymes thus compromising the use of mice to model human AKR1C function in normal 
physiology and cancer. Other animal models should be considered and validated, particularly 
inside the primate order, in order to study the role of AKR1C enzymes in prostate and breast 
cancer and leukaemias and test novel anti-cancer drugs. 
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7.2 PGD2 inhibits C2C12 myogenesis via an unknown mechanism 
Disruption of muscle tissue occurring after injury or exercise triggers a series of physiological 
processes aimed to repair the damaged tissue. One process involves the activation of satellite 
cells into myoblasts that proliferate, commit to differentiation and finally fuse with and repair 
the damaged myofibers. In parallel, muscle damage also activates tissue-resident mast cells 
which initiate an inflammatory response by attracting neutrophils and macrophages from the 
blood stream. These two processes are known to cross-talk and coordinate tissue healing. A 
major signaling molecule secreted during early inflammation is PGD2. Thus, despite 
proliferating myoblasts being exposed to high concentrations of PGD2 during adult muscle 
regeneration, the effect of this eicosanoid in myogenesis had never been addressed. 
I have shown here that C2C12 myoblast differentiation into myotubes is inhibited by PGD2 in 
a dose-dependent manner with an IC50 of ~ 5 μM, a dose likely to occur in inflammatory 
fluids (Anhut et al., 1979). The block imposed by PGD2 caused de-regulated expression of 
myogenic regulators MyoD and myogenin that could be observed already in the first 24 to 48 
hours. Markers of terminal differentiation were also suppressed such as α-actin expression, 
creatine kinase activity and cell fusion. Inhibition of myogenesis did not occur when cells 
were exposed to equimolar doses of PGE2 and PGF2α, despite their structural resemblance 
with PGD2. Curiously, the synthetic molecule 15R-methyl-PGD2, which has the same 9-
hydroxyl, 11-keto configuration in the carbon ring as PGD2, also inhibited myogenesis in the 
same range. Since this configuration is not present in PGE2 or PGF2α it is likely that this is the 
moiety responsible for inhibition. 
The mechanism by which PGD2 inhibits C2C12 myogenesis could not be uncovered in this 
study but some potential pathways were excluded. Firstly, the two surface receptors for PGD2, 
DP1 and DP2, were not expressed in C2C12. A DP-mediated action was unlikely since these 
receptors are activated by nanomolar doses of PGD2 rather than the micromolar doses 
required to exert effect. Alternatively, the spontaneous conversion of PGD2 into the 
cyclopentenone prostaglandin 15d-PGJ2 could account for the observed effects. Indeed, a 
significant proportion of PGD2 was shown to spontaneously dehydrate in culture media. 
However, unlike 15d-PGJ2, addition of PGD2 to culture media did not result in generation of 
mitochondrial superoxide. Also, inhibition of myogenesis by PGD2 did not require PPARγ 
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activation suggesting that spontaneous generation of 15d-PGJ2 is not the mechanism of 
action. Therefore, the results shown here suggest an alternative form of PGD2 signaling that 
responds to high concentrations, such as those observed at the onset of inflammation. 
The findings presented here show that micromolar PGD2 concentrations inhibit myogenesis in 
two commonly used myoblast models. Endogenous production of PGD2 was found to be 
insufficient to bring about the block in myogenesis. Therefore I hypothesize that high levels 
of leukocyte-derived PGD2 is the most likely signal for myoblasts to halt myogenic 
differentiation during the early noxious phases of inflammation in the wounded muscle. This 
mechanism would allow the local high PGD2 levels to repress the onset of myogenesis while 
the diffused signaling from the same molecule would recruit inflammatory leucocytes via 
more conventional DP1 and DP2 signaling. Later in the process, when inflammation is 
resolved and PGD2 is less prevalent, the myogenic block would be lifted and tissue 
regeneration could proceed. This coordinated process, involving cross talk between 
leucocytes and muscle cells, will be disrupted in the presence of COX inhibitory NSAIDs, 
resulting in reduced inflammation and deregulated myoblast function leading ultimately to 
improper healing. 
7.3 L-PGDS up-regulation in C2C12 differentiation 
L-PGDS was found to be markedly upregulated during C2C12 myogenesis, in a fashion 
similar to that of α-actin, a marker of terminal differentiation (Figure 81). Conversely, COX-2 
expression was suppressed and, in agreement, prostanoid production (including PGD2) 
decreased during differentiation. Thus, it was hypothesised that the increase in L-PGDS 
mRNA was related to its extracellular lipocalin functions rather than its cytosolic PGD2-
synthase activity. In agreement, L-PGDS protein was found to be efficiently exported to the 
culture supernatant after cells were cultured with differentiation medium (5% horse serum), 
further supporting a role of the protein in the extracellular space. The protein detected in the 
supernatant had a molecular weight higher than the predicted 21 kDa suggesting that L-PGDS 
is post-translationally modified, possibly by N-glycosylation (Ragolia et al., 2007). 
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Figure 81 - Correlation between L-PGDS and α-actin mRNA levels during C2C12 differentiation 
 
The physiological significance of L-PGDS upregulation and secretion in C2C12 myogenesis 
remains unclear. The promoter region of the L-PGDS gene contains thyroid hormone 
responsive elements, and its expression has been shown to be upregulated by T3 (Garcia-
Fernandez et al., 2000). Myogenin and α-actin are also target genes of the thyroid hormone 
receptor (Baumgartner et al., 2007) further implying that L-PGDS upregulation is co-
regulated with markers of terminal myogenic differentiation. However, we could not show a 
T3-mediated effect on either L-PGDS, myogenin of α-actin expression. 
Several links between L-PGDS and muscle homeostasis have been previously made that can 
justify its expression in C2C12. L-PGDS induces glucose uptake in L6 myoblasts, an essential 
process for muscle function (Ragolia et al., 2008). Additionally, L-PGDS knock-out mice 
develop a glucose-intolerant phenotype very similar to that observed in diabetes type II 
(Ragolia et al., 2005). Thus, L-PGDS upregulation may be important in promoting the 
metabolic functions of the muscle tissue. 
Future experiments such as knock-down and over-expression of L-PGDS in C2C12 will 
elucidate if its expression is essential during differentiation or only relevant in myotube 
function. Also, validation of L-PGDS expression in primary myoblast differentiation and in 
vivo muscle injury as well as studies with the L-PGDS null mice would be valuable. 
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